Patent Grant
12077739
Cell Expansion Systems (CESs) may be used to expand and differentiate cells. Cell expansion systems may be used to expand, e.g., grow, a variety of adherent and suspension cells. For example, cell expansion systems may be used to expand mesenchymal stem cells (MSCs) and other types of cells, such as bone marrow cells. Stem cells which are expanded from donor cells may be used to repair or replace damaged or defective tissues and have broad clinical applications for a wide range of diseases. Cells, of both adherent and non-adherent type, may be grown in a bioreactor in a cell expansion system.
Embodiments of the present disclosure generally relate to a cell expansion system for expanding cells. Such expansion may occur through the use of a bioreactor or cell growth chamber comprising a hollow fiber membrane. In embodiments, a hollow fiber membrane comprises a plurality of hollow fibers. Such hollow fiber membrane may include an extracapillary (EC) space and an intracapillary (IC) space. A cell expansion system may expand a variety of cell types, such as mesenchymal stem cells, cancer cells, T-cells, fibroblasts, and myoblasts. In expanding cells, a compound or coating agent may be applied to a cell growth surface. For example, an adherence-promoting compound may be applied to a cell growth surface to promote contact, e.g., adherence, and subsequent expansion of cells, such as a cell line including human mesenchymal stem cells (hMSCs). In embodiments, for cells to adhere to the surface of the hollow fibers, the surface may be modified in some way, such as by coating at least the cell growth surface with a protein, for example. In embodiments, a coating agent may be applied to the inner surface or inner aspect of bioreactor fibers. For example, a coating agent may be applied to the intracapillary (IC) surface of a hollow fiber(s). In another embodiment, a coating agent may be applied to the extracapillary (EC) surface of a hollow fiber(s). As non-limiting examples of coating agent(s), cryoprecipitate (CPPT), fibronectin (FN), human fibronectin (hFN), and/or combinations of such coating agents may be used. In other embodiments, a plurality of coating agents, or a combination of coating agent(s), may be used.
Embodiments provide for fluid movement in a cell growth chamber or bioreactor to be controlled to actively promote a coating agent(s) to a cell growth surface, e.g., to a surface of a hollow fiber(s). For example, such fluid movement may be controlled so as to move fluid from one side, e.g., IC side, of a hollow fiber to the other side, e.g., EC side, of the hollow fiber. In an embodiment, ultrafiltration may be used to move fluid in a bioreactor. For example, positive ultrafiltration may be used to move fluid from the IC side of a bioreactor to the EC side of the bioreactor. In another embodiment, negative ultrafiltration may be used to move fluid from the EC side of a bioreactor to the IC side of the bioreactor. In embodiments, other types of ultrafiltration or directions of fluid movement may be used. The direction of fluid movement may depend on the surface upon which cells are being expanded.
By controlling fluid movement, a coating solution, e.g., a fluid(s) and a coating agent(s), may be actively pushed to the IC (or EC) loop, and the fluid(s) may be pushed through the pores, for example, of a hollow fiber(s), leaving a residual layer of adherence-promoting protein(s), for example, on the IC (or EC) side of the hollow fiber(s) and therefore facilitating the contact, e.g., attachment, of cells, e.g., adherent cells. Such fluid movement, e.g., ultrafiltration, may decrease the time required for a chemical reaction between a coating agent and the growth surface of the bioreactor to occur to coat the fiber(s). Such fluid movement may be controlled through the adjusting of one or more valve(s), pump(s), or other type of fluid flow control device(s).
Embodiments of the present disclosure provide for implementing such coating procedure(s) through the use of one or more protocols or tasks for use with a cell expansion system. Such protocols or tasks may include pre-programmed protocols or tasks for use with an automated CES, for example. In embodiments, a pre-programmed, default, or otherwise previously saved task may be selected. A task may comprise one or more steps. In other embodiments, such protocols or tasks may include custom or user-defined protocols or tasks for use with an automated CES, for example. Through a user interface (UI) and graphical user interface (GUI) elements, a custom or user-defined protocol or task may be created. In embodiments, a combination of pre-programmed, default, custom, and/or user-defined tasks, for example, may be used.
In addition, ultrafiltration may be combined with other processes for coating a cell growth surface, e.g., a surface of a hollow fiber. For example, some coating processes referred to as a bulls-eye coat process may provide for changing flow rates, flow directions, and rotation of a bioreactor during a coating process to improve distribution of the coating agent throughout the bioreactor. Embodiments provide for combining ultrafiltration, such as by continuously introducing a wash fluid into the bioreactor, while other steps (e.g., changing flow rates, flow directions, and rotation of a bioreactor) are performed.
Other embodiments provide for combining processes of coating a cell growth surface, e.g., a surface of a hollow fiber with processes for loading and attaching cells. For example, a bulls-eye coat process may be combined with a bulls-eye load process. The coating process may provide for changing flow rates, flow directions, and rotation of a bioreactor during a coating process, while the bulls-eye load may provide for changing flow rates, flow directions, and rotation of a bioreactor during a process of loading and attaching cells.
This Summary is included to provide a selection of concepts in a simplified form, in which such concepts are further described below in the Detailed Description. This Summary is not intended to be used in any way to limit the claimed subject matter's scope. Features, including equivalents and variations thereof, may be included in addition to those provided herein.
Embodiments of the present disclosure may be described by referencing the accompanying figures. In the figures, like numerals refer to like items.
The following Detailed Description provides a discussion of illustrative embodiments with reference to the accompanying drawings. The inclusion of specific embodiments herein should not be construed as limiting or restricting the present disclosure. Further, while language specific to features, acts, and/or structures, for example, may be used in describing embodiments herein, the claims are not limited to the features, acts, and/or structures described. A person of skill in the art will appreciate that other embodiments, including improvements, are within the spirit and scope of the present disclosure. Further, any alternatives or additions, including any listed as separate embodiments, may be used or incorporated with any other embodiments herein described.
Embodiments of the present disclosure are generally directed to methods and systems for applying a coating agent or reagent to a cell growth surface to promote cell contact, e.g., adherence, and subsequent expansion of cells. In an embodiment, such application comprises an active promotion of a coating agent or reagent to the cell growth surface, such as the cell growth surface of a hollow fiber(s) where a hollow fiber bioreactor may be used for cell expansion in a cell expansion system. Controlling fluid movement in a bioreactor or cell growth chamber allows for the active promotion of a coating agent or reagent to a cell growth surface.
Passive coating processes may involve the passive application of a coating agent to a cell growth surface, in which a coating agent(s) may be passively applied to a cell growth chamber of an automated cell expansion system using circulating flow, for example. A coating agent(s) may be loaded into an intracapillary or extracapillary side of a bioreactor, for example. The coating agent(s) may then be circulated in the intracapillary or extracapillary loop for a particular, e.g., first, time period. As such, the bioreactor may be passively coated using circulating flow in the IC (or EC) loop, in which such process may take multiple hours, for example. Such coating procedure may take from about four (4) hours to about twenty-four (24) hours, for example, of circulation of a coating agent to achieve coating of the cell growth surface. As an example, a bioreactor coating protocol may load a coating agent into the intracapillary side of a bioreactor in a cell expansion system. The coating agent may then be circulated in the intracapillary circulation loop for a minimum of sixteen (16) hours. A user utilizing such process may therefore use at least two cell expansion systems, in which the user may begin, in a second cell expansion system, any additional expansion of a population of cells harvested from a first cell expansion system (where cells may not be stored in a non-cryopreserved state for up to sixteen (16) hours, for example).
Embodiments herein provide for the active pushing or active promotion of a coating agent solution to a cell growth surface. Rather than passively coating the bioreactor using circulating flow in the IC loop, for example, for many hours, a coating solution, e.g., a fluid(s) and a coating agent(s), can be actively pushed into the IC loop, and the fluid(s) may be pushed through the pores of the bioreactor, leaving a residual layer of adherence promoting proteins on the IC side of the bioreactor fibers to facilitate the attachment of adherent cells. In an embodiment, ultrafiltration may be used to allow a coating agent or reagent to be promoted to the growth surface of a hollow fiber, for example. Ultrafiltration, e.g., positive ultrafiltration, may be used to move fluid from a first side of a hollow fiber to a second side of a hollow fiber. For example, utilizing positive ultrafiltration of a fluid, the fluid may be moved from the IC side of a hollow fiber or hollow fiber membrane to the EC side of the hollow fiber or hollow fiber membrane. Such fluid movement may decrease the time it takes for a chemical reaction to occur between a coating agent or reagent and a growth surface of the bioreactor to coat the cell growth surface. The molecular barrier created by the specified construction of the hollow fibers in the bioreactor may be such that the coating agent or reagent may not be able to pass through the fiber wall along with the fluid in which it is suspended. The adherence promoting proteins of the coating agent may remain in a residual layer on a first side of the hollow fiber(s) as the solution is pushed through the pores of the fibers to a second side of the hollow fiber(s). Moving the fluid using ultrafiltration, e.g., positive ultrafiltration, may thus result in “actively” promoting the coating agent or reagent to the surface of the hollow fiber(s), according to embodiments.
For example, a coating agent(s) may be introduced to the fibers of a hollow fiber bioreactor on the IC (or EC) side. Such coating agent(s) may be suspended in a solution, e.g., coating solution. The IC outlet or waste valve may be closed, with the EC outlet or waste valve open. The IC inlet rate may be set to wash the IC side with media, such as phosphate buffered saline (PBS), for example. Such fluid may have no pathway but through the pores of the fibers (IC outlet valve closed). Accordingly, the solution may flow through the pores of the fibers from the IC side to the EC side. The coating agent, e.g., CPPT, may be hydrostatically deposited onto the inner wall(s) of the bioreactor fiber for a defined time period. For example, such time period may be about ten (10) minutes, according to an embodiment. Such membrane ultrafiltration method allows adherence promoting proteins to be physisorbed on the bioreactor fibers as the solution flows through the pores of the fiber from the IC side to the EC side, for example.
In an embodiment, such active moving of the coating agent to the cell growth surface(s) may significantly decrease the amount of time it may take to coat the cell growth surface as compared to other methods of coating a cell growth surface. In embodiments, such coating procedure using ultrafiltration may be referred to as an expedited coating procedure. Such expedited coating procedure using active moving of the coating agent to the cell growth surface(s) through ultrafiltration may use less time to coat the cell growth surface than procedures using passive coating procedures which may take overnight or about twelve (12) hours to about sixteen (16) hours to coat the bioreactor. For example, such expedited coating procedure may take less than or equal to about four (4) hours. In embodiments, such expedited coating procedure may take any time period in a range from above or equal to about five (5) minutes to less than or equal to about sixty (60) minutes, or any other range therein, depending on the procedure. For example, such coating procedure may take less than or equal to about ten (10) minutes, less than or equal to about twelve (12) minutes, less than or equal to about fifteen (15) minutes, less than or equal to about twenty (20) minutes, less than or equal to about thirty (30) minutes, less than or equal to about forty-five (45) minutes, less than or equal to about sixty (60) minutes, etc.
Embodiments are directed to a cell expansion system, as described above. In embodiments, such cell expansion system is closed, in which a closed cell expansion system comprises contents that are not directly exposed to the atmosphere. Such cell expansion system may be automated. In embodiments, cells, of both adherent and non-adherent or suspension type, may be grown in a bioreactor in the cell expansion system. According to embodiments, the cell expansion system may include base media or other type of media. Methods for replenishment of media are provided for cell growth occurring in a bioreactor of the closed cell expansion system. In embodiments, the bioreactor used with such systems is a hollow fiber bioreactor. Many types of bioreactors may be used in accordance with embodiments of the present disclosure.
The system may include, in embodiments, a bioreactor that further includes a first fluid flow path having at least opposing ends, a first opposing end of the first fluid flow path fluidly associated with a first port of a hollow fiber membrane and a second end of the first fluid flow path fluidly associated with a second port of the hollow fiber membrane, in which the first fluid flow path comprises an intracapillary portion of the hollow fiber membrane. In embodiments, a hollow fiber membrane comprises a plurality of hollow fibers. The system may further include a fluid inlet path fluidly associated with the first fluid flow path, in which a plurality of cells are introduced into the first fluid flow path through a first fluid inlet path. A first pump for circulating fluid in the first fluid flow path of the bioreactor may also be included. In embodiments, the system includes a controller for controlling operation of the first pump. In an embodiment, the controller is a computing system, including a processor, for example. The controller is configured, in embodiments, to control the pump to circulate a fluid at a first rate within the first fluid flow path. In some embodiments, a second pump for transferring intracapillary inlet fluid from an intracapillary media bag to the first fluid flow path and a second controller for controlling operation of the second pump are included. The second controller, in embodiments, controls the second pump to transfer cells from a cell inlet bag to the first fluid flow path, for example. Additional controllers, e.g., third controller, fourth controller, fifth controller, sixth controller, etc., may be used in accordance with embodiments. Further, additional pumps, e.g., third pump, fourth pump, fifth pump, sixth pump, etc., may be used in accordance with embodiments of the present disclosure. In addition, while the present disclosure may refer to a media bag, a cell inlet bag, etc., multiple bags, e.g., a first media bag, a second media bag, a third media bag, a first cell inlet bag, a second cell inlet bag, a third cell inlet bag, etc., and/or other types of containers, may be used in embodiments. In other embodiments, a single media bag, a single cell inlet bag, etc., may be used. Further, additional or other fluid paths, e.g., a second fluid flow path, a second fluid inlet path, etc., may be included in embodiments.
In other embodiments, the system is controlled by, for example: a processor coupled to the cell expansion system; a display device, in communication with the processor, and operable to display data; and a memory, in communication with and readable by the processor, and containing a series of instructions. In embodiments, when the instructions are executed by the processor, the processor receives an instruction to coat the bioreactor, for example. In response to the instruction to coat the bioreactor, the processor may execute a series of steps to coat the bioreactor and may next receive an instruction to load cells into the bioreactor, for example. In response to the instruction to load cells, the processor may execute a series of steps to load the cells from a cell inlet bag, for example, into the bioreactor.
A schematic of an example cell expansion system (CES) is depicted in
Second fluid circulation path 14 includes second fluid flow path 34, cell growth chamber 24, and a second fluid flow control device 32. The second fluid flow path 34 has at least opposing ends 36 and 38, according to embodiments. Opposing ends 36 and 38 of second fluid flow path 34 may be fluidly associated with inlet port 40 and outlet port 42 respectively of cell growth chamber 24. Fluid flowing through cell growth chamber 24 may be in contact with the outside of hollow fiber membrane 117 (see
First and second fluid circulation paths 12 and 14 may thus be separated in cell growth chamber 24 by a hollow fiber membrane 117 (see
Fluid inlet path 44 may be fluidly associated with first fluid circulation path 12. Fluid inlet path 44 allows fluid into first fluid circulation path 12, while fluid outlet path 46 allows fluid to leave CES 10. Third fluid flow control device 48 may be operably associated with fluid inlet path 44. Alternatively, third fluid flow control device 48 may alternatively be associated with first outlet path 46.
Fluid flow control devices as used herein may comprise a pump, valve, clamp, or combination thereof, according to embodiments. Multiple pumps, valves, and/or clamps can be arranged in any combination. In various embodiments, the fluid flow control device is or includes a peristaltic pump. In embodiments, fluid circulation paths, inlet ports, and outlet ports may be constructed of tubing of any material.
Various components are referred to herein as “operably associated.” As used herein, “operably associated” refers to components that are linked together in operable fashion and encompasses embodiments in which components are linked directly, as well as embodiments in which additional components are placed between the two linked components. “Operably associated” components can be “fluidly associated.” “Fluidly associated” refers to components that are linked together such that fluid can be transported between them. “Fluidly associated” encompasses embodiments in which additional components are disposed between the two fluidly associated components, as well as components that are directly connected. Fluidly associated components can include components that do not contact fluid, but contact other components to manipulate the system (e.g., a peristaltic pump that pumps fluids through flexible tubing by compressing the exterior of the tube).
Generally, any kind of fluid, including buffers, protein containing fluid, and cell-containing fluid, for example, can flow through the various circulations paths, inlet paths, and outlet paths. As used herein, “fluid,” “media,” and “fluid media” are used interchangeably.
Turning to
According to embodiments of the present disclosure, fluid in a first circulation path enters cell growth chamber 100 through IC inlet port 108 at a first longitudinal end 112 of the cell growth chamber 100, passes into and through the intracapillary side (referred to in various embodiments as the intracapillary (“IC”) side or “IC space” of a hollow fiber membrane) of a plurality of hollow fibers 116 comprising hollow fiber membrane 117, and out of cell growth chamber 100 through IC outlet port 120 located at a second longitudinal end 124 of the cell growth chamber 100. The fluid path between the IC inlet port 108 and the IC outlet port 120 defines the IC portion 126 of the cell growth chamber 100. Fluid in a second circulation path flows in the cell growth chamber 100 through EC inlet port 128, comes in contact with the extracapillary side or outside (referred to as the “EC side” or “EC space” of the membrane) of the hollow fibers 116, and exits cell growth chamber 100 via EC outlet port 132. The fluid path between the EC inlet port 128 and the EC outlet port 132 comprises the EC portion 136 of the cell growth chamber 100. Fluid entering cell growth chamber 100 via the EC inlet port 128 may be in contact with the outside of the hollow fibers 116. Small molecules (e.g., ions, water, oxygen, lactate, etc.) may diffuse through the hollow fibers 116 from the interior or IC space of the hollow fiber to the exterior or EC space, or from the EC space to the IC space. Large molecular weight molecules, such as growth factors, are typically too large to pass through the hollow fiber membrane, and may remain in the IC space of the hollow fibers 116. The media may be replaced as needed, in embodiments. Media may also be circulated through an oxygenator or gas transfer module to exchange gasses as needed. Cells may be contained within a first circulation path and/or a second circulation path, as described below, and may be on either the IC side and/or EC side of the membrane, according to embodiments.
The material used to make the hollow fiber membrane 117 may be any biocompatible polymeric material which is capable of being made into hollow fibers. One material which may be used is a synthetic polysulfone-based material, according to an embodiment of the present disclosure. In order for the cells to adhere to the surface of the hollow fibers, the surface may be modified in some way, either by coating at least the cell growth surface with a protein such as fibronectin or collagen, for example, or by exposing the surface to radiation, according to embodiments. Gamma treating the membrane surface allows for attachment of adherent cells without additionally coating the membrane with fibronectin, cryoprecipitate, or the like. Bioreactors made of gamma treated membranes may be reused. Other coatings and/or treatments for cell attachment may be used in accordance with embodiments of the present disclosure.
In embodiments, the CES (such as CES 500 (see
A first rotational rocking component 138 rotates the bioreactor 100 around central axis 142 of the bioreactor 100. Rotational rocking component 138 may be rotationally associated with bioreactor 100. In embodiments, bioreactor 100 may be rotated continuously in a single direction around central axis 142 in a clockwise or counterclockwise direction. Alternatively, bioreactor 100 may rotate in alternating fashion, first clockwise, then counterclockwise, for example, around central axis 142, according to embodiments.
The CES may also include a second rotational rocking component that rotates bioreactor 100 around rotational axis 144. Rotational axis 144 may pass through the center point of bioreactor 100 and may be normal to central axis 142. Bioreactor 100 may be rotated continuously in a single direction around rotational axis 144 in a clockwise or counterclockwise direction, in embodiments. Alternatively, bioreactor 100 may be rotated around rotational axis 144 in an alternating fashion, first clockwise, then counterclockwise, for example. In various embodiments, bioreactor 100 may also be rotated around rotational axis 144 and positioned in a horizontal or vertical orientation relative to gravity.
In embodiments, lateral rocking component 140 may be laterally associated with bioreactor 100. The plane of lateral rocking component 140 moves laterally in the −x and −y directions, in embodiments. The settling of cells in the bioreactor may be reduced by movement of cell-containing media within the hollow fibers, according to embodiments.
The rotational and/or lateral movement of a rocking device may reduce the settling of cells within the device and reduce the likelihood of cells becoming trapped within a portion of the bioreactor. The rate of cells settling in the cell growth chamber is proportional to the density difference between the cells and the suspension media, according to Stoke's Law. In some embodiments, a 180 degree rotation (fast) with a pause (having a total combined time of 30 seconds, for example) repeated as described above keeps non-adherent red blood cells suspended. A minimum rotation of about 180 degrees would be preferred in an embodiment; however, one could use rotation of up to 360 degrees or greater. Different rocking components may be used separately, or may be combined in any combination. For example, a rocking component that rotates bioreactor 100 around central axis 142 may be combined with the rocking component that rotates bioreactor 100 around axis 144. Likewise, clockwise and counterclockwise rotation around different axes may be performed independently in any combination.
Turning to
Next,
In accordance with embodiments, a shaft or rocker control 258 for rotating the bioreactor 100 is shown. Shaft fitting 260 associated with the shaft or rocker control 258 allows for proper alignment of a shaft access aperture, see e.g., 424 (
Turning to
According to embodiments, the pre-mounted fluid conveyance assembly 400 includes tubing 408A, 4088, 408C, 4080, 408E, etc., and various tubing fittings to provide the fluid paths shown in
Next,
With regard to the IC loop 502, samples of media may be obtained from sample port 516 or sample coil 518 during operation. Pressure/temperature gauge 520 disposed in first fluid circulation path 502 allows detection of media pressure and temperature during operation. Media then returns to IC inlet port 501A to complete fluid circulation path 502. Cells grown/expanded in cell growth chamber 501 may be flushed out of cell growth chamber 501 into harvest bag 599 through valve 598 or redistributed within the hollow fibers for further growth.
Fluid in second fluid circulation path 504 enters cell growth chamber 501 via EC inlet port 501C, and leaves cell growth chamber 501 via EC outlet port 501D. Media in the EC loop 504 may be in contact with the outside of the hollow fibers in the cell growth chamber 501, thereby allowing diffusion of small molecules into and out of the hollow fibers.
Pressure/temperature gauge 524 disposed in the second fluid circulation path 504 allows the pressure and temperature of media to be measured before the media enters the EC space of the cell growth chamber 501, according to an embodiment. Pressure gauge 526 allows the pressure of media in the second fluid circulation path 504 to be measured after it leaves the cell growth chamber 501. With regard to the EC loop, samples of media may be obtained from sample port 530 or a sample coil during operation.
In embodiments, after leaving EC outlet port 501D of cell growth chamber 501, fluid in second fluid circulation path 504 passes through EC circulation pump 528 to oxygenator or gas transfer module 532. EC circulation pump 528 may also pump the fluid in opposing directions. Second fluid flow path 522 may be fluidly associated with oxygenator or gas transfer module 532 via oxygenator inlet port 534 and oxygenator outlet port 536. In operation, fluid media flows into oxygenator or gas transfer module 532 via oxygenator inlet port 534, and exits oxygenator or gas transfer module 532 via oxygenator outlet port 536. Oxygenator or gas transfer module 532 adds oxygen to, and removes bubbles from, media in the CES 500, for example. In various embodiments, media in second fluid circulation path 504 may be in equilibrium with gas entering oxygenator or gas transfer module 532. The oxygenator or gas transfer module 532 may be any appropriately sized oxygenator or gas transfer device. Air or gas flows into oxygenator or gas transfer module 532 via filter 538 and out of oxygenator or gas transfer device 532 through filter 540. Filters 538 and 540 reduce or prevent contamination of oxygenator or gas transfer module 532 and associated media. Air or gas purged from the CES 500 during portions of a priming sequence may vent to the atmosphere via the oxygenator or gas transfer module 532.
In the configuration depicted for CES 500, fluid media in first fluid circulation path 502 and second fluid circulation path 504 flows through cell growth chamber 501 in the same direction (a co-current configuration). The CES 500 may also be configured to flow in a counter-current conformation.
In accordance with at least one embodiment, media, including cells (from bag 562), and fluid media from bag 546 may be introduced to first fluid circulation path 502 via first fluid flow path 506. Fluid container 562 (e.g., Cell Inlet Bag or Saline Priming Fluid for priming air out of the system) may be fluidly associated with the first fluid flow path 506 and the first fluid circulation path 502 via valve 564.
Fluid containers, or media bags, 544 (e.g., Reagent) and 546 (e.g., IC Media) may be fluidly associated with either first fluid inlet path 542 via valves 548 and 550, respectively, or second fluid inlet path 574 via valves 570 and 576. First and second sterile sealable input priming paths 508 and 509 are also provided. An air removal chamber (ARC) 556 may be fluidly associated with first circulation path 502. The air removal chamber 556 may include one or more ultrasonic sensors including an upper sensor and lower sensor to detect air, a lack of fluid, and/or a gas/fluid interface, e.g., an air/fluid interface, at certain measuring positions within the air removal chamber 556. For example, ultrasonic sensors may be used near the bottom and/or near the top of the air removal chamber 556 to detect air, fluid, and/or an air/fluid interface at these locations. Embodiments provide for the use of numerous other types of sensors without departing from the spirit and scope of the present disclosure. For example, optical sensors may be used in accordance with embodiments of the present disclosure. Air or gas purged from the CES 500 during portions of the priming sequence or other protocols may vent to the atmosphere out air valve 560 via line 558 that may be fluidly associated with air removal chamber 556.
EC media (e.g., from bag 568) or wash solution (e.g., from bag 566) may be added to either the first or second fluid flow paths. Fluid container 566 may be fluidly associated with valve 570 that may be fluidly associated with first fluid circulation path 502 via distribution valve 572 and first fluid inlet path 542. Alternatively, fluid container 566 may be fluidly associated with second fluid circulation path 504 via second fluid inlet path 574 and EC inlet path 584 by opening valve 570 and closing distribution valve 572. Likewise, fluid container 568 may be fluidly associated with valve 576 that may be fluidly associated with first fluid circulation path 502 via first fluid inlet path 542 and distribution valve 572. Alternatively, fluid container 568 may be fluidly associated with second fluid inlet path 574 by opening valve 576 and closing distribution valve 572.
An optional heat exchanger 552 may be provided for media reagent or wash solution introduction.
In the IC loop, fluid may be initially advanced by the IC inlet pump 554. In the EC loop, fluid may be initially advanced by the EC inlet pump 578. An air detector 580, such as an ultrasonic sensor, may also be associated with the EC inlet path 584.
In at least one embodiment, first and second fluid circulation paths 502 and 504 are connected to waste or outlet line 588. When valve 590 is opened, IC media may flow through waste line 588 and to waste or outlet bag 586. Likewise, when valve 582 is opened, EC media may flow through waste line 588 to waste or outlet bag 586.
In embodiments, cells may be harvested via cell harvest path 596. Here, cells from cell growth chamber 501 may be harvested by pumping the IC media containing the cells through cell harvest path 596 and valve 598 to cell harvest bag 599.
Various components of the CES 500 may be contained or housed within a machine or housing, such as cell expansion machine 202 (
Turning to
With regard to the IC loop, samples of media may be obtained from sample coil 618 during operation. Media then returns to IC inlet port 601A to complete fluid circulation path 602. Cells grown/expanded in cell growth chamber 601 may be flushed out of cell growth chamber 601 into harvest bag 699 through valve 698 and line 697. Alternatively, when valve 698 is closed, the cells may be redistributed within chamber 601 for further growth.
Fluid in second fluid circulation path 604 enters cell growth chamber 601 via EC inlet port 601C and leaves cell growth chamber 601 via EC outlet port 601D. Media in the EC loop may be in contact with the outside of the hollow fibers in the cell growth chamber 601, thereby allowing diffusion of small molecules into and out of the hollow fibers that may be within chamber 601, according to an embodiment.
Pressure/temperature sensor 624 disposed in the second fluid circulation path 604 allows the pressure and temperature of media to be measured before the media enters the EC space of the cell growth chamber 601. Sensor 626 allows the pressure and/or temperature of media in the second fluid circulation path 604 to be measured after it leaves the cell growth chamber 601. With regard to the EC loop, samples of media may be obtained from sample port 630 or a sample coil during operation.
After leaving EC outlet port 601D of cell growth chamber 601, fluid in second fluid circulation path 604 passes through EC circulation pump 628 to oxygenator or gas transfer module 632. EC circulation pump 628 may also pump the fluid in opposing directions, according to embodiments. Second fluid flow path 622 may be fluidly associated with oxygenator or gas transfer module 632 via an inlet port 632A and an outlet port 6328 of oxygenator or gas transfer module 632. In operation, fluid media flows into oxygenator or gas transfer module 632 via inlet port 632A, and exits oxygenator or gas transfer module 632 via outlet port 632B. Oxygenator or gas transfer module 632 adds oxygen to, and removes bubbles from, media in the CES 600, for example. In various embodiments, media in second fluid circulation path 604 may be in equilibrium with gas entering oxygenator or gas transfer module 632. The oxygenator or gas transfer module 632 may be any appropriately sized device useful for oxygenation or gas transfer. Air or gas flows into oxygenator or gas transfer module 632 via filter 638 and out of oxygenator or gas transfer device 632 through filter 640. Filters 638 and 640 reduce or prevent contamination of oxygenator or gas transfer module 632 and associated media. Air or gas purged from the CES 600 during portions of a priming sequence may vent to the atmosphere via the oxygenator or gas transfer module 632.
In the configuration depicted for CES 600, fluid media in first fluid circulation path 602 and second fluid circulation path 604 flows through cell growth chamber 601 in the same direction (a co-current configuration). The CES 600 may also be configured to flow in a counter-current conformation, according to embodiments.
In accordance with at least one embodiment, media, including cells (from a source such as a cell container, e.g., a bag) may be attached at attachment point 662, and fluid media from a media source may be attached at attachment point 646. The cells and media may be introduced into first fluid circulation path 602 via first fluid flow path 606. Attachment point 662 may be fluidly associated with the first fluid flow path 606 via valve 664, and attachment point 646 may be fluidly associated with the first fluid flow path 606 via valve 650. A reagent source may be fluidly connected to point 644 and be associated with fluid inlet path 642 via valve 648, or second fluid inlet path 674 via valves 648 and 672.
Air removal chamber (ARC) 656 may be fluidly associated with first circulation path 602. The air removal chamber 656 may include one or more sensors including an upper sensor and lower sensor to detect air, a lack of fluid, and/or a gas/fluid interface, e.g., an air/fluid interface, at certain measuring positions within the air removal chamber 656. For example, ultrasonic sensors may be used near the bottom and/or near the top of the air removal chamber 656 to detect air, fluid, and/or an air/fluid interface at these locations. Embodiments provide for the use of numerous other types of sensors without departing from the spirit and scope of the present disclosure. For example, optical sensors may be used in accordance with embodiments of the present disclosure. Air or gas purged from the CES 600 during portions of a priming sequence or other protocol(s) may vent to the atmosphere out air valve 660 via line 658 that may be fluidly associated with air removal chamber 656.
An EC media source may be attached to EC media attachment point 668, and a wash solution source may be attached to wash solution attachment point 666, to add EC media and/or wash solution to either the first or second fluid flow path. Attachment point 666 may be fluidly associated with valve 670 that may be fluidly associated with first fluid circulation path 602 via valve 672 and first fluid inlet path 642. Alternatively, attachment point 666 may be fluidly associated with second fluid circulation path 604 via second fluid inlet path 674 and second fluid flow path 684 by opening valve 670 and closing valve 672. Likewise, attachment point 668 may be fluidly associated with valve 676 that may be fluidly associated with first fluid circulation path 602 via first fluid inlet path 642 and valve 672. Alternatively, fluid container 668 may be fluidly associated with second fluid inlet path 674 by opening valve 676 and closing distribution valve 672.
In the IC loop, fluid may be initially advanced by the IC inlet pump 654. In the EC loop, fluid may be initially advanced by the EC inlet pump 678. An air detector 680, such as an ultrasonic sensor, may also be associated with the EC inlet path 684.
In at least one embodiment, first and second fluid circulation paths 602 and 604 are connected to waste or outlet line 688. When valve 690 is opened, IC media may flow through waste line 688 and to waste or outlet bag 686. Likewise, when valve 692 is opened, EC media may flow to waste or outlet bag 686.
After cells have been grown in cell growth chamber 601, they may be harvested via cell harvest path 697. Here, cells from cell growth chamber 601 may be harvested by pumping the IC media containing the cells through cell harvest path 697, with valve 698 open, into cell harvest bag 699.
Various components of the CES 600 may be contained or housed within a machine or housing, such as cell expansion machine 202 (
Examples and further description of cell expansion systems are provided in U.S. patent application Ser. No. 12/042,798 (U.S. Pat. No. 8,309,347), entitled, “Cell Expansion System and Methods of Use,” issued on Nov. 13, 2012, which is hereby incorporated by reference herein in its entirety for all that it teaches and for all purposes.
While various example embodiments of a cell expansion system and methods associated therewith have been described,
In an embodiment, to further prime the bioreactor 501, 601, a bag (e.g., 568) may be attached (for example, to connection point 668) to the system 500, 600. Valve 576, 676 may be opened. A media, e.g., PBS, can then be directed into the second fluid circulation path 504, 604 by the EC inlet pump 578, 678 set to pump the media into the second fluid circulation path 504, 604. Valve 582, 692 may be closed while the media enters the bioreactor 501, 601 through the inlet 501C, 601C and out the outlet 501D, 601D of the EC loop. Once the bioreactor 501, 601 and/or the second fluid circulation path 504, 604 have media therein with air removed, e.g., by an air removal chamber, the bioreactor 501, 601 is primed, according to an embodiment.
Process 700 then proceeds to coat the cell growth surface, e.g., bioreactor 501, 601, in step 708, in which the cell growth surface may be coated with a coating agent or reagent. Any coating agent(s) or reagent(s), such as fibronectin or cryoprecipitate, for example, understood by those of skill in the art may be used. In embodiments, any combination of coating agent(s) or reagent(s) may be used. In an embodiment, an outlet or waste valve 590, 690 to one of the circulation loops, e.g., IC loop 502, 602, may be closed, while the outlet or waste valve 582, 692 to the other circulation loop, e.g., EC loop 504, 604, may be opened or remains open. For example, the IC waste or outlet valve 590, 690 may be closed while the EC waste or outlet valve 582, 692 is open. In embodiments, a coating agent or reagent may be loaded into a circulation loop, e.g., IC loop 502, 602, of the cell expansion system 500, 600 until the reagent bag (e.g., 544) or container is empty. Next, the reagent may be chased from an air removal chamber 556, 656 into the circulation loop, e.g., IC loop 502, 602. The bioreactor 501, 601, e.g., cell growth surface of hollow fibers where a hollow fiber bioreactor is used, may then be coated by controlling the fluid movement in the bioreactor 501, 601. In embodiments, such control of the fluid movement uses ultrafiltration, e.g., positive ultrafiltration, to move fluid from one side (e.g., the IC side 502, 602) of the bioreactor 501, 601 to the other side (e.g., the EC side 504, 604). For example, where the IC outlet or waste valve 590, 690 may be closed, with the EC outlet or waste valve open 582, 692, a fluid in the bioreactor 501, 601 may have no pathway but through the pores of the fibers (IC outlet valve 590, 690 closed). In an embodiment, the IC inlet rate may be set to wash the IC side 502, 602 with media or a fluid, such as phosphate buffered saline (PBS), for example. Accordingly, the solution may then flow through the pores of the fibers from the IC side 502, 602 to the EC side 504, 604. The coating agent, e.g., CPPT, may be hydrostatically deposited onto the wall(s), e.g., inner wall(s), of the bioreactor fiber for a defined time period. For example, such time period may be about ten (10) minutes, according to an embodiment. Other time periods may apply according to other embodiments of the present disclosure. Such membrane ultrafiltration method allows adherence promoting proteins to be physisorbed on the bioreactor fibers as the solution flows through the pores of the fiber from the IC side 502, 602 to the EC side 504, 604.
An example of the solutions being introduced to the system 500, 600 to coat the bioreactor may be as shown below:
The coating of the bioreactor may occur in three stages. An example of the settings for the system 500, 600 for the first stage of introducing the solution(s) above may be as shown below:
An example of the settings for the system 500, 600 for the second stage of coating the bioreactor, which chases or washes reagent from the air removal chamber 556, 656, may be as shown below:
An example of the settings for the system 500, 600 for the third stage of coating the bioreactor, which causes ultrafiltration from the IC side 502, 602 to the EC side 504, 604, for example, may be as shown below:
In an embodiment, such active promoting of the coating agent to a cell growth surface, as described above, may significantly decrease the amount of time to coat the cell growth surface as compared to other methods of coating a cell growth surface. In embodiments, such coating procedure using ultrafiltration may be referred to as an expedited coating procedure. Such expedited coating procedure using active moving of the coating agent to the cell growth surface(s) through ultrafiltration may use less time to coat the cell growth surface than procedures using passive coating procedures which may take overnight or about twelve (12) hours to about sixteen (16) hours to coat the bioreactor. For example, such expedited coating procedure may take less than or equal to about four (4) hours. In embodiments, such expedited coating procedure may take any time period in a range from above or equal to about five (5) minutes to less than or equal to about sixty (60) minutes, or any other range therein, depending on the procedure. For example, such coating procedure may take less than or equal to about ten (10) minutes, less than or equal to about twelve (12) minutes, less than or equal to about fifteen (15) minutes, less than or equal to about twenty (20) minutes, less than or equal to about thirty (30) minutes, less than or equal to about forty-five (45) minutes, less than or equal to about sixty (60) minutes, etc. As described above, passive coating procedures may take about sixteen (16) hours to coat the bioreactor, for example. A significant time savings may be realized by using ultrafiltration for coating the bioreactor.
Returning to
An example of the settings for an IC/EC Washout task of the system 500, 600 may be as shown below:
Next, to maintain the proper or desired gas concentration across the fibers in the bioreactor membrane, the condition media task 712 may be executed to allow the media to reach equilibrium with the provided gas supply before cells are loaded into the bioreactor. For example, rapid contact between the media and the gas supply provided by the gas transfer module or oxygenator 532, 632 may be provided by using a high EC circulation rate. The system 500, 600 may then be maintained in a proper or desired state until a user or operator, for example, is ready to load cells into the bioreactor 501, 601. In an embodiment, the system 500, 600 may be conditioned with complete media, for example. Complete media may be any media source used for cell growth. In an embodiment, complete media may comprise alpha-MEM (a-MEM) and fetal bovine serum (FBS), for example. Any type of media known to those of skill in the art may be used.
The condition media task 712 may be a two-step process where, in the first step, the system 500, 600 provides rapid contact between the media and the gas supply by using a high EC circulation rate.
In the second step, the system 500, 600 maintains the bioreactor 501, 601 in a proper state until an operator, for example, is ready to load the cells. An example of the solutions being introduced to the system 500, 600 during the condition media task 712 may be as shown below.
While an example media is shown in Table 7, any type of media known to those of skill in the art may be used.
An example of the settings for a first step of the condition media task 712 may be as shown below:
An example of the settings for a second step of the condition media task 712 may be as shown below:
Process 700 next proceeds to loading cells 714 into the bioreactor 501, 601 from a cell inlet bag 562 (at connection point 662), for example. In an embodiment, the cells are loaded with uniform suspension 714. In an embodiment, the cells may be loaded into the bioreactor 501, 601 from the cell inlet bag 562 (at connection point 662) until the bag 562 is empty. Cells may then be chased or washed from the air removal chamber 556, 656 to the bioreactor 501, 601, according to an embodiment. In embodiments that utilize larger chase volumes, cells may be spread and move toward the IC outlet port 5018, 6018. The distribution of cells may be promoted across the membrane via IC circulation, such as through an IC circulation pump 512, 612, with no IC inlet, for example. Examples and further description of loading and distributing cells are provided in U.S. patent application Ser. No. 13/971,500 (U.S. Pat. No. 9,175,259), entitled, “Method of Loading and Distributing Cells in a Bioreactor of a Cell Expansion System,” issued Nov. 3, 2015, which is hereby incorporated by reference herein in its entirety for all that it teaches and for all purposes.
In another embodiment, the cells may be loaded 714 using another type of cell loading, such as a high flux cell load. In yet another embodiment, the cells may be loaded 714 using another type of loading, such as a bulls-eye cell loading technique. Examples and further description of bulls-eye cell loading procedure(s) are provided in U.S. patent application Ser. No. 14/542,276 (U.S. Pat. No. 9,617,506), entitled, “Expanding Cells in a Bioreactor,” issued on Apr. 11, 2017, which is hereby incorporated by reference herein in its entirety for all that it teaches and for all purposes.
An example of the solutions being introduced to the system 500, 600 to load cells 714 may be as shown below:
The loading of cells 714 may occur in stages. An example of the settings for the system 500, 600 for an example first stage may be as shown below:
An example of the settings for the system 500, 600 for an example second stage may be as shown below:
An example of the settings for the system 500, 600 for an example third stage may be as shown below:
Further, the cells, e.g., adherent cells, may be allowed to attach 716 to the hollow fibers. In an embodiment, in allowing the cells to attach 716, adherent cells are enabled to attach to the bioreactor membrane while allowing flow on the EC circulation loop 504, 604, with the pump (e.g., 512, 612, 554, 654) flow rate to the IC loop 502, 602 set to zero. An example of the solutions being introduced to the system 500, 600 during the process of cells attaching to the membrane 716 may be as shown below:
An example of the settings for attaching to the membrane 716 in the system 500, 600 may be as shown below:
Next, the cells may be fed in step 718, in which a flow rate, e.g., low flow rate in an embodiment, is continuously added to the IC circulation loop 502, 602 and/or the EC circulation loop 504, 604. In an embodiment, the cells may be fed with media, such as media with protein, for example. Outlet settings allow for the removal of fluid added to the system, in accordance with embodiments. An example of the solutions being introduced to the system 500, 600 during the feed step 718 may be as shown below:
An example of the settings for the feed step 718 in the system 500, 600 may be as shown below:
When it is determined to harvest the expanded cells, such as after the cells have reached confluence, after a defined period of time, according to user preference, etc., process 700 proceeds to release cells 720, in which the cells may be released from the membrane of the bioreactor 501, 601 and may be suspended in the IC loop 502, 602. Following the release of any adherent cells, harvest operation 722 transfers the cells in suspension from the IC circulation loop 502, 602, including any cells remaining in the bioreactor 501, 601, to a harvest bag 599, 699 or other container. Process 700 then terminates at END operation 724.
The releasing of cells 720 and harvesting of those cells 722 may be a five-step process, according to embodiments. An example of the solutions being introduced to the system 500, 600 during the release/harvest steps 720, 722 may be as shown below:
A first step in the releasing of cells 720 may perform an IC/EC Washout task in preparation for adding a reagent. For example, IC/EC media may be replaced with a phosphate buffered saline (PBS) to remove protein, calcium (Ca2+), and magnesium (Mg2+) in preparation for adding trypsin, or another chemical-releasing agent, to release any adherent cells. An example of the settings for an example first step of the release step 720 with the system 500, 600 may be as shown below:
A second step of the releasing cell process 720 includes loading a reagent into the system 500, 600 until the reagent bag 544 is empty. An example of the settings for an example second step of the release step 720 with the system 500, 600 may be as shown below:
A third step in the releasing cell process can chase the reagent into the IC loop 502, 602. An example of the settings for an example third step of the release step 720 with the system 500, 600 may be as shown below:
A fourth step in the releasing cell process 720 can mix the reagent within the IC loop 502, 602. An example of the settings for an example fourth step of the release step 720 with the system 500, 600 may be as shown below:
An example of the settings for an example fifth step, which may generally be a harvest step 722, with the system 500, 600 may be as shown below:
As described above, following release step 720 and harvest step 722, process 700 terminates at END operation 724.
Turning to
In an embodiment, prior to loading such reagent or coating agent, an outlet or waste valve 590, 690 to one of the circulation loops, e.g., IC loop 502, 602, may be closed, while the outlet or waste valve 582, 692 to the other circulation loop, e.g., EC loop 504, 604, remains open. For example, the IC waste or outlet valve 590, 690 may be closed while the EC waste or outlet valve 582, 692 may be open, according to an embodiment. In another embodiment, such closing of an outlet or waste valve, e.g., IC waste or outlet valve 590, 690, while keeping another outlet or waste valve, e.g., EC waste or outlet valve 582, 692, open may occur after loading the reagent into the circulation loop 502, 602. In other embodiments, other types of fluid flow control device(s) to control fluid movement may be used as understood by a person of skill in the art.
Next, the reagent may be chased or washed 806 from an air removal chamber 556, 656 into the circulation loop, e.g., IC loop 502, 602. Example parameters 824 and 828 for such chase step 806 may be found in
The cell growth surface of the bioreactor 501, 601, e.g., cell growth surface of hollow fibers where a hollow fiber bioreactor is used, may then be coated 808 by controlling the fluid movement, e.g., ultrafiltration, in the bioreactor 501, 601. Example parameters 826 and 828 for such coating step 808 may be found in
As described above, control of the fluid movement may use ultrafiltration, such as positive ultrafiltration, to move fluid from one side (the IC side 502, 602) of the bioreactor 501, 601 to the other side (the EC side 504, 604), according to embodiments. For example, where the IC outlet or waste valve 590, 690 may be closed, with the EC outlet or waste valve 582, 692 open, a fluid in the bioreactor 501, 601 may have no pathway but through the pores of the fibers (IC outlet valve 590, 690 closed). In an embodiment, the IC inlet rate may be set to wash the IC side 502, 602 with media or a fluid, such as phosphate buffered saline (PBS), for example. Accordingly, the solution may flow through the pores of the fibers from the IC side 502, 602 to the EC side 504, 604. Such coating agent, e.g., CPPT, may be hydrostatically deposited onto the inner wall(s) of the bioreactor fiber for a defined time period. For example, such time period may be about ten (10) minutes, according to an embodiment. Such membrane ultrafiltration method allows adherence promoting proteins to be physisorbed on the bioreactor fibers as the coating solution flows through the pores of the fiber from the IC side to the EC side, for example.
As described above, the active promoting of the coating agent to a cell growth surface may significantly decrease the amount of time it may take to coat the growth surface as compared to other methods of coating a growth surface. In embodiments, such coating procedure using ultrafiltration may be referred to as an expedited coating procedure. Such expedited coating procedure using active moving of the coating agent to the cell growth surface(s) through ultrafiltration may use less time to coat the cell growth surface than procedures using passive coating procedures which may take overnight or about twelve (12) hours to about sixteen (16) hours to coat the bioreactor. For example, such expedited coating procedure may take less than or equal to about four (4) hours. In embodiments, such expedited coating procedure may take any time period in a range from above or equal to about five (5) minutes to less than or equal to about sixty (60) minutes, or any other range therein, depending on the procedure. For example, such coating procedure may take less than or equal to about ten (10) minutes, less than or equal to about twelve (12) minutes, less than or equal to about fifteen (15) minutes, less than or equal to about twenty (20) minutes, less than or equal to about thirty (30) minutes, less than or equal to about forty-five (45) minutes, less than or equal to about sixty (60) minutes, etc.
Following the application of the reagent or coating agent to the cell growth surface, process 800 then terminates at END operation 810.
While
Returning to
Turning to
Returning to
Next, the agent or reagent may be chased or washed 908 from an air removal chamber 556, 656 into the circulation loop, e.g., IC loop 502, 602. Process 900 next proceeds to set a first inlet rate 910, e.g., IC inlet rate, to wash a first side, e.g., IC side 816 (
Such washing, or increased inlet rate, promotes the movement of fluid 912 from a first side 816 (
Turning to
Returning to
Next, process 916 proceeds to optional step 924, in which the settings for a first wash may be set. During such first wash, the agent may be chased or washed from an air removal chamber 556, 656 into the circulation loop, e.g., IC loop 502, 602. The settings may include, for example, optionally setting a first inlet rate 926 and/or optionally setting a first stop condition 928. An example of a first stop condition may include a particular volume, e.g., an IC volume. Optional settings 926 and 928 are offered merely for illustrative purposes. Other settings and/or subsets of settings to control a first wash may be included. There may be fewer or more settings as represented by ellipsis 927. When settings for a first wash are set, process 916 next proceeds to optional first wash 930.
Following optional first wash 930 (or where no first wash is desired, following load agent 922), process 916 proceeds to set second wash settings 932. For example, a second inlet rate, e.g., IC inlet rate, may be set 934 to wash a first side, e.g., IC side 816 (
Additional or other settings may also be set to control such second wash. For example, a second stop condition may be set 936. Such stop condition may include a time period, or time interval, in which the second wash may be stopped when such stop condition is reached. As an example, a ten (10) minute time period may be set as a second stop condition for a second wash. Any time period may be used in accordance with embodiments of the present disclosure. Settings 934 and 936 are offered merely for illustrative purposes. Other settings and/or subsets of settings to control a second wash may be included. There may be fewer or more settings as represented by ellipsis 935.
Following the entering of the second wash settings at step 932, process 916 next proceeds to conducting a second wash 938. Such washing, or increased inlet rate, promotes the movement of fluid from a first side 816 (
Active promoting of the coating agent to a cell growth surface may significantly decrease the amount of time it may take to coat the growth surface as compared to other methods of coating a growth surface. In embodiments, such coating procedure using ultrafiltration may be referred to as an expedited coating procedure. For example, such expedited coating procedure may take less than or equal to about four (4) hours. In an embodiment, such fluid movement may occur for a specified time period, e.g., about ten (10) minutes, to allow for such coating. For example, such coating procedure may take any time period in a range from above or equal to about five (5) minutes to less than or equal to about sixty (60) minutes, or any other range therein, depending on the procedure. For example, such coating procedure may take less than or equal to about ten (10) minutes, less than or equal to about twelve (12) minutes, less than or equal to about fifteen (15) minutes, less than or equal to about twenty (20) minutes, less than or equal to about thirty (30) minutes, less than or equal to about forty-five (45) minutes, less than or equal to about sixty (60) minutes, etc. Any time period may be used in accordance with embodiments of the present disclosure. In an embodiment, such time period may be based on a stop condition, such as a second stop condition set in step 936. For example, a stop condition may be set where an automated CES is used to expand cells. In other embodiments, other conditions may be used to determine when to stop or decrease the active promotion of the fluid. For example, such active promotion may be stopped or decreased when a media bag (e.g., 566) containing the wash solution is empty. Other conditions may be used according to embodiments. Process 916 then terminates at END operation 940.
Referring now to
As part of introducing the fluid with the reagent into the cell expansion system, step 1008 may involve optional step 1012, where a wash fluid (e.g., PBS) may be used to chase the reagent from parts of the CES. For example, the wash fluid may move any reagent left behind in an ARC, such as ARC 556/656. The wash fluid may chase any lingering reagent into the bioreactor and/or a fluid flow path associated with the bioreactor e.g., 502/602.
Flow 1000 then passes to step 1014 where a second wash fluid may be introduced into the bioreactor. In embodiments, step 1014 may involve activating a pump, such as pumps 554,654 to introduce the second wash fluid from a bag (562) or connection point (662) into a fluid flow path and into the bioreactor (100, 501, and/or 601). In embodiments, the second wash fluid is introduced to create conditions for ultrafiltration, as described above. Ultrafiltration allows proteins or molecules (e.g., the coating reagent) that are too large to pass through the pores 818 (
Flow 1000 then passes to step 1016 where fluid that includes the coating reagent may be circulated through the bioreactor such as bioreactors 100, 501, and/or 601. In embodiments, step 1016 may involve activating one or more pumps to circulate fluid with the reagent through the bioreactor. For example, an IC circulation pump (e.g., 512 or 612) may be activated to circulate fluid through the IC side of a bioreactor at a first circulation flow rate. In at least one embodiment, fluid may pass through hollow fibers (e.g., the lumen).
In embodiments, the first rate may be a relatively high flow rate. In embodiments, the first circulation flow rate may be less than about 500 ml/min, less than about 400 ml/min, or even less than about 300 ml/min. In other embodiments, the first circulation rate may be greater than about 50 ml/min, greater than about 100 ml/min, or even greater than about 150 ml/min. In one embodiment, the first circulation flow rate is between about 100 ml/min and about 500 ml/min, such as about 300 ml/min.
Step 1016 may be performed for a first predetermined period of time. In one specific example, the first period of time may be about 4 minutes, about 8 minutes, about 12 minutes, or even about 16 minutes. In other embodiments, the first predetermined period of time may be less than about 20 minutes, less than about 15 minutes, less than about 10 minutes, or even less than about 5 minutes. In some embodiments, the first predetermined period of time may be greater than about 2 minutes, greater than about 4 minutes, greater than about 6 minutes, greater than about 8 minutes, greater than about 10 minutes, greater than about 12 minutes, greater than about 14 minutes, greater than about 16 minutes, greater than about 18 minutes, or even greater than about 20 minutes. Step 1016 may be performed in embodiments to provide time to allow the reagent to coat portions of the bioreactor. For example, when the bioreactor comprises hollow fibers, step 1016 may be performed to allow the reagent time to coat interior surfaces of the hollow fibers.
Flow 1000 passes to step 1020, wherein fluid with the reagent is circulated at a second flow rate, which may be less than the first flow rate. In embodiments, the second flow rate may be less than about 400 ml/min, less than about 300 ml/min, or even less than about 200 ml/min. In other embodiments, the second circulation rate may be greater than about 25 ml/min, greater than about 50 ml/min, or even greater than about 75 ml/min. In one embodiment, the second circulation flow rate is between about 100 ml/min and about 300 ml/min, such as about 250 ml/min.
Step 1020 may be performed for a second predetermined period of time. In one specific example, the second period of time may be about 4 minutes, about 8 minutes, about 12 minutes, or even about 16 minutes. In other embodiments, the second predetermined period of time may be less than about 20 minutes, less than about 15 minutes, less than about 10 minutes, or even less than about 5 minutes. In some embodiments, the second predetermined period of time may be greater than about 2 minutes, greater than about 4 minutes, greater than about 6 minutes, greater than about 8 minutes, greater than about 10 minutes, greater than about 12 minutes, greater than about 14 minutes, greater than about 16 minutes, greater than about 18 minutes, or even greater than about 20 minutes. Step 1020 may be performed in embodiments to provide time to allow the reagent to coat portions of the bioreactor. For example, when the bioreactor comprises hollow fibers, step 1020 may be performed to allow the reagent time to coat interior surfaces of the hollow fibers.
Flow 1000 passes to optional step 1024, wherein fluid with the reagent is circulated at a third flow rate, which may be less than the first flow rate. In embodiments, the third flow rate may be less than the second flow rate. In embodiments, the third flow rate may be less than about 350 ml/min, less than about 300 ml/min, or even less than about 250 ml/min. In other embodiments, the second circulation rate may be greater than about 25 ml/min, greater than about 50 ml/min, or even greater than about 75 ml/min. In one embodiment, the third circulation flow rate is between about 50 ml/min and about 250 ml/min, such as about 200 ml/min.
Optional step 1024 may be performed for a third predetermined period of time. In one specific example, the second period of time may be about 4 minutes, about 8 minutes, about 12 minutes, or even about 16 minutes. In other embodiments, the third predetermined period of time may be less than about 20 minutes, less than about 15 minutes, less than about 10 minutes, or even less than about 5 minutes. In some embodiments, the third predetermined period of time may be greater than about 2 minutes, greater than about 4 minutes, greater than about 6 minutes, greater than about 8 minutes, greater than about 10 minutes, greater than about 12 minutes, greater than about 14 minutes, greater than about 16 minutes, greater than about 18 minutes, or even greater than about 20 minutes. Step 1024 may be performed in embodiments to provide time to allow the reagent to coat portions of the bioreactor. For example, when the bioreactor comprises hollow fibers, step 1024 may be performed to allow the reagent time to coat interior surfaces of the hollow fibers.
Flow 1000 then passes to optional step 1028, where fluid with the reagent is circulated at a fourth flow rate, which may be less than the third flow rate. In embodiments, the fourth flow rate may be less than about 250 ml/min, less than about 200 ml/min, or even less than about 150 ml/min. In other embodiments, the second circulation rate may be greater than about 25 ml/min, greater than about 50 ml/min, or even greater than about 75 ml/min. In one embodiment, the fourth circulation flow rate is between about 25 ml/min and about 200 ml/min, such as about 150 ml/min.
Optional step 1028 may be performed for a fourth predetermined period of time. In one specific example, the second period of time may be about 4 minutes, about 8 minutes, about 12 minutes, or even about 16 minutes. In other embodiments, the fourth predetermined period of time may be less than about 20 minutes, less than about 15 minutes, less than about 10 minutes, or even less than about 5 minutes. In some embodiments, the fourth predetermined period of time may be greater than about 2 minutes, greater than about 4 minutes, greater than about 6 minutes, greater than about 8 minutes, greater than about 10 minutes, greater than about 12 minutes, greater than about 14 minutes, greater than about 16 minutes, greater than about 18 minutes, or even greater than about 20 minutes. Step 1028 may be performed in embodiments to provide time to allow the reagent to coat portions of the bioreactor. For example, when the bioreactor comprises hollow fibers, step 1028 may be performed to allow the reagent time to coat interior surfaces of the hollow fibers.
Flow passes to optional step 1032, where fluid with the reagent is circulated at a fifth flow rate, which may be less than the fourth flow rate. In embodiments, the fifth flow rate may be less than about 200 ml/min, less than about 150 ml/min, or even less than about 100 ml/min. In other embodiments, the fifth circulation rate may be greater than about 25 ml/min, greater than about 50 ml/min, or even greater than about 75 ml/min. In one embodiment, the fifth circulation flow rate is between about 25 ml/min and about 150 ml/min, such as about 100 ml/min.
Optional step 1032 may be performed for a fifth predetermined period of time. In one specific example, the fifth period of time may be about 4 minutes, about 8 minutes, about 12 minutes, or even about 16 minutes. In other embodiments, the fifth predetermined period of time may be less than about 20 minutes, less than about 15 minutes, less than about 10 minutes, or even less than about 5 minutes. In some embodiments, the fifth predetermined period of time may be greater than about 2 minutes, greater than about 4 minutes, greater than about 6 minutes, greater than about 8 minutes, greater than about 10 minutes, greater than about 12 minutes, greater than about 14 minutes, greater than about 16 minutes, greater than about 18 minutes, or even greater than about 20 minutes. Step 1032 may be performed in embodiments to provide time to allow the reagent to coat portions of the bioreactor. For example, when the bioreactor comprises hollow fibers, step 1032 may be performed to allow the reagent time to coat interior surfaces of the hollow fibers.
Flow 1000 passes to optional step 1036, where fluid with the reagent is circulated at a sixth flow rate, which may be less than the fifth flow rate. In embodiments, the sixth flow rate may be less than about 100 ml/min, less than about 50 ml/min, or even less than about 25 ml/min. In other embodiments, the sixth circulation rate may be greater than about 5 ml/min, greater than about 10 ml/min, or even greater than about 15 ml/min. In one embodiment, the sixth circulation flow rate is between about 25 ml/min and about 100 ml/min, such as about 50 ml/min.
Optional step 1036 may be performed for a sixth predetermined period of time. In one specific example, the sixth period of time may be about 4 minutes, about 8 minutes, about 12 minutes, or even about 16 minutes. In other embodiments, the sixth predetermined period of time may be less than about 20 minutes, less than about 15 minutes, less than about 10 minutes, or even less than about 5 minutes. In some embodiments, the sixth predetermined period of time may be greater than about 2 minutes, greater than about 4 minutes, greater than about 6 minutes, greater than about 8 minutes, greater than about 10 minutes, greater than about 12 minutes, greater than about 14 minutes, greater than about 16 minutes, greater than about 18 minutes, or even greater than about 20 minutes. Step 1036 may be performed in embodiments to provide time to allow the reagent to coat portions of the bioreactor. For example, when the bioreactor comprises hollow fibers, step 1036 may be performed to allow the reagent time to coat interior surfaces of the hollow fibers.
Flow 1000 passes to optional step 1040, where fluid with the reagent is circulated at a seventh flow rate, which may be less than the sixth flow rate. In embodiments, the seventh flow rate may be less than about 100 ml/min, less than about 50 ml/min, or even less than about 25 ml/min. In other embodiments, the seventh circulation rate may be greater than about 10 ml/min, greater than about 15 ml/min, or even greater than about 20 ml/min. In one embodiment, the seventh circulation flow rate is between about 10 ml/min and about 50 ml/min, such as about 25 ml/min.
Optional step 1040 may be performed for a seventh predetermined period of time. In one specific example, the seventh period of time may be about 4 minutes, about 8 minutes, about 12 minutes, or even about 16 minutes. In other embodiments, the sixth predetermined period of time may be less than about 20 minutes, less than about 15 minutes, less than about 10 minutes, or even less than about 5 minutes, in some embodiments, the sixth predetermined period of time may be greater than about 2 minutes, greater than about 4 minutes, greater than about 6 minutes, greater than about 8 minutes, greater than about 10 minutes, greater than about 12 minutes, greater than about 14 minutes, greater than about 16 minutes, greater than about 18 minutes, or even greater than about 20 minutes. Step 1040 may be performed in embodiments to provide time to allow the reagent to coat portions of the bioreactor. For example, when the bioreactor comprises hollow fibers, step 1040 may be performed to allow the reagent time to coat interior surfaces of the hollow fibers (e.g., the lumen).
Flow 1000 then passes to step 1042 where introduction of the second wash fluid into the bioreactor is stopped. In embodiments, step 1042 may involve deactivating a pump, such as pump 554, 654 to stop the introduction of the second wash fluid in the fluid flow path and into the bioreactor (100, 501, and/or 601). In embodiments, stopping the introduction of the second wash fluid stops the process of ultrafiltration.
Flow 1000 then passes to step 1044, where a second fluid, that may not include the reagent, or have a lower concentration of the reagent, may be circulated through the bioreactor. In embodiments, step 1044 may be performed to wash any remaining reagent that has not coated a surface of the bioreactor out of the bioreactor and CES. As noted above, flow 1000 may be part of a larger process such as a process for growing and harvesting cells in a cell expansion system, such as flow 700. Therefore, in embodiments, step 1044 may be implemented as part of steps performed in the larger process, such as step 710 (
Referring now to
Also shown in
It is believed that having steps 1016, 1020, 1024, 1028, 1032, 1036, 1040, 1044, and 1048 circulate at different flow rates, allows the fluid to flow through more of the hollow fibers 1108 than if just a single flow rate would be used. In one embodiment of a process that follows flow chart 1000, at steps 1016 and 1020 (at the flow rates described above), fluid may flow mainly through the hollow fibers in zone 1012. At steps 1024 and 1028 (at the flow rates described above), fluid may flow mainly through the hollow fibers in zones 1112 and 1116.
At steps 1032 and 1136 (at the flow rates described above), fluid may flow mainly through the hollow fibers in zone 1112, 1116, and 1120 because the rate is slower and the fluid may disperse more. At step 1040 (at the flow rates described above), fluid may flow through the hollow fibers in zones 1112, 1116, 1120, and 1124 because the flow rate is yet slower and fluid may disperse even more. Thus, it is believe that fluid with the reagent may flow into more of the hollow fibers using a sequence of different flow rates, than if a single high flow rate circulation is used.
Furthermore, it is also believed that the different flow rates may also affect the longitudinal distribution of the reagent along the bioreactor, e.g., along a hollow fiber. That is, a higher flow rate may allow the reagent to flow further along inside a hollow fiber. For example, at a higher flow rate, the reagent being carried by fluid may reach beyond half the length of the hollow fiber. At a lower flow rate, the reagent being carried by fluid may reach half the length of the hollow fiber. At even a lower flow rate, the reagent being carried by fluid may reach less than half the length of the hollow fiber. Accordingly, in some embodiments, it is believed that the use of different flow rates may provide some improvement in longitudinal distribution of the reagent along the length of the bioreactor, e.g., a hollow fiber.
Moreover, it is believed that the continuous addition of wash fluid (starting at step 1014 and ending at step 1042), to create ultrafiltration conditions, further promotes the coating of growth surfaces with the coating reagent. For example, as described above, the ultrafiltration moves the coating reagent toward an inside surface of hollow fiber walls, which may shorten the coating process, in addition to the more complete/uniform distribution of the coating agent provided by the other steps of flow 1000.
As noted above, steps in flow 1000 may be performed for predetermined periods of time. In embodiments, flow 1000 is designed to be performed within a period of time, e.g., 28 minutes, 56 minutes, 60 minutes, 90 minutes, and 120 minutes. For example, in embodiments, the predetermined period of times may be selected so that substantially all (or most) of the steps of flow 1000 may be performed in less than 90 minutes, such as less than 80 minutes, less than 70 minutes, less than 60 minutes, less than 50 minutes, less than 40 minutes, or even less than 30 minutes. In some embodiments, the steps of flow 1000 may be performed in greater than 10 minutes, greater than 20 minutes, greater than 30 minutes, greater than 40 minutes, or greater than 50 minutes. In selecting the periods of time, embodiments provide for each period to be the same in duration. In other embodiments, each period of time may have a different duration. In yet other embodiments, some periods of time may have the same duration while others have different durations. These are merely some examples and flow 1000 is not necessarily limited to being performed during any specific duration.
In one specific embodiment, flow 1000 may provide for performing each of steps 1016 through 1040 in less than 30 minutes. As one example, each of the steps may be performed for 4 minutes resulting in a 28 minute coating process. As yet another example, each of steps 1016 through 1040 may be performed for 8 minutes resulting in a 56 minute coating process. These are merely some non-limiting examples.
Referring now to flow 1200, it starts at step 1204 and proceeds to step 1208 where fluid that includes a reagent may be introduced into a cell expansion system and a bioreactor such as bioreactors 100, 501, and/or 601. In embodiments, step 1208 may be similar to step 808 and involve activating one or more pumps (564, 664) to introduce fluid with the reagent from a bag (562) or connection point (662) into a fluid flow path.
As part of introducing the fluid with the reagent into the cell expansion system, step 1208 may involve optional step 1212, where a wash fluid (e.g., PBS) may be used to chase the reagent from parts of the CES. For example, the wash fluid may move any reagent left behind in an ARC, such as ARC 556/656. The wash fluid may chase any lingering reagent into the bioreactor and/or a fluid flow path associated with the bioreactor e.g., 502/602.
Flow 1200 then passes to step 1214 where a second wash fluid may be introduced into the bioreactor. In embodiments, step 1214 may involve activating a pump, such as pumps 554,654 to introduce the second wash fluid from a bag (562) or connection point (662) into a fluid flow path and into the bioreactor (100, 501, and/or 601). In embodiments, the second wash fluid is introduced to create conditions for ultrafiltration, as described above. Ultrafiltration allows proteins or molecules (e.g., the coating reagent) that are too large to pass through the pores 818 (
Flow 1200 passes to step 1216 where fluid that includes a reagent may be circulated through a bioreactor such as bioreactors 100, 501, and/or 601. In embodiments, step 1216 may involve activating one or more pumps to circulate fluid with the reagent through the bioreactor. For example, an IC circulation pump (e.g., 512 or 612) may be activated to circulate fluid through the IC side of a bioreactor at a first circulation flow rate. In at least one embodiment, fluid may pass through hollow fibers (e.g., the lumen). Step 1216 may involve circulating fluid at a first flow rate. The first flow rate may in embodiments be one of the first flow rates described above with respect to step 1016 (
In some embodiments, step 1216 may involve circulation in a specific direction. In other words, in some embodiments, step 1216 may involve activating a pump such as IC circulation pump (e.g., 512 or 612) in a specific direction, e.g., a counter clockwise or a clockwise direction. As one example, referring now to
Flow 1200 passes to step 1220, where fluid with the reagent is circulated at a second flow rate. In embodiments, the second flow rate may be one of the second flow rates described above with respect to step 1020 (
Flow 1200 then passes to optional step 1224, where fluid with the reagent is circulated at a third flow rate. In embodiments, the third flow rate may be one of the third flow rates described above with respect to step 1024 (
In some embodiments, step 1224 may involve circulation in a specific direction, such as the first direction. Step 1224 may involve activating a pump such as IC circulation pump (e.g., 512 or 612) in a direction, e.g., a counter clockwise or a clockwise. Continuing with the example above, step 1224 may involve activating pump 612 to circulate fluid through path in a counter clock wise direction. That is, fluid may enter through port 601A and exit through port 6018.
Flow 1200 then passes to optional step 1228, where fluid with the reagent is circulated at a fourth flow rate. In embodiments, the fourth flow rate may be one of the fourth flow rates described above with respect to step 1028 (
In some embodiments, step 1228 may involve circulation in a specific direction, such as opposite the first direction. Step 1228 may involve activating a pump such as IC circulation pump (e.g., 512 or 612) in a direction, e.g., a counter clockwise or a clockwise. Continuing with the example above, step 1228 may involve activating pump 612 to circulate fluid through path 602 in a clock wise direction. That is, fluid may enter through port 601B and exit through port 601A.
Flow 1200 then passes to optional step 1232, where fluid with the reagent is circulated at a fifth flow rate. In embodiments, the fifth flow rate may be one of the fifth flow rates described above with respect to step 1032 (
In some embodiments, step 1232 may involve circulation in a specific direction, such as the first direction. Step 1232 may involve activating a pump such as IC circulation pump (e.g., 512 or 612) in a direction, e.g., a counter clockwise or a clockwise. Continuing with the example above, step 1232 may involve activating pump 612 to circulate fluid through path 602 in a counter clock wise direction. That is, fluid may enter through port 601A and exit through port 6018.
Flow 1200 then passes to optional step 1236, where fluid with the reagent is circulated at a sixth flow rate. In embodiments, the sixth flow rate may be one of the sixth flow rates described above with respect to step 1036 (
In some embodiments, step 1236 may involve circulation in a specific direction, such as opposite the first direction. Step 1236 may involve activating a pump such as IC circulation pump (e.g., 512 or 612) in a direction, e.g., a counter clockwise or a clockwise. Continuing with the example above, step 1236 may involve activating pump 612 to circulate fluid through path 602 in a clock wise direction. That is, fluid may enter through port 6018 and exit through port 601A.
Flow 1200 then passes to optional step 1240, where fluid with the reagent is circulated at a seventh flow rate. In embodiments, the seventh flow rate may be one of the seventh flow rates described above with respect to step 1040 (
Flow 1200 then passes to step 1242 where introduction of the second wash fluid into the bioreactor is stopped. In embodiments, step 1242 may involve deactivating a pump, such as pump 554, 654 to stop the introduction of the second wash fluid into the fluid flow path and into the bioreactor (100, 501, and/or 601). In embodiments, stopping the introduction of the second wash fluid stops the process of ultrafiltration.
Flow 1200 then passes to step 1244, where a second fluid, that may not include the reagent, or have a lower concentration of the reagent, may be circulated through the bioreactor. In embodiments, step 1244 may be performed to wash any remaining reagent that has not coated a surface of the bioreactor out of the bioreactor and CES. As noted above, flow 1200 may be part of a larger process such as a process for growing and harvesting cells in a cell expansion system, such as flow 700. Therefore, in embodiments, step 1244 may be implemented as part of steps performed in the larger process, such as step 710 (
Without being bound by theory, it is believed that having steps 1216, 1220, 1224, 1228, 1232, 1236, 1240, 1244, and 1248 circulate at different flow rates, allows the fluid to flow through more of the hollow fibers e.g., 1108 (
At steps 1232 and 1236 (at the flow rates described above), fluid may flow mainly through the hollow fibers in zone 1112, 1116, and 1120 because the rate is slower and the fluid may disperse more. At step 1240 (at the flow rates described above), fluid may flow through the hollow fibers in zones 1112, 1116, 1120, and 1124 because the flow rate is yet slower and fluid may disperse even more. Thus, it is believe that fluid with the reagent may flow into more of the hollow fibers using a sequence of different flow rates, than if a single high flow rate circulation is used.
As noted above, it is also believed that the different flow rates may also affect the longitudinal distribution of the reagent along the bioreactor, e.g., along a hollow fiber. That is, a higher flow rate may allow the reagent to flow further along inside a hollow fiber. For example, at a higher flow rate, the reagent being carried by fluid may reach beyond half the length of the hollow fiber. At a lower flow rate, the reagent being carried by fluid may reach half the length of the hollow fiber. At even a lower flow rate, the reagent being carried by fluid may reach less than half the length of the hollow fiber. Accordingly, in some embodiments, it is believed that the use of different flow rates may provide some improvement in longitudinal distribution of the reagent along the length of the bioreactor, e.g., a hollow fiber. Additionally, with the changing of directions provided for in flow 1200, the reagent may be distributed along the length of the hollow fibers from both sides of a hollow fiber. The combination of flow rate changes and changes in direction, may allow for more even distribution of the reagent along the length of a hollow fiber.
Moreover, it is believed that the continuous addition of wash fluid (starting at step 1214 and ending at step 1242), to create ultrafiltration conditions, further promotes the coating of growth surfaces with the coating reagent. For example, as described above, the ultrafiltration moves the coating reagent toward an inside surface of hollow fiber walls, which may shorten the coating process, in addition to the more complete/uniform distribution of the coating agent provided by the other steps of flow 1200.
As noted above, steps in flow 1200 may be performed for predetermined periods of time. In embodiments, flow 1200 is designed to be performed within a period of time, e.g., relatively quickly. For example, in embodiments, the predetermined period of times may be selected so that substantially all (or most) of the steps of flow 1200 may be performed in less than 90 minutes, such as less than 80 minutes, less than 70 minutes, less than 60 minutes, less than 50 minutes, less than 40 minutes, or even less than 30 minutes. In some embodiments, the steps of flow 800 may be performed in greater than 10 minutes, greater than 20 minutes, greater than 30 minutes, greater than 40 minutes, or greater than 50 minutes. In selecting the periods of time, embodiments provide for each period to be the same in duration. In other embodiments, each period of time may have a different duration. In yet other embodiments, some periods of time may have the same duration while others have different durations. These are merely some examples and flow 1200 is not necessarily limited to being performed during any specific duration.
In one specific embodiment, flow 1200 may provide for performing each of steps 1216 through 1240 in less than 30 minutes. As one example, each of the steps may be performed for 4 minutes resulting in a 28 minute coating process. As yet another example, each of steps 1216 through 1240 may be performed for 8 minutes resulting in a 56 minute coating process. These are merely some non-limiting examples.
Referring now to
As part of introducing the fluid with the reagent into the cell expansion system, step 1304 may involve optional step 1306, where a wash fluid (e.g., PBS) may be used to chase the reagent from parts of the CES. For example, the wash fluid may move any reagent left behind in an ARC, such as ARC 556/656. The wash fluid may chase any lingering reagent into the bioreactor and/or a fluid flow path associated with the bioreactor e.g., 502/602.
Flow 1300 then passes to step 1307 where a second wash fluid may be introduced into the bioreactor. In embodiments, step 1307 may involve activating a pump, such as pumps 554, 654 to introduce the second wash fluid from a bag (562) or connection point (662) into a fluid flow path and into the bioreactor (100, 501, and/or 601). In embodiments, the second wash fluid is introduced to create conditions for ultrafiltration, as described above. Ultrafiltration allows proteins or molecules (e.g., the coating reagent) that are too large to pass through the pores 818 (
Flow 1300 passes to step 1308 which may be performed to orient a bioreactor, e.g. bioreactor 100, 501, and/or 601, to an initial orientation. In embodiments, a bioreactor may already be oriented in an initial orientation, in which case step 1308 would not be performed. When performed, step 1308 may in some embodiments be performed by one or rotation mechanisms that may include one or more motors, gears, connectors, shafts, etc. that rotate the bioreactor to a first orientation. In embodiments, the orientation may be an initial horizontal orientation.
Referring now to
Flow 1300 passes from optional step 1308 to step 1310 where fluid that includes a reagent may be circulated through a bioreactor such as bioreactors 100, 501, and/or 601. In embodiments, step 1310 may involve activating one or more pumps to circulate fluid with the reagent through the bioreactor. For example, an IC circulation pump (e.g., 512 or 612) may be activated to circulate fluid through the IC side of a bioreactor at a first circulation flow rate.
In at least one embodiment, fluid may pass through hollow fibers (e.g., the lumen). Step 1310 may involve circulating fluid at a first flow rate. The first flow rate may in embodiments be one of the first flow rates described above with respect to step 1016 (
In other embodiments, fluid with the reagent may be circulated through the EC side of the bioreactor. Step 1310 may therefore, in embodiments, involve activating an EC circulation pump (e.g., 528 or 628) to circulate fluid through the EC side of bioreactor at a first circulation flow rate.
In embodiments, the reagent may be any protein, nutrient, or other material that is useful in creating conditions for expansion of cells. As described above, the reagent may be a protein that coats a surface in the bioreactor to which cell (e.g., adherent cells) may attach and grow. As one example, a glycoprotein (such as fibronectin, collagen, cryoprecipitate, etc.) may be the reagent that is circulated through a bioreactor, e.g., through the IC circuit of the bioreactor, to coat an inside surface of hollow fibers. The coating may promote the attachment of adherent cells that may later be added to the bioreactor and expanded in the bioreactor. This is merely one example and flow 1300 is not limited to this application.
In some embodiments, step 1310 may involve circulation in a specific direction. In other words, in some embodiments, step 1310 may involve activating a pump such as IC circulation pump (e.g., 512 or 612) in a first direction 1312, e.g., a counter clockwise or a clockwise direction. As one example, referring now to
Flow 1300 passes from step 1310 to step 1314 where the bioreactor is maintained in the first orientation, e.g., a horizontal orientation (
After step 1314, flow 1300 may pass to optional step 1316, where the bioreactor is rotated to a second orientation. In embodiments, the second orientation may be a horizontal orientation that is about 180 degrees from the original (e.g., first) orientation (e.g.,
Flow passes to step 1318, wherein fluid with the reagent is circulated at a second flow rate, which may be less than the first flow rate. In embodiments, the second flow rate may be one of the second flow rates described above with respect to step 1020 (
In some embodiments, step 1318 may involve circulation in a specific direction. In other words, in some embodiments, step 1318 may involve activating a pump such as IC circulation pump (e.g., 512 or 612) in a second direction 1320, e.g., a counter clockwise or a clockwise direction. Continuing with the example above, referring
Flow 1300 passes from step 1318 to optional step 1322 where the bioreactor is maintained in the second orientation, e.g., a second horizontal orientation (
After optional step 1322, flow 1300 may pass to optional step 1324, where the bioreactor is rotated back to the first orientation. In embodiments, the first orientation may be a horizontal orientation that is about the same as the original (e.g., first) orientation (e.g.,
Flow passes to step 1326, wherein fluid with the reagent is circulated at a third flow rate, which may be less than the second flow rate. In embodiments, the third flow rate may be one of the third flow rates described above with respect to step 1024 (
In some embodiments, step 1326 may involve circulation in a specific direction. In other words, in some embodiments, step 1326 may involve activating a pump such as IC circulation pump (e.g., 512 or 612) in the first direction 1328 e.g., a counter clockwise or a clockwise direction. Continuing with the example above, referring to
Flow 1300 passes from step 1326 to optional step 1330 where the bioreactor is maintained in the first orientation, e.g., a first horizontal orientation (
After optional step 1326, flow 1300 may pass to optional step 1332, where the bioreactor is rotated back to the second orientation. In embodiments, the second orientation may be a horizontal orientation that is about 180 degrees from the first orientation (e.g.,
Flow 1300 then passes to optional step 1334, where fluid with the reagent is circulated at a fourth flow rate, which may be less than the third flow rate. In embodiments, the fourth flow rate may be one of the fourth flow rates described above with respect to step 1028 (
In some embodiments, step 1334 may involve circulation in a specific direction. In other words, in some embodiments, step 1334 may involve activating a pump such as IC circulation pump (e.g., 512 or 612) in the second direction 1336 e.g., a counter clockwise or a clockwise direction. Continuing with the example above, referring to
Flow 1300 passes from step 1334 to optional step 1338 where the bioreactor is maintained in the second orientation, e.g., a second horizontal orientation (
After optional step 1338, flow 1300 may pass to optional step 1340, where the bioreactor is rotated back to the first orientation. In embodiments, the first orientation may be a horizontal orientation that is about the same as the original (e.g., first) orientation (e.g.,
Flow passes to step 1342, wherein fluid with the reagent is circulated at a fifth flow rate, which may be less than the fourth flow rate. In embodiments, the fifth flow rate may be one of the fifth flow rates described above with respect to step 1032 (
In some embodiments, step 1342 may involve circulation in a specific direction. In other words, in some embodiments, step 1342 may involve activating a pump such as IC circulation pump (e.g., 512 or 612) in the first direction 1344 e.g., a counter clockwise or a clockwise direction. Continuing with the example above, referring to
Flow 1300 passes from step 1342 to optional step 1346 where the bioreactor is maintained in the first orientation, e.g., a first horizontal orientation (
After optional step 1346, flow 1300 may pass to optional step 1348, where the bioreactor is rotated back to the second orientation. In embodiments, the second orientation may be a horizontal orientation that is about 180 degrees from the original (e.g., first) orientation (e.g.,
Flow 1300 then passes to optional step 1350, where fluid with the reagent is circulated at a sixth flow rate, which may be less than the fifth flow rate. In embodiments, the fifth flow rate may be one of the fifth flow rates described above with respect to step 1032 (
In some embodiments, step 1350 may involve circulation in a specific direction. In other words, in some embodiments, step 1350 may involve activating a pump such as IC circulation pump (e.g., 512 or 612) in the second direction 1352 e.g., a counterclockwise or a clockwise direction. Continuing with the example above, referring to
Flow 1300 passes from step 1350 to optional step 1354 where the bioreactor is maintained in the second orientation, e.g., a second horizontal orientation (
After optional step 1346, flow 1300 may pass to optional step 1348, where the bioreactor is rotated back to the first orientation. In embodiments, the first orientation may be a horizontal orientation that is substantially the same as the original (e.g., first) orientation (e.g.,
Flow passes to step 1358, wherein fluid with the reagent is circulated at a seventh flow rate, which may be less than the sixth flow rate. In embodiments, the seventh flow rate may be one of the fifth flow rates described above with respect to step 1040 (
In some embodiments, step 1358 may involve circulation in a specific direction. In other words, in some embodiments, step 1358 may involve activating a pump such as IC circulation pump (e.g., 512 or 612) in the first direction 1360 e.g., a counter clockwise or a clockwise direction. Continuing with the example above, referring to
Flow 1300 passes from step 1358 to optional step 1362 where the bioreactor is maintained in the first orientation, e.g., a first horizontal orientation (
Flow 1300 then passes to step 1363 where introduction of the second wash fluid into the bioreactor is stopped. In embodiments, step 1363 may involve deactivating a pump, such as pump 554, 654 to stop the introduction of the second wash fluid into the fluid flow path and into the bioreactor (100, 501, and/or 601). In embodiments, stopping the introduction of the second wash fluid stops the process of ultrafiltration.
Flow 1300 then passes to step 1364, where a second fluid, that may not include the reagent, or have a lower concentration of the reagent, may be circulated through the bioreactor. In embodiments, step 1364 may be performed to wash any remaining reagent that has not coated a surface of the bioreactor out of the bioreactor and CES. As noted above, flow 1300 may be part of a larger process such as a process for growing and harvesting cells in a cell expansion system, such as flow 700. Therefore, in embodiments, step 1364 may be implemented as part of steps performed in the larger process, such as step 710 (
Without being bound by theory, it is believed that having steps 1310, 1318, 1326, 1334, 1342, 1350, and 1358 circulate at different flow rates, allows the fluid to flow through more of the hollow fibers e.g., 1108 (
At steps 1342 and 1350 (at the flow rates described above), fluid may flow mainly through the hollow fibers in zone 1112, 1116, and 1120 because the rate is slower and the fluid may disperse more. At step 1358 (at the flow rates described above), fluid may flow through the hollow fibers in zones 1112, 1116, 1120, and 1124 because the flow rate is yet slower and fluid may disperse even more. Thus, it is believe that fluid with the reagent may flow into more of the hollow fibers using a sequence of different flow rates, than if a single high flow rate circulation is used.
As noted above, it is also believed that the different flow rates may also affect the longitudinal distribution of the reagent along the bioreactor, e.g., along a hollow fiber. That is, a higher flow rate may allow the reagent to flow further along inside a hollow fiber. For example, at a higher flow rate, the reagent being carried by fluid may reach beyond half the length of the hollow fiber. At a lower flow rate, the reagent being carried by fluid may reach half the length of the hollow fiber. At even a lower flow rate, the reagent being carried by fluid may reach less than half the length of the hollow fiber. Accordingly, in some embodiments, it is believed that the use of different flow rates may provide some improvement in longitudinal distribution of the reagent along the length of the bioreactor, e.g., a hollow fiber. Additionally, with the changing of directions provided for in flow 1300, the reagent may be distributed along the length of the hollow fibers from both sides of a hollow fiber. The combination of flow rate changes and changes in direction, may allow for more even distribution of the reagent along the length of a hollow fiber.
Furthermore, flow 1300 provides for rotation of the bioreactor, as described above. It is also believed that rotation of the bioreactor, in addition to changes in direction and flow rates, provides a process where the reagent may be distributed/coated on hollow fibers more completely and/or uniformly.
Moreover, it is believed that the continuous addition of wash fluid (starting at step 1307 and ending at step 1363), to create ultrafiltration conditions, further promotes the coating of growth surfaces with the coating reagent. For example, as described above, the ultrafiltration moves the coating reagent toward an inside surface of hollow fiber walls, which may shorten the coating process, in addition to the more complete/uniform distribution of the coating agent provided by the other steps of flow 1300.
As noted above, steps in flow 1300 may be performed for predetermined periods of time. In embodiments, flow 1300 is designed to be performed within a period of time, e.g., relatively quickly. For example, in embodiments, the predetermined period of times may be selected so that substantially all (or most) of the steps of flow 1300 may be performed in less than 90 minutes, such as less than 80 minutes, less than 70 minutes, less than 60 minutes, less than 50 minutes, less than 40 minutes, or even less than 30 minutes. In some embodiments, the steps of flow 800 may be performed in greater than 10 minutes, greater than 20 minutes, greater than 30 minutes, greater than 40 minutes, or greater than 50 minutes. In selecting the periods of time, embodiments provide for each period to be the same in duration. In other embodiments, each period of time may have a different duration. In yet other embodiments, some periods of time may have the same duration while others have different durations. These are merely some examples and flow 1300 is not necessarily limited to being performed during any specific duration.
In one specific embodiment, flow 1300 may provide for performing all of steps 1310, 1318, 1326, 1334, 1342, 1350, and 1358 in less than 30 minutes. As one example, each of the steps may be performed for 4 minutes resulting in a 28 minute coating process. As yet another example, each of steps 1310, 1318, 1326, 1334, 1342, 1350, and 1358 may be performed for 8 minutes resulting in a 56 minute coating process. These are merely some non-limiting examples.
Turning now to
In embodiments, the first circulation flow rate may be a relatively high flow rate. In embodiments, the first circulation flow rate may be less than about 500 ml/min, less than about 400 ml/min, or even less than about 300 ml/min. In other embodiments, the first circulation rate may be greater than about 50 ml/min, greater than about 100 ml/min, or even greater than about 150 ml/min. In one embodiment, the first circulation flow rate is between about 100 ml/min and about 300 ml/min, such as about 200 ml/min.
Step 1408 may in some embodiments involve also rotating the bioreactor in a particular sequence to facilitate distribution of the cells through the bioreactor and circulation paths of the CES to which the bioreactor may be fluidly associated. In other embodiments, the circulating step 1408 may involve rotating the bioreactor for some periods of time, but maintaining the bioreactor stationary for other periods of time.
After step 1408, the fluid circulation rate is reduced at step 1412. The circulation rate may be reduced to about zero (0) ml/min, or in other embodiments may be reduced to a rate that is above zero (0) ml/min but still allows cells to settle and attach to the bioreactor e.g., an inside surface of hollow fibers of bioreactor. In embodiments, step 1412 may involve stopping or turning off one or more pumps used in step 1408 to circulate the fluid.
Flow passes from step 1412 to optional step 1416, which may be performed to orient a bioreactor, e.g. bioreactor to an initial orientation. In embodiments, a bioreactor may already be oriented in an initial orientation, whereby step 1416 would not be performed. When performed, step 1416 may in some embodiments be performed by one or more motors.
Referring now to
Flow passes from 1416, to step 1420 where the bioreactor is maintained at a first orientation to allow cells to settle and in some embodiments attach to a first portion of bioreactor 300. Step 1420 may be performed for a first predetermined period of time.
Referring now to
In embodiments, with the bioreactor 300 in the first horizontal orientation (
In some embodiments, the first predetermined period of time may be long enough in duration to allow the cells to settle and attach to portion 2008 and 2108. In these embodiments, the cells may only need to travel the distance of the inner diameter of hollow fiber 2000 or 2100. For example, in embodiments where the hollow fiber has an inner diameter of between about 150 microns and about 300 microns, the first predetermined period of time may be less than about 20 minutes, less than about 15 minutes, or even less than about 10 minutes. In other embodiments, the first predetermined period of time may be greater than about 1 minute, greater than about 2 minutes, greater than about 3 minutes, or even greater than about 4 minutes. In one embodiment, the first period of time may be between about 3 minutes and about 8 minutes, such as about 5 minutes.
After step 1420, flow passes to step 1424, where the bioreactor 300 is rotated to a second horizontal orientation that is about 180 degrees from the first horizontal orientation. As shown in
In some embodiments, flow 1400 will pass from step 1424 to step 1436 where the bioreactor 300 is maintained in the second horizontal orientation (
In some embodiments, flow 1400 may include optional steps 1428 and 1432 prior to proceeding to step 1436. Similar to step 1408, step 1428 provides for circulating fluid through the bioreactor 300. In embodiments, step 1428 may involve activating one or more pumps to circulate fluid through the bioreactor 300. As noted above, an IC circulation pump (e.g., 512,612) may be activated to circulate fluid through the IC side of bioreactor 300 at a second circulation flow rate. In at least one embodiment, fluid carrying the cells may pass through hollow fibers of the bioreactor 300. In other embodiments, cells may be loaded into the EC side of the bioreactor 300 and have the fluid carrying the cells. In these embodiments, an EC circulation pump (e.g., 528, 628) may be activated to circulate fluid through the EC side of bioreactor 300 at a second circulation flow rate.
In embodiments, the second circulation flow rate may be less than the first circulation rate. In embodiments, the second circulation flow rate may be less than about 400 ml/min, less than about 300 ml/min, or even less than about 200 ml/min. In other embodiments, the second circulation rate may be greater than about 25 ml/min, greater than about 500 ml/min, or even greater than about 75 ml/min. In one embodiment, the second circulation flow rate is between about 50 ml/min and about 150 ml/min, such as about 100 ml/min.
In some embodiments, step 1428 may also involve circulation in a different direction than the circulation performed in step 1408, in other words, in some embodiments, step 708 may involve circulating fluid in a counter clockwise direction (see IC loop in
Optional step 1428 may in some embodiments involve also rotating the bioreactor 300 in a particular sequence to facilitate distribution of the cells through the bioreactor 300 and circulation paths of the CES to which the bioreactor 300 may be fluidly associated. In other embodiments, the circulating step 1428 may involve rotating the bioreactor 300 for some periods of time, but maintaining the bioreactor 300 stationary for other periods of time.
After optional step 1428, the fluid circulation rate is once again reduced at step 1432. The circulation rate may be reduced to about zero (0) ml/min, or in other embodiments may be reduced to a rate that is above zero (0) m/min but still allows cells to settle and attach to the bioreactor 300, e.g., an inside surface of hollow fibers of bioreactor 300. In embodiments, step 1432 may involve stopping or turning off one or more pumps used in step 1428 to circulate the fluid.
Referring once again to step 1436, maintaining the bioreactor in the second horizontal orientation allows cells to settle on portion 2012 (or 2112 in
In some embodiments, the second predetermined period of time may be long enough in duration allow the cells to settle and attach to portion 2012 (or 2112 in
In some embodiments, after step 1436, flow 1400 may pass to step 1472 where cells are expanded. Step 1472 may involve a number of substeps, such as circulating fluid into the bioreactor to feed and provide nutrients to the cells attached in the bioreactor. As can be appreciated, step 1472 may also involve providing oxygen to the cells so that they may multiply. Several other parameters in the bioreactor may be controlled in order to optimize the expansion, i.e. growth of the cells. In some embodiments, step 1472 may include circulating fluid to feed the cells for about 24 hours, about 36 hours, about 48 hours, about 60 hours, or even about 72 hours. In some embodiments, the feeding of the cells as part of step 1472 may be performed for less than about 120 hours, less than about 108 hours, less than about 96 hours, less than about 84 hours, or even less than about 72 hours.
In other embodiments, flow 1400 may pass to step 1440, where the bioreactor 300 is rotated back to its original first horizontal orientation.
In other embodiments, flow 1400 passes from step 1440 to step 1444, or in other embodiments, flow may pass directly from step 1436, to step 1444 (when no additional rotation is performed), where fluid is again circulated but at a third circulation flow rate. Similar to steps 1408 and 1428, fluid is circulated through the bioreactor 300. In embodiments, step 1444 may involve activating one or more pumps to circulate fluid through the bioreactor 300. As noted above, an IC circulation pump (e.g., 512 or 612) may be activated to circulate fluid through the IC side of bioreactor 300 at a third circulation flow rate. In at least one embodiment, fluid carrying the cells may pass through (the lumen of) hollow fibers of the bioreactor 300. In other embodiments, cells may be loaded into the EC side of the bioreactor 300 and have the fluid carrying the cells. In these embodiments, an EC circulation pump (e.g., 528, 628) may be activated to circulate fluid through the EC side of bioreactor 300 at the third circulation flow rate.
In embodiments, the third circulation flow rate may be less than the second circulation rate. In embodiments, the third circulation flow rate may be less than about 200 ml/min, less than about 150 ml/min, or even less than about 100 ml/min. In other embodiments, the third circulation rate may be greater than about 10 ml/min, greater than about 20 ml/min, or even greater than about 30 ml/min. In one embodiment, the third circulation flow rate is between about 20 ml/min and about 100 ml/min, such as about 50 ml/min.
In some embodiments, step 1444 may also involve circulation in a different direction than the circulation performed in step 1428. In other words, in some embodiments, step 1428 may involve circulating fluid in a clockwise direction. In some embodiments, the circulation at step 1444 may be similar to step 1408 and be in a counter clockwise direction (see IC loop in
Optional step 1444 may in some embodiments involve also rotating the bioreactor 300 in a particular sequence to facilitate distribution of the cells through the bioreactor 300 and circulation paths of the CES to which the bioreactor 300 may be fluidly associated. In other embodiments, the circulating step 1444 may involve rotating the bioreactor 300 for some periods of time, but maintaining the bioreactor 300 stationary for other periods of time.
Flow passes from 1444 to step 1448, where, the fluid circulation rate is once again reduced. The circulation rate may be reduced to about zero (0) ml/min, or in other embodiments may be reduced to a rate that is above zero (0) ml/min but still allows cells to settle and attach to the bioreactor 300, e.g., an inside surface of hollow fibers of bioreactor 300. In embodiments, step 1448 may involve stopping or turning off one or more pumps used in step 1444 to circulate the fluid.
From step 1448, flow passes to step 1452 where the bioreactor is maintained in a horizontal orientation. In those embodiments that include step 1444 (rotate to first orientation), step 1452 will involve maintaining the first horizontal orientation. In those embodiments that do not include the rotation of step 1440, step 1452 will involve maintaining the second horizontal orientation. In any case, step 1452 is performed to allow cells to settle again, such as on portion 2108 (See
In some embodiments, the third predetermined period of time may be long enough in duration to allow the cells to settle and attach to portion 2108. In these embodiments, the cells may only need to travel the distance of the inner diameter of hollow fiber 2100. For example, in embodiments where the hollow fiber 2100 has an inner diameter of between about 150 microns and about 300 microns, the third predetermined period of time may be less than about 20 minutes, less than about 15 minutes, or even less than about 10 minutes. In other embodiments, the third predetermined period of time may be greater than about 1 minute, greater than about 2 minutes, greater than about 3 minutes, or even greater than about 4 minutes. In one embodiment, the third period of time may be between about 3 minutes and about 8 minutes, such as about 5 minutes.
In some embodiments, flow 1400 may pass from step 1452 to step 1472 where the cells are expanded.
In other embodiments, as described below, flow 1400 may include additional rotation (1456), circulation (1460), reduce circulation (1464), and maintain orientation (1468) steps before moving to step 1472 where cells are expanded. In these embodiments, flow 1400 may pass from step 1452 to step 1456, where the bioreactor 300 is rotated back to the second horizontal orientation, if it was rotated at step 1440 to the first horizontal orientation.
Flow 1400 passes to step 1460 where fluid is again circulated but at a fourth circulation flow rate. Similar to steps 1408, 1428, and 1444, fluid is circulated through the bioreactor 300. In embodiments, step 1444 may involve activating one or more pumps to circulate fluid through the bioreactor 300, as noted above, an IC circulation pump (e.g., 512, 612) may be activated to circulate fluid through the IC side of bioreactor 300 at a fourth circulation flow rate. In at least one embodiment, fluid carrying the cells may pass through hollow fibers of the bioreactor 300. In other embodiments, cells may be loaded into the EC side of the bioreactor 300 and have the fluid carrying the cells. In these embodiments, an EC circulation pump (e.g., 528, 628) may be activated to circulate fluid through the EC side of bioreactor 300 at the fourth circulation flow rate.
In embodiments, the fourth circulation flow rate may be less than the third circulation rate. In embodiments, the fourth circulation flow rate may be less than about 100 ml/min, less than about 75 ml/min, or even less than about 50 ml/min. In other embodiments, the fourth circulation rate may be greater than about 5 ml/min, greater than about 10 ml/min, or even greater than about 15 ml/min. In one embodiment, the fourth circulation flow rate is between about 15 ml/min and about 35 ml/min, such as about 25 ml/min.
In some embodiments, step 1460 may also involve circulation in a different direction than the circulation performed in step 1444. In other words, in some embodiments, step 1444 may involve circulating fluid in a counter clockwise direction. In some embodiments, the circulation at step 1460 may be similar to step 1428 and be in a clockwise direction. In other words, the circulation at step 1460 may flow opposite to the circulation at step 1444, and the same as the direction of circulation of step 1428. In other embodiments, the circulation in steps 1408, 1428, 1444 and 1460 may flow in the same direction, clockwise or counter clockwise.
Step 1460 may in some embodiments involve also rotating the bioreactor 300 in a particular sequence to facilitate distribution of the cells through the bioreactor 300 and circulation paths of the CES to which the bioreactor 300 may be fluidly associated. In other embodiments, the circulating step 1460 may involve rotating the bioreactor 300 for some periods of time, but maintaining the bioreactor 300 stationary for other periods of time.
Flow passes from 1460 to step 1464, where, the fluid circulation rate is once again reduced. The circulation rate may be reduced to about zero (0) ml/min, or in other embodiments may be reduced to a rate that is above zero (0) ml/min but still allows cells to settle and attach to the bioreactor 300, e.g., an inside surface of hollow fibers of bioreactor 300. In embodiments, step 1464 may involve stopping or turning off one or more pumps used in step 1460 to circulate the fluid.
From step 1464, flow passes to step 1468 where the bioreactor is maintained in the second horizontal orientation to allow cells to settle on for example portion 2112 again (see
In some embodiments, the fourth predetermined period of time may be long enough in duration to allow the cells to settle and attach. In these embodiments, the cells may only need to travel the distance of the inner diameter of the hollow fiber, e.g., fiber 2100. For example, in embodiments where the hollow fiber 2100 has an inner diameter of between about 150 microns and about 300 microns, the fourth predetermined period of time may be less than about 20 minutes, less than about 15 minutes, or even less than about 10 minutes. In other embodiments, the fourth predetermined period of time may be greater than about 1 minute, greater than about 2 minutes, greater than about 3 minutes, or even greater than about 4 minutes. In one embodiment, the fourth period of time may be between about 3 minutes and about 8 minutes, such as about 5 minutes.
After step 1468, flow 1400 passes to step 1472 where the cells settled and attached to the bioreactor 300, e.g., to hollow fibers of the bioreactor, are expanded, i.e., multiplied. Flow 1400 then ends at 1476.
Without being bound by theory, it is believe that in embodiments, the cell expansion is improved if the steps of flow 1400 are performed. It is believed that these embodiments help to ensure that more portions of the bioreactor, e.g., surface of hollow fibers in the bioreactor, are seeded with cells prior to cell expansion. This may provide for more cells to initially be seeded, and ultimately may improve cell yield and reduce cell doubling time, as compared to conventional processes.
Although flow 1400 includes specific number of steps that provide for rotating, circulating, reducing circulation, and maintaining the orientation of the bioreactor, other embodiments are not limited to these specific number of steps. In other embodiments, even after step 1468, the bioreactor may be rotated again, circulation can be restarted again, followed by another period of reducing circulation to allow cells to settle and maintain the orientation for a period of time to allow cells to attach to portion of a bioreactor. These steps may be performed any number of times. In embodiments, each time the circulation is restarted, it is at a lower rate than the previous circulation. In other embodiments, the circulation rates may be the same each time circulation is started. In yet other embodiments, the direction of circulation may be changed, with circulation in a first direction, followed by stopping the circulation to allow the cells to settle and attach, circulation in a direction opposite the first direction (clockwise vs. counter clockwise) and again stopping the circulation to allow the cells to settle.
Referring back to
It is believed that having steps 1408, 1428, 1444 and 1452 circulate at different flow rates, allows the fluid to flow through more of the hollow fibers 1108 than if just a single flow rate would be used. In one embodiment of a process that follows flow chart 1400, at step 1408 (at the flow rates described above), fluid may flow through the hollow fibers in zone 1112. At step 1428 (at the flow rates described above), fluid may flow through the hollow fibers in both zones 1112 and 1116 because the rate is slower and the fluid may disperse more. At step 1444 (at the flow rates described above), fluid may flow through the hollow fibers in zones 1112, 1116, and 1120 because the flow rate is yet slower and fluid may disperse even more. At step 1452 (at the flow rates described above), fluid may flow through the hollow fibers in all the zones 1112, 1116, 1120 and 1124 because the flow rates are even slower and the fluid may disperse through all of the fibers in the various zones. Thus, it is believe that fluid with the cells may flow into more of the hollow fibers using a sequence of different flow rates, than if a single high flow rate circulation is used.
Furthermore, it is also believed that the different flow rates may also affect the longitudinal distribution of cells along the bioreactor, e.g., along a hollow fiber. That is, a higher flow rate may allow cells to flow further along inside a hollow fiber. For example, at a higher flow rate, a cell being carried by fluid may reach beyond half the length of the hollow fiber. At a lower flow rate, a cell being carried by fluid may reach half the length of the hollow fiber. At even a lower flow rate, a cell being carried by fluid may reach less than half the length of the hollow fiber. Accordingly, in some embodiments, it is believed that the use of different flow rates may provide some improvement in longitudinal distribution of cells along the length of the bioreactor, e.g., a hollow fiber.
Referring now to
From step 2208, flow 2200 passes to steps 2212 where a bulls-eye cell load process is performed on the CES (e.g., CES 500 and/or CES 600) to load cells into the bioreactor (bioreactors 501, 601). In embodiments, step 2212 may involve performing steps of one or more of the processes described above with respect to flow 1400, which may be referred to as a bulls-eye cell loading process. As described in detail above, flow 1400 provides for changing flow rates, changing direction of flows, and/or rotating of a bioreactor to improve the distribution of cells loaded/attached in a bioreactor. As described above, changing flow rates, changing direction of flows, and/or rotating of a bioreactor may allow cells to be more uniformly distributed on interior surfaces of hollow fibers (in a hollow fiber bioreactor).
After step 2212, flow passes to step 2216 where cell are expanded. In embodiments, the expanding of cells may involve a number of steps. For example, step 2216 may involve performing one or more of the steps described above with respect to step 718 in flow 700 (
At step 2220 cells expanded at step 2216 are harvested. In embodiments, the harvesting of cells may involve a number of steps. For example, step 2220 may involve performing one or more of the steps described above with respect to step 722 in flow 700 (
With respect to the processes illustrated in
Examples and further description of tasks and protocols, including custom tasks and pre-programmed tasks, for use with a cell expansion system are provided in U.S. patent application Ser. No. 13/269,323 (“Configurable Methods and Systems of Growing and Harvesting Cells in a Hollow Fiber Bioreactor System,” filed Oct. 7, 2011, now U.S. Pat. No. 9,725,689) and U.S. patent application Ser. No. 13/269,351 (“Customizable Methods and Systems of Growing and Harvesting Cells in a Hollow Fiber Bioreactor System,” filed Oct. 7, 2011, now U.S. Pat. No. 9,677,042), which applications are hereby incorporated by reference herein in their entireties for all that they teach and for all purposes.
Next,
The computing system 2300 may include a user interface 2302, a processing system 2304, and/or storage 2306. The user interface 2302 may include output device(s) 2308, and/or input device(s) 2310 as understood by a person of skill in the art. Output device(s) 2308 may include one or more touch screens, in which the touch screen may comprise a display area for providing one or more application windows. The touch screen may also be an input device 2310 that may receive and/or capture physical touch events from a user or operator, for example. The touch screen may comprise a liquid crystal display (LCD) having a capacitance structure that allows the processing system 2304 to deduce the location(s) of touch event(s), as understood by those of skill in the art. The processing system 2304 may then map the location of touch events to UI elements rendered in predetermined locations of an application window. The touch screen may also receive touch events through one or more other electronic structures, according to embodiments. Other output devices 2308 may include a printer, speaker, etc. Other input devices 2310 may include a keyboard, other touch input devices, mouse, voice input device, etc., as understood by a person of skill in the art.
Processing system 2304 may include a processing unit 2312 and/or a memory 2314, according to embodiments of the present disclosure. The processing unit 2312 may be a general purpose processor operable to execute instructions stored in memory 2314. Processing unit 2312 may include a single processor or multiple processors, according to embodiments. Further, in embodiments, each processor may be a multi-core processor having one or more cores to read and execute separate instructions. The processors may include general purpose processors, application specific integrated circuits (ASICs), field programmable gate arrays (FPGAs), other integrated circuits, etc., as understood by a person of skill in the art.
The memory 2314 may include any short-term or long-term storage for data and/or processor executable instructions, according to embodiments. The memory 2314 may include, for example, Random Access Memory (RAM), Read-Only Memory (ROM), or Electrically Erasable Programmable Read-Only Memory (EEPROM), as understood by a person of skill in the art. Other storage media may include, for example, CD-ROM, tape, digital versatile disks (DVD) or other optical storage, tape, magnetic disk storage, magnetic tape, other magnetic storage devices, etc., as understood by a person of skill in the art.
Storage 2306 may be any long-term data storage device or component. Storage 2306 may include one or more of the systems described in conjunction with the memory 2314, according to embodiments. The storage 2306 may be permanent or removable. In embodiments, storage 2306 stores data generated or provided by the processing system 2304.
Results for some examples of protocols/methods/processes that may be used with a cell expansion system, such as CES 500 (
It is noted that the example protocols/methods/processes are provided for illustrative purposes and are not intended to limit other embodiments, which may include different or additional steps, parameters, or other features. The example protocols/methods/processes, including the steps (and any sub-steps), may be performed automatically in some embodiments, such as by a processor executing custom tasks or pre-programmed tasks stored in memory. In other embodiments, the steps (and any sub-steps) may be performed through the combination of automated and manual execution of operations. In further embodiments, the steps (and any sub-steps) may be performed by an operator(s) or user(s) or through other manual means.
Some examples provide example data from embodiments providing for the expansion of cells using various coating procedures, various cell loading procedures, various coating materials (e.g., cryoprecipitate (CPPT), fibronectin (FN)), and/or combination(s) of such procedures and/or materials. Such procedures include, for example: positive ultrafiltration coating procedure; positive ultrafiltration coating procedure with a bulls-eye (BE) cell load procedure; positive ultrafiltration coating procedure with a load cells with uniform suspension (LWUS) cell loading procedure; overnight coating with cryoprecipitate; overnight coating with fibronectin; bulls-eye coating procedure; 28-minute bulls-eye coating procedure; etc. Examples and further description of a bulls-eye coating procedure(s) are provided in an application U.S. patent application Ser. No. 15/616,745, now U.S. Pat. No. 10,577,575, entitled. “Coating a Bioreactor,” filed on Jun. 7, 2017, which similar to the present application, also claims priority to U.S. Provisional Application Ser. No. 62/347,012, entitled “Coating a Bioreactor,” and filed on Jun. 7, 2016. Examples of other coating processes/steps that, in embodiments, may be utilized in combination with the embodiments described herein are described in U.S. patent application Ser. No. 15/616,635, entitled “METHODS AND SYSTEMS FOR COATING A CELL GROWTH SURFACE,” filed Jun. 7, 2017, which similar to the present application also claims priority to U.S. Provisional Patent Application No. 62/347,025, entitled “GROWTH SURFACE COATING,” filed Jun. 7, 2016. These applications are hereby incorporated by reference in their entireties for all that they teach and for all purposes. As described above, examples and further description of a bulls-eye cell loading procedure(s) are provided in U.S. patent application Ser. No. 14/542,276 (U.S. Pat. No. 9,617,506), entitled, “Expanding Cells in a Bioreactor,” issued on Apr. 11, 2017, which is hereby incorporated by reference herein in its entirety for all that it teaches and for all purposes.
Below is an example of a protocol that may be used for implementing embodiments of flows 1000, 1200, and/or 1300 on CES systems such as CES 500, 600. Although specific settings are shown and described below, other embodiments may provide for different values.
Day: 0 Bulls-Eye Coat Bioreactor
Purpose: coats the bioreactor membrane with a reagent.
Table 24 describes the bags of solution attached to each line when performing Coat Bioreactor. These solutions and corresponding volumes are based on some settings for this task.
Coat Bioreactor Pathway: Task>System Management>Coat Bioreactor
Example results of expanding cells using a coating procedure(s) with, for example, the above methods 800, 1000, and/or 1100 and/or with systems 500, 600, are shown in graph 1600 of
For Donor 1 and Donor 2, 5×106 MSC may be loaded into a bioreactor, e.g., bioreactor 501, 601, preconditioned with cell culture media comprised of αMEM+GlutaMAX (Gibco CAT #32561102) and 10% FBS (Hyclone CAT #SH30070.03). Donor 1 MSC may be cultured for 6.8 days and Donor 2 MSC may be cultured for 6.9 days. For Donor 1, n=1 (where n=number of machines or CESs, e.g., QUANTUM® Systems) for both overnight-coated and 10-minute coated bioreactors. For Donor 2, n=1 for the overnight-coated CES, e.g., QUANTUM® System, and n=2 for the two 10-minute coated CESs, e.g., QUANTUM® Systems.
Harvest yields for Donor 1 QUANTUM® System runs may both be observed to be 1.93×108 MSC. For example, overnight coating with load with uniform suspension cell loading procedure (LWUS) may yield 193×106 MSC 1604; and 10-minute ultrafiltration coating with load with uniform suspension cell loading procedure (LWUS) may yield 193×106 MSC 1608. To confirm efficacy of the 10-minute coating technique with other cell load protocols, an additional comparison may be made between QUANTUM® Systems loaded using the bulls-eye cell loading procedure (BullsEye Load). The Donor 1 MSC yield for the Overnight coated with bulls-eye cell loading may be observed to be 223×106 MSC 1612, and MSC yield for the 10-minute ultrafiltration coat with bulls-eye cell loading procedure (BullsEye Load) may be observed to be 215×106 MSC 1616. The Donor 2 MSC expansion may be observed to yield 191×106 MSC 1620 from the Overnight coated QUANTUM® System (n=1) with load with uniform suspension cell loading procedure (LWUS), and 205×106 MSC 1624 and 193×106 MSC 1628, respectively, for the two runs of 10-minute ultrafiltration coated QUANTUM® Systems (n=2) with load with uniform suspension cell loading procedure (LWUS).
Example results (not shown in
Example results of expanding cells by coating a cell growth surface of a cell expansion system, such as CES 500 (
As shown in graph 1700 of
These example yields are compared in
Example results of expanding cells by coating a cell growth surface of a cell expansion system, such as CES 500 (
The Overnight coating procedure with bulls-eye cell loading procedure (BullsEye) may outperform the following: the Overnight coating procedure with load with uniform suspension cell loading procedure (LWUS); the 28-minute bulls-eye coating (28 min BE) procedure with load with uniform suspension cell loading procedure (LWUS); the 28-minute bulls-eye coating (28 min BE) procedure with bulls-eye cell loading procedure (BullsEye); the 10-minute ultrafiltration coating procedure (10 min UF) with load with uniform suspension cell loading procedure (LWUS); and the 10-minute ultrafiltration coating procedure (10 min UF) with bulls-eye cell loading procedure (BullsEye). As shown in graph 1800 of
These example yields are compared in
Example results of expanding cells by coating a cell growth surface of a cell expansion system, such as CES 500 (
The Overnight coating procedure with uniform suspension cell loading procedure (LWUS) may outperform the following: the 56-minute bulls-eye coating (56 min BE) procedure with uniform suspension cell loading procedure (LWUS) and the 56-minute bulls-eye coating procedure (56 min BE) with BullsEye loading procedure. As shown in graph 1900 of
These example yields are compared in
The objective of this study is to characterize the expansion of human bone marrow derived mesenchymal stem cells (hMSCs) using two unique cell seeding methodologies in the QUANTUM® cell expansion system.
The current cell loading procedure used on the QUANTUM cell expansion system for pre-selected hMSCs distributes the cells in the bioreactor via uniform cell suspension. The cells are loaded into the IC Circulation loop of the QUANTUM cell expansion system and then circulated at relatively high flow rates (200 mL/min) for two minutes. This circulation method, coinciding with deliberate bioreactor motion, results in a uniform suspension of cells. Once the cells are uniformly suspended, circulation and bioreactor motion stops and the cells settle onto the bioreactor surface.
One limitation of this cell loading procedure is that only the trough of the bioreactor fiber is seeded with cells. hMSCs are frequently seeded at a specified cell density (e.g., 500 cells/cm2). In order to achieve a specified seed density, only approximately 50% of the bioreactor surface area can be considered when determining the appropriate number of cells to load. At 500 cells/cm2, the QUANTUM cell expansion system bioreactor can be seeded with 10.5E+06 cells (500 cells/cm2×21000 cm2). However, only 50% of the bioreactor surface area can be considered “seed able” due to the aforementioned mechanics of the current cell load protocol. In addition, expanding cells attempting to migrate to the “unseedable” surface of the bioreactor must overcome gravity in order to utilize that surface. It is theorized here that migrating cells may take the path of least resistance; resulting in rapid confluence within the cell population compared to those expanded in its flask counter-part.
A total of seven sterilized QUANTUM CES Disposable sets with a bioreactor may be fibronectin coated (5 mg) overnight. All QUANTUM systems may be seeded with pre-cultured hMSCs. One QUANTUM cell expansion system may use the current Load with Circulation Task and serve as the experiment control. Three QUANTUM cell expansion systems may use “Load with Circulation Task: Modification 1” (Modification 1) and three QUANTUM cell expansion systems may use “Load with Circulation Task: Modification 2” (Modification 2).
Disposable Sets: All bioreactors may be integrated into a QUANTUM cell expansion system (CES) disposable set and sterilized with ethylene oxide.
Cell Source and Density: The bioreactor that may be used may have a 2.1 m2 inner (IC) surface area. As a result, an adjustment to seeding densities for control flasks may need to be made based on the bioreactor volume fraction of the IC loop. All bioreactors may be uniformly loaded with a maximum of 20E+06 pre-selected MSCs (existing passages 1-3) from a direct re-load of the same cell source. Cells from a single donor are preferred. Seed three (3) T25 control flasks with hMSCs at the same density per cm2 as the bioreactor for comparative purposes.
CES Media IC Input Q Management & Harvest: The media feed rate (IC Input Q) may be doubled when the glucose levels fall below 70 mg/dL; the IC Input Q may be doubled a second time in the course of one day if the glucose values continue to fall below 70 mg/dL All disposable sets may be harvested at the same time and no later than Day 8 to limit potential aggregation. Cell harvest time may be determined as a result of the metabolic characteristics displayed by the cell cultures. The target harvest time may be post-log phase growth of the cells.
Post-Harvest Evaluation: Evaluations may be performed on each of the harvest products. These evaluations may include cell count and viability.
QUANTUM CES Cell Load Modification 1
The current cell load procedure may be performed with the following modifications shown in bold. After allowing the cells to attach for 5 minutes, all bioreactors may be rotated 180 degrees to allow unattached cells to settle to the top of the hollow fiber membrane for an additional 5 minutes. Then bioreactor may be rotated back to the home horizontal position and proceed with the expansion protocol. The rationale for the modification is to distribute the cells over the entire surface area of the bioreactor hollow fiber.
Day: 0 Attach Cells with One (1) Rotation
Purpose: enables adherent cells to attach to the bioreactor membrane while allowing flow on the EC circulation loop. The pump flow rate to the IC loop may be set to zero.
Table 34 describes the bags of solution that may be attached to each line when performing Attach Cells. These solutions and corresponding volumes are based on the default settings for this task.
Cells Pathway: Task>Load and Attach>Attach Cells
Enter the values for each setting for Attach Cells shown in Protocol Table 35-37.
0.1
QUANTUM CES Cell Load Modification 2
The current cell load procedure, pre-selected MSC Expansion Protocol, may be performed with the following modifications shown in bold. Cells may be attached to the top of the hollow fiber by rotating the bioreactor to the 180 degree position during the cell attachment phase (18-24 hours). Then rotate the bioreactor back to the home position and proceed with the expansion protocol. The rationale for the modification is to allow gravity to influence the direction of cell migration toward the empty growth surface during cell expansion.
The force of gravity may be used to “influence” the cell migration during expansion. This may be accomplished by seeding the cells as described in the current cell load procedure, then during expansion the bioreactor may be rotated 1800. In this configuration the unoccupied growth surface of the bioreactor is below the seeded cells. The cells may then expand in the direction of least resistance (e.g., downward, aided by gravity).
Day: 0 Attach Cells with One (1) Rotation
Purpose: enables adherent cells to attach to the bioreactor membrane while allowing flow on the EC circulation loop. The pump flow rate to the IC loop may be set to zero.
Table 38 describes the bags of solution that may be attached to each line when performing Attach Cells. These solutions and corresponding volumes are based on the default settings for this task.
Cells Pathway: Task>Load and Attach>Attach Cells
0.1
The results may be as follows:
Table 42
The Bull's Eye cell loading procedure is a series of steps designed to increase cell yield by allowing for a more even distribution of cells within the bioreactor of the QUANTUM® cell expansion system and by reducing the number of cells lost during a seeding process.
The Bull's Eye cell loading technique for the QUANTUM cell expansion system provides a series of steps that include and add to the ‘Load Cells with Uniform Suspension’ protocol (QUANTUM Cell Expansion System Operator's Manual for Software Version 2.0) that is commonly used to seed the bioreactor. In Load Cells with Uniform Suspension (LCWUS), suspended cells have a single opportunity to enter and attach to the internal surface of one fiber of the bioreactor after the cell suspension is circulated through the IC loop at 200 mL/min. Bull's Eye may allow cells that do not attach after the initial suspension and those that may be left in the IC loop rather than in the bioreactor to be re-suspended and transported to a different fiber within the bioreactor for subsequent attachment.
The Bull's Eye load may operate on the principle that a cell suspension introduced to the bioreactor via circulation of the IC loop may pass through a different set of bioreactor fibers depending on the rate of circulation of that cell suspension in the IC loop.
Following an initial 200 mL/min suspension cycle in loading cells with uniform suspension (LCWUS), the cell suspension in the IC loop may be circulated alternately in the positive and negative directions at sequentially lower circulation rates: −100 mL/min, 50 mL/min, −25 mL/min. Each progressively slower cycle of the IC loop may allow those cells still left in suspension an additional opportunity to enter and attach to the inner surface of a bioreactor fiber.
Each cycling of the fluid in the IC loop may be followed by a 7-minute cell-attachment period during which the IC circulation rate may be zero. MSC cells have been demonstrated to attach within 5 minutes to the inner surface of a fiber in a bioreactor used in the QUANTUM cell expansion system. As such, the 7-minute attachment may allow for 5 minutes for cell attachment, and 2 extra minutes to allow for slower-attaching cells. The four total cycles of cell suspension and cell attachment in the IC loop may be followed by a 24 hr attachment period after which an appropriate cell feeding schedule may be input as desired.
Day: −1 Coat Bioreactor
Purpose: coats the bioreactor membrane with a reagent.
Before starting this task, the following preconditions may be satisfied:
Table 43 describes the bags of solution that may be used to attach to each line when performing Coat Bioreactor. These solutions and corresponding volumes may be based on the default settings for this task.
Coat Bioreactor Pathway: Task>System Management>Coat Bioreactor
Enter the values for each setting for step 1 shown in Table 44.
Enter the values for each setting for step 2 shown in Table 45.
Enter the values for each setting for step 3 shown in Table 46.
Day: 0 IC EC Washout
Purpose: used to replace the fluid on both the IC circulation loop and the EC circulation loop. The replacement volume is specified by the number of IC Volumes and EC Volumes exchanged. Table 47 describes the bags of solution that may be attached to each line when performing IC EC Washout. These solutions and corresponding volumes may be based on the default settings for this task.
IC EC Washout Pathway: Task>Washout>IC EC Washout
Confirm the values for each setting for IC EC Washout shown in Table 48.
Day: 0 Condition Media
Follow the instructions in this task to allow the media to reach equilibrium with the provided gas supply before loading the cells. This task may include two separate steps:
Table 49 describes the bags of solution that may be attached to each line when performing Condition Media. These solutions and corresponding volumes may be based on the default settings for this task.
Condition Media Pathway: Task>System Management>Condition Media
Enter the values for each setting for step 1 shown in Table 50.
Enter the values for each setting for step 2 shown in Table 51.
Day: 0 Load Cells with Uniform Suspension
Purpose: loads the cells into the bioreactor from the cell inlet bag until the bag is empty. This task only uses IC circulation to distribute the cells and does not attempt to chase the cells from the line into the bioreactor. This task may include three separate steps.
Before starting this task, the following preconditions may be satisfied:
Include at least 40 mL of air in the cell inlet bag.
Table 52 describes the bags of solution that may be attached to each line when performing Load Cells With Uniform Suspension. These solutions and corresponding volumes may be based on the default settings for this task.
Load Cells with Uniform Suspension Pathway: Task>Load and Attach>Load Cells with Uniform Suspension
Confirm the values for each setting for step 1 shown in Table 53.
Confirm the values for each setting for step 2 shown in Table 54.
Confirm the values for each setting for step 3 shown in Table 55.
Day: 0 Bull's Eye Attachment
Purpose: allows adherent cells to attach to the bioreactor membrane while allowing flow on the EC circulation loop. The pump flow rate to the IC loop may be set to zero.
Table 56 describes the bags of solution that may be attached to each line when performing Bull's Eye Attachment. These solutions and corresponding volumes may be based on the default settings for this task.
Bull's Eye Attachment Cells Pathway: Task>Custom>Custom
Enter the values for each setting shown in Table 57.
Enter the values for each setting shown in Table 58.
Enter the values for each setting shown in Table 59.
Enter the values for each setting shown in Table 60.
Enter the values for each setting shown in Table 61.
Enter the values for each setting shown in Table 62.
Enter the values for each setting shown in Table 63.
Day: 1 Feed Cells
Purpose: continuously adds a low flow rate to the IC circulation loop and/or the EC circulation loop. There are several outlet settings that can be used to remove the fluid added to the system during this task.
Table 64 describes the bags of solution that may be attached to each line when performing Feed Cells. These solutions and corresponding volumes may be based on the default settings for this task.
Confirm the values for each setting for step 1 for shown in Table 65.
Increase IC Inlet rate as needed.
Release Adherent Cells and Harvest
Purpose: releases cells from the membrane, leaving the cells in the IC loop and transfers cells in suspension from the IC circulation loop, including cells in the bioreactor, into the harvest bag.
Before starting this task, the following preconditions may be satisfied:
Include at least 40 mL of air on the cell inlet bag.
Table 66 describes the bags of solution that may be attached to each line when performing Release Adherent Cells And Harvest. These solutions and corresponding volumes may be based on the default settings for this task.
Release Adherent Cells Pathway: Task>Release and Harvest>Release Adherent Cells And Harvest
Confirm the values for each setting for step 1 shown in Table 67.
Confirm the values for each setting for step 2 shown in Table 68.
Confirm the values for each setting for step 3 shown in Table 69.
Confirm the values for each setting for step 4 shown in Table 70.
Confirm the values for each setting for step 5 shown in Table 71.
The results of the study may be as follows:
The Bull's Eye load may be evaluated using MSC from four different donors. Yields from Bull's Eye loaded harvests may be consistently higher than the yields loaded using LCWUS and cultured under identical conditions. The mean cell yield increase using Bull's Eye (n=6) vs. LCWUS (n=4) may be 25%.
Viability of MSC samples from the IC loop taken immediately after performing the Bull's Eye load may be 100%. Viability of MSC from Bull's Eye harvests may be over 98% for all samples. MSC from Bull's Eye harvests may display typical morphology in culture, and all MSC biomarkers measured by flow cytometry may conform to ISCT standards.
The same protocol as described above with respect to EXAMPLE 7 may be used to study modifications to the Bulls Eye attachment protocol. The modifications to the Bulls Eye attachment (Bulls Eye II), and to the protocol described above, include eliminating the attachments phases after the circulation rates: 100 ml/min; −50 ml/min; and 25 ml/min. That is, instead of having 7 minute stop conditions as described above, there is no stop condition so that the next circulation rate follows the previous circulation rate. A control, as well as an original Bulls Eye run (Bulls Eye 1) may also be performed as a comparison.
The results of this study may be as follows:
It will be apparent to those skilled in the art that various modifications and variations can be made to the methods and structure of the present invention without departing from its scope. Thus it should be understood that the present invention is not be limited to the specific examples given. Rather, the present invention is intended to cover modifications and variations within the scope of the following claims and their equivalents.
As used herein, “at least one,” “one or more,” and “and/or” are open-ended expressions that are both conjunctive and disjunctive in operation. For example, each of the expressions “at least one of A, B and C,” “at least one of A, B, or C,” “one or more of A, B, and C,” “one or more of A, B, or C” and “A, B, and/or C” can mean A alone, B alone, C alone, A and B together, A and C together, B and C together, or A, B and C together.
While example embodiments and applications of the present invention have been illustrated and described, it is to be understood that the invention is not limited to the precise configuration and resources described above. Various modifications, changes, and variations apparent to those skilled in the art may be made in the arrangement, operation, and details of the methods and systems of the present invention disclosed herein without departing from the scope of the present invention.
This application is a divisional application of, and claims priority to, U.S. patent application Ser. No. 16/845,791, entitled, “Coating A Bioreactor In A Cell Expansion System”, filed on Apr. 10, 2020, which is a divisional application of, and claims priority to, U.S. patent application Ser. No. 15/616,876, entitled, “Coating a Bioreactor,” filed on Jun. 7, 2017, now U.S. Pat. No. 11,104,874, issued on Aug. 31, 2021, which claims priority to, and the benefit of, U.S. Provisional Application Ser. No. 62/347,025, filed on Jun. 7, 2016, and entitled, “Growth Surface Coating,” and U.S. Provisional Application Ser. No. 62/347,012, filed on Jun. 7, 2016, and entitled, “Coating a Bioreactor.” The disclosures of the above-identified applications are hereby incorporated by reference in their entireties as if set forth herein in full for all that they teach and for all purposes.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2997077 | Rodrigues | Aug 1961 | A |
| 3013435 | Rodrigues | Dec 1961 | A |
| 3067915 | Shapiro et al. | Dec 1962 | A |
| 3191807 | Rodrigues | Jun 1965 | A |
| 3283727 | Rodrigues | Nov 1966 | A |
| 3701717 | Ingvorsen | Oct 1972 | A |
| 4173415 | Wyatt | Nov 1979 | A |
| 4301010 | Eddleman et al. | Nov 1981 | A |
| 4301118 | Eddleman et al. | Nov 1981 | A |
| 4412990 | Lundblad et al. | Nov 1983 | A |
| 4418691 | Yannas et al. | Dec 1983 | A |
| 4439901 | Eddleman | Apr 1984 | A |
| 4478829 | Landaburu et al. | Oct 1984 | A |
| 4486188 | Altshuler et al. | Dec 1984 | A |
| 4509695 | Bessman | Apr 1985 | A |
| 4585654 | Landaburu et al. | Apr 1986 | A |
| 4618586 | Walker | Oct 1986 | A |
| 4629686 | Gruenberg | Dec 1986 | A |
| 4670544 | Schwinn et al. | Jun 1987 | A |
| 4727059 | Binder et al. | Feb 1988 | A |
| 4828706 | Eddleman | May 1989 | A |
| 4897358 | Carrasco | Jan 1990 | A |
| 4960521 | Keller | Oct 1990 | A |
| 4988623 | Schwarz et al. | Jan 1991 | A |
| 5015585 | Robinson | May 1991 | A |
| 5019054 | Clement et al. | May 1991 | A |
| 5126238 | Gebhard et al. | Jun 1992 | A |
| 5130141 | Law et al. | Jul 1992 | A |
| 5149544 | Gentile et al. | Sep 1992 | A |
| 5169930 | Ruoslahti et al. | Dec 1992 | A |
| 5192553 | Boyse et al. | Mar 1993 | A |
| 5197985 | Caplan et al. | Mar 1993 | A |
| 5202254 | Amiot et al. | Apr 1993 | A |
| 5225346 | Matsumiya et al. | Jul 1993 | A |
| 5226914 | Caplan et al. | Jul 1993 | A |
| 5240614 | Ofsthun et al. | Aug 1993 | A |
| 5240861 | Bieri | Aug 1993 | A |
| 5283058 | Faustman | Feb 1994 | A |
| 5310676 | Johansson et al. | May 1994 | A |
| 5324428 | Flaherty | Jun 1994 | A |
| 5342752 | Platz et al. | Aug 1994 | A |
| 5422197 | Zito | Jun 1995 | A |
| 5436151 | McGlave et al. | Jul 1995 | A |
| 5437994 | Emerson et al. | Aug 1995 | A |
| 5439757 | Zito | Aug 1995 | A |
| 5459069 | Palsson et al. | Oct 1995 | A |
| 5460964 | McGlave et al. | Oct 1995 | A |
| H1509 | Eran et al. | Dec 1995 | H |
| 5478739 | Slivka et al. | Dec 1995 | A |
| 5486359 | Caplan et al. | Jan 1996 | A |
| 5496659 | Zito | Mar 1996 | A |
| 5507949 | Ho | Apr 1996 | A |
| 5512180 | Ho | Apr 1996 | A |
| 5527467 | Ofsthun et al. | Jun 1996 | A |
| 5543316 | Zawadzka et al. | Aug 1996 | A |
| 5545492 | Zito | Aug 1996 | A |
| 5549674 | Humes et al. | Aug 1996 | A |
| 5571720 | Grandics et al. | Nov 1996 | A |
| 5591625 | Gerson et al. | Jan 1997 | A |
| 5593580 | Kopf | Jan 1997 | A |
| 5595909 | Hu et al. | Jan 1997 | A |
| 5599703 | Davis et al. | Feb 1997 | A |
| 5605822 | Emerson et al. | Feb 1997 | A |
| 5605829 | McGlave et al. | Feb 1997 | A |
| 5605835 | Hu et al. | Feb 1997 | A |
| 5622857 | Goffe | Apr 1997 | A |
| 5626731 | Cooley et al. | May 1997 | A |
| 5627070 | Gruenberg | May 1997 | A |
| 5635386 | Palsson et al. | Jun 1997 | A |
| 5635387 | Fei et al. | Jun 1997 | A |
| 5643736 | Bruder et al. | Jul 1997 | A |
| 5646043 | Emerson et al. | Jul 1997 | A |
| 5654186 | Cerami et al. | Aug 1997 | A |
| 5656421 | Gebhard et al. | Aug 1997 | A |
| 5658995 | Kohn et al. | Aug 1997 | A |
| 5667985 | O'Leary et al. | Sep 1997 | A |
| 5670147 | Emerson et al. | Sep 1997 | A |
| 5674750 | Kraus et al. | Oct 1997 | A |
| 5684712 | Goffe et al. | Nov 1997 | A |
| 5686289 | Humes et al. | Nov 1997 | A |
| 5695989 | Kalamasz | Dec 1997 | A |
| 5700289 | Breitbart et al. | Dec 1997 | A |
| 5705534 | D'Agostino et al. | Jan 1998 | A |
| 5707859 | Miller et al. | Jan 1998 | A |
| 5712163 | Parenteau et al. | Jan 1998 | A |
| 5728581 | Schwartz et al. | Mar 1998 | A |
| 5733541 | Taichman et al. | Mar 1998 | A |
| 5733542 | Haynesworth et al. | Mar 1998 | A |
| 5736396 | Bruder et al. | Apr 1998 | A |
| 5744347 | Wagner et al. | Apr 1998 | A |
| 5750651 | Oppermann et al. | May 1998 | A |
| 5753506 | Johe | May 1998 | A |
| 5763197 | Tsukamoto et al. | Jun 1998 | A |
| 5763266 | Palsson et al. | Jun 1998 | A |
| 5766944 | Ruiz | Jun 1998 | A |
| 5772994 | Ildstad et al. | Jun 1998 | A |
| 5783075 | Eddleman et al. | Jul 1998 | A |
| 5783216 | Faustman | Jul 1998 | A |
| 5785912 | Cooley et al. | Jul 1998 | A |
| 5804446 | Cerami et al. | Sep 1998 | A |
| 5806529 | Reisner et al. | Sep 1998 | A |
| 5807686 | Wagner et al. | Sep 1998 | A |
| 5811094 | Caplan et al. | Sep 1998 | A |
| 5811397 | Francavilla et al. | Sep 1998 | A |
| 5817773 | Wilson et al. | Oct 1998 | A |
| 5821218 | Toback et al. | Oct 1998 | A |
| 5827735 | Young et al. | Oct 1998 | A |
| 5827740 | Pittenger | Oct 1998 | A |
| 5830921 | Cooley et al. | Nov 1998 | A |
| 5833979 | Schinstine et al. | Nov 1998 | A |
| 5837258 | Grotendorst | Nov 1998 | A |
| 5837539 | Caplan et al. | Nov 1998 | A |
| 5840502 | Van Vlasselaer | Nov 1998 | A |
| 5840576 | Schinstine et al. | Nov 1998 | A |
| 5840580 | Terstappen et al. | Nov 1998 | A |
| 5842477 | Naughton et al. | Dec 1998 | A |
| 5843633 | Yin et al. | Dec 1998 | A |
| 5846796 | Cerami et al. | Dec 1998 | A |
| 5853247 | Shroyer | Dec 1998 | A |
| 5853717 | Schinstine et al. | Dec 1998 | A |
| 5855608 | Brekke et al. | Jan 1999 | A |
| 5855613 | Antanavich et al. | Jan 1999 | A |
| 5855619 | Caplan et al. | Jan 1999 | A |
| 5858747 | Schinstine et al. | Jan 1999 | A |
| 5858782 | Long et al. | Jan 1999 | A |
| 5861315 | Nakahata | Jan 1999 | A |
| 5866115 | Kanz et al. | Feb 1999 | A |
| 5866420 | Talbot et al. | Feb 1999 | A |
| 5868930 | Kopf | Feb 1999 | A |
| 5882295 | Kope | Mar 1999 | A |
| 5882918 | Goffe | Mar 1999 | A |
| 5882929 | Fofonoff et al. | Mar 1999 | A |
| 5888807 | Palsson et al. | Mar 1999 | A |
| 5902741 | Purchio et al. | May 1999 | A |
| 5906827 | Khouri et al. | May 1999 | A |
| 5906934 | Grande et al. | May 1999 | A |
| 5908782 | Marshak et al. | Jun 1999 | A |
| 5908784 | Johnstone et al. | Jun 1999 | A |
| 5912177 | Turner et al. | Jun 1999 | A |
| 5914108 | Tsukamoto et al. | Jun 1999 | A |
| 5922597 | Verfaillie et al. | Jul 1999 | A |
| 5922847 | Broudy et al. | Jul 1999 | A |
| 5925567 | Kraus et al. | Jul 1999 | A |
| 5928945 | Seliktar et al. | Jul 1999 | A |
| 5935849 | Schinstine et al. | Aug 1999 | A |
| 5938929 | Shimagaki et al. | Aug 1999 | A |
| 5939323 | Valentini et al. | Aug 1999 | A |
| 5942225 | Bruder et al. | Aug 1999 | A |
| 5955353 | Amiot | Sep 1999 | A |
| 5958763 | Goffe | Sep 1999 | A |
| 5965436 | Thiede et al. | Oct 1999 | A |
| 5972703 | Long et al. | Oct 1999 | A |
| 5980795 | Klotzer et al. | Nov 1999 | A |
| 5981211 | Hu et al. | Nov 1999 | A |
| 5981708 | Lawman et al. | Nov 1999 | A |
| 5998184 | Shi | Dec 1999 | A |
| 6001585 | Gramer | Dec 1999 | A |
| 6001643 | Spaulding | Dec 1999 | A |
| 6001647 | Peck et al. | Dec 1999 | A |
| 6004743 | Kenyon et al. | Dec 1999 | A |
| 6010696 | Caplan et al. | Jan 2000 | A |
| 6015554 | Galy | Jan 2000 | A |
| 6022540 | Bruder et al. | Feb 2000 | A |
| 6022742 | Kopf | Feb 2000 | A |
| 6022743 | Naughton et al. | Feb 2000 | A |
| 6027743 | Khouri et al. | Feb 2000 | A |
| 6030836 | Thiede et al. | Feb 2000 | A |
| 6040180 | Johe | Mar 2000 | A |
| 6045818 | Cima et al. | Apr 2000 | A |
| 6048721 | Armstrong et al. | Apr 2000 | A |
| 6048727 | Kopf | Apr 2000 | A |
| 6049026 | Muschler | Apr 2000 | A |
| 6054121 | Cerami et al. | Apr 2000 | A |
| 6060270 | Humes | May 2000 | A |
| 6066317 | Yang et al. | May 2000 | A |
| 6071691 | Hoekstra et al. | Jun 2000 | A |
| 6074366 | Rogers et al. | Jun 2000 | A |
| 6082364 | Balian et al. | Jul 2000 | A |
| 6083747 | Wong et al. | Jul 2000 | A |
| 6086643 | Clark et al. | Jul 2000 | A |
| 6087113 | Caplan et al. | Jul 2000 | A |
| 6096537 | Chappel | Aug 2000 | A |
| 6103117 | Shimagaki et al. | Aug 2000 | A |
| 6103522 | Torok-Storb et al. | Aug 2000 | A |
| 6110176 | Shapira | Aug 2000 | A |
| 6110482 | Khouri et al. | Aug 2000 | A |
| 6114307 | Jaspers et al. | Sep 2000 | A |
| 6117985 | Thomas et al. | Sep 2000 | A |
| 6120491 | Kohn et al. | Sep 2000 | A |
| 6127141 | Kopf | Oct 2000 | A |
| 6129911 | Faris | Oct 2000 | A |
| 6143293 | Weiss et al. | Nov 2000 | A |
| 6146360 | Rogers et al. | Nov 2000 | A |
| 6146888 | Smith et al. | Nov 2000 | A |
| 6149902 | Artavanis-Tsakonas et al. | Nov 2000 | A |
| 6149906 | Mosca | Nov 2000 | A |
| 6150164 | Humes | Nov 2000 | A |
| 6152964 | Van Blitterswijk et al. | Nov 2000 | A |
| 6162643 | Wille, Jr. | Dec 2000 | A |
| 6165225 | Antanavich et al. | Dec 2000 | A |
| 6165785 | Ogle et al. | Dec 2000 | A |
| 6174333 | Kadiyala et al. | Jan 2001 | B1 |
| 6174526 | Cerami et al. | Jan 2001 | B1 |
| 6174666 | Pavlakis et al. | Jan 2001 | B1 |
| 6179871 | Halpern | Jan 2001 | B1 |
| 6197325 | MacPhee et al. | Mar 2001 | B1 |
| 6197575 | Griffith et al. | Mar 2001 | B1 |
| 6200606 | Peterson et al. | Mar 2001 | B1 |
| 6214369 | Grande et al. | Apr 2001 | B1 |
| 6214574 | Kopf | Apr 2001 | B1 |
| 6224860 | Brown | May 2001 | B1 |
| 6225119 | Qasba et al. | May 2001 | B1 |
| 6225368 | D'Agostino et al. | May 2001 | B1 |
| 6228117 | De Bruijn et al. | May 2001 | B1 |
| 6228607 | Kersten et al. | May 2001 | B1 |
| 6238908 | Armstrong et al. | May 2001 | B1 |
| 6239157 | Mbalaviele | May 2001 | B1 |
| 6242252 | Reid et al. | Jun 2001 | B1 |
| 6248319 | Zsebo et al. | Jun 2001 | B1 |
| 6248587 | Rodgers et al. | Jun 2001 | B1 |
| 6255112 | Thiede et al. | Jul 2001 | B1 |
| 6258597 | Bachovchin et al. | Jul 2001 | B1 |
| 6258778 | Rodgers et al. | Jul 2001 | B1 |
| 6261549 | Fernandez et al. | Jul 2001 | B1 |
| 6280718 | Kaufman et al. | Aug 2001 | B1 |
| 6280724 | Moore | Aug 2001 | B1 |
| 6281012 | McIntosh et al. | Aug 2001 | B1 |
| 6281195 | Rueger et al. | Aug 2001 | B1 |
| 6287864 | Bagnis et al. | Sep 2001 | B1 |
| 6291249 | Mahant et al. | Sep 2001 | B1 |
| 6297213 | Oppermann et al. | Oct 2001 | B1 |
| 6299650 | Van Blitterswijk et al. | Oct 2001 | B1 |
| 6306424 | Vyakamam et al. | Oct 2001 | B1 |
| 6306575 | Thomas et al. | Oct 2001 | B1 |
| 6322784 | Pittenger et al. | Nov 2001 | B1 |
| 6322786 | Anderson | Nov 2001 | B1 |
| 6326198 | Emerson et al. | Dec 2001 | B1 |
| 6326201 | Fung et al. | Dec 2001 | B1 |
| 6328765 | Hardwick et al. | Dec 2001 | B1 |
| 6328960 | McIntosh et al. | Dec 2001 | B1 |
| 6333029 | Vyakamam et al. | Dec 2001 | B1 |
| 6335195 | Rodgers et al. | Jan 2002 | B1 |
| 6338942 | Kraus et al. | Jan 2002 | B2 |
| 6340592 | Stringer | Jan 2002 | B1 |
| 6342370 | Connolly et al. | Jan 2002 | B1 |
| 6355239 | Bruder et al. | Mar 2002 | B1 |
| 6358252 | Shapira | Mar 2002 | B1 |
| 6361997 | Huss | Mar 2002 | B1 |
| 6365149 | Vyakarnam et al. | Apr 2002 | B2 |
| 6368636 | McIntosh et al. | Apr 2002 | B1 |
| 6372210 | Brown | Apr 2002 | B2 |
| 6372244 | Antanavich et al. | Apr 2002 | B1 |
| 6372494 | Naughton et al. | Apr 2002 | B1 |
| 6372892 | Ballinger et al. | Apr 2002 | B1 |
| 6376742 | Zdrahala et al. | Apr 2002 | B1 |
| 6379953 | Bruder et al. | Apr 2002 | B1 |
| 6387367 | Davis-Sproul et al. | May 2002 | B1 |
| 6387369 | Pittenger et al. | May 2002 | B1 |
| 6387693 | Rieser et al. | May 2002 | B2 |
| 6387964 | D'Agostino et al. | May 2002 | B1 |
| 6392118 | Hammang et al. | May 2002 | B1 |
| 6394812 | Sullivan et al. | May 2002 | B1 |
| 6399580 | Elias et al. | Jun 2002 | B1 |
| 6410320 | Humes | Jun 2002 | B1 |
| 6414219 | Denhardt et al. | Jul 2002 | B1 |
| 6416496 | Rogers et al. | Jul 2002 | B1 |
| 6417205 | Cooke et al. | Jul 2002 | B1 |
| 6419829 | Ho et al. | Jul 2002 | B2 |
| 6420138 | Gentz et al. | Jul 2002 | B1 |
| 6423681 | Barasch et al. | Jul 2002 | B1 |
| 6426332 | Rueger et al. | Jul 2002 | B1 |
| 6428802 | Atala | Aug 2002 | B1 |
| 6429012 | Kraus et al. | Aug 2002 | B1 |
| 6429013 | Halvorsen et al. | Aug 2002 | B1 |
| 6432653 | Okarma | Aug 2002 | B1 |
| 6432711 | Dinsmore et al. | Aug 2002 | B1 |
| 6440407 | Bauer et al. | Aug 2002 | B1 |
| 6440734 | Pykett et al. | Aug 2002 | B1 |
| 6451562 | Ruben et al. | Sep 2002 | B1 |
| 6454811 | Sherwood et al. | Sep 2002 | B1 |
| 6455678 | Yin et al. | Sep 2002 | B1 |
| 6458585 | Vachula et al. | Oct 2002 | B1 |
| 6458589 | Rambhatla et al. | Oct 2002 | B1 |
| 6461495 | Morrissey et al. | Oct 2002 | B1 |
| 6461853 | Zhu | Oct 2002 | B1 |
| 6464983 | Grotendorst | Oct 2002 | B1 |
| 6465205 | Hicks, Jr. | Oct 2002 | B2 |
| 6465247 | Weissman et al. | Oct 2002 | B1 |
| 6465249 | Reya et al. | Oct 2002 | B2 |
| 6468794 | Uchida et al. | Oct 2002 | B1 |
| 6472200 | Mitrani | Oct 2002 | B1 |
| 6475481 | Talmadge | Nov 2002 | B2 |
| 6479064 | Atala | Nov 2002 | B1 |
| 6482231 | Abatangelo et al. | Nov 2002 | B1 |
| 6482411 | Ahuja et al. | Nov 2002 | B1 |
| 6482645 | Atala | Nov 2002 | B2 |
| 6482926 | Thomas et al. | Nov 2002 | B1 |
| 6488925 | Ruben et al. | Dec 2002 | B2 |
| 6491918 | Thomas et al. | Dec 2002 | B1 |
| 6495129 | Li et al. | Dec 2002 | B1 |
| 6495364 | Hammang et al. | Dec 2002 | B2 |
| 6497875 | Sorrell et al. | Dec 2002 | B1 |
| 6498034 | Strobl | Dec 2002 | B1 |
| 6506574 | Rambhatla et al. | Jan 2003 | B1 |
| 6511510 | de Bruijn et al. | Jan 2003 | B1 |
| 6511767 | Calver et al. | Jan 2003 | B1 |
| 6511958 | Atkinson et al. | Jan 2003 | B1 |
| 6514514 | Atkinson et al. | Feb 2003 | B1 |
| 6524452 | Clark et al. | Feb 2003 | B1 |
| 6528052 | Smith et al. | Mar 2003 | B1 |
| 6528245 | Sanchez-Ramos et al. | Mar 2003 | B2 |
| 6531445 | Cohen et al. | Mar 2003 | B1 |
| 6534084 | Vyakarnam et al. | Mar 2003 | B1 |
| 6537807 | Smith et al. | Mar 2003 | B1 |
| 6541024 | Kadiyala et al. | Apr 2003 | B1 |
| 6541249 | Wager et al. | Apr 2003 | B2 |
| 6544506 | Reisner | Apr 2003 | B2 |
| 6548734 | Glimcher et al. | Apr 2003 | B1 |
| 6555324 | Olweus et al. | Apr 2003 | B1 |
| 6555374 | Gimble et al. | Apr 2003 | B1 |
| 6559119 | Burgess et al. | May 2003 | B1 |
| 6562616 | Toner et al. | May 2003 | B1 |
| 6565843 | Cohen et al. | May 2003 | B1 |
| 6569421 | Hodges | May 2003 | B2 |
| 6569427 | Boyse et al. | May 2003 | B1 |
| 6569428 | Isner et al. | May 2003 | B1 |
| 6569654 | Shastri et al. | May 2003 | B2 |
| 6576188 | Rose et al. | Jun 2003 | B1 |
| 6576428 | Assenmacher et al. | Jun 2003 | B1 |
| 6576464 | Gold et al. | Jun 2003 | B2 |
| 6576465 | Long | Jun 2003 | B1 |
| 6582471 | Bittmann et al. | Jun 2003 | B1 |
| 6582955 | Martinez et al. | Jun 2003 | B2 |
| 6586192 | Peschle et al. | Jul 2003 | B1 |
| 6589728 | Csete et al. | Jul 2003 | B2 |
| 6589786 | Mangano et al. | Jul 2003 | B1 |
| 6596274 | Abatangelo et al. | Jul 2003 | B1 |
| 6599300 | Vibe-Hansen et al. | Jul 2003 | B2 |
| 6599520 | Scarborough et al. | Jul 2003 | B2 |
| 6610535 | Lu et al. | Aug 2003 | B1 |
| 6613798 | Porter et al. | Sep 2003 | B1 |
| 6616912 | Eddleman et al. | Sep 2003 | B2 |
| 6617070 | Morrissey et al. | Sep 2003 | B1 |
| 6617152 | Bryhan et al. | Sep 2003 | B2 |
| 6617159 | Cancedda et al. | Sep 2003 | B1 |
| 6623749 | Williams et al. | Sep 2003 | B2 |
| 6623942 | Ruben et al. | Sep 2003 | B2 |
| 6624108 | Clark et al. | Sep 2003 | B1 |
| 6626950 | Brown et al. | Sep 2003 | B2 |
| 6627191 | Bartelmez et al. | Sep 2003 | B1 |
| 6632425 | Li et al. | Oct 2003 | B1 |
| 6632620 | Makarovskiy | Oct 2003 | B1 |
| 6632934 | Moreadith et al. | Oct 2003 | B1 |
| 6638765 | Rosenberg | Oct 2003 | B1 |
| 6642048 | Xu et al. | Nov 2003 | B2 |
| 6642049 | Chute et al. | Nov 2003 | B1 |
| 6642201 | Khavinson et al. | Nov 2003 | B1 |
| 6645489 | Pykett et al. | Nov 2003 | B2 |
| 6645727 | Thomas et al. | Nov 2003 | B2 |
| 6645763 | Kobayashi et al. | Nov 2003 | B2 |
| 6649189 | Talmadge et al. | Nov 2003 | B2 |
| 6649595 | Clackson et al. | Nov 2003 | B2 |
| 6649631 | Orme et al. | Nov 2003 | B1 |
| 6653105 | Triglia et al. | Nov 2003 | B2 |
| 6653134 | Prockop et al. | Nov 2003 | B2 |
| 6660523 | Blom et al. | Dec 2003 | B2 |
| 6662805 | Frondoza et al. | Dec 2003 | B2 |
| 6667034 | Palsson et al. | Dec 2003 | B2 |
| 6667176 | Funk et al. | Dec 2003 | B1 |
| 6670169 | Schob et al. | Dec 2003 | B1 |
| 6670175 | Wang et al. | Dec 2003 | B2 |
| 6673603 | Baetge et al. | Jan 2004 | B2 |
| 6673606 | Tennekoon et al. | Jan 2004 | B1 |
| 6677306 | Veis et al. | Jan 2004 | B1 |
| 6683192 | Baxter et al. | Jan 2004 | B2 |
| 6685936 | McIntosh et al. | Feb 2004 | B2 |
| 6685971 | Xu | Feb 2004 | B2 |
| 6686198 | Melton et al. | Feb 2004 | B1 |
| 6696575 | Schmidt et al. | Feb 2004 | B2 |
| 6699716 | Sullivan et al. | Mar 2004 | B2 |
| 6703017 | Peck et al. | Mar 2004 | B1 |
| 6703209 | Baetscher et al. | Mar 2004 | B1 |
| 6706293 | Quintanilla Almagro et al. | Mar 2004 | B1 |
| 6709864 | Pittenger et al. | Mar 2004 | B1 |
| 6712850 | Vyakarnam et al. | Mar 2004 | B2 |
| 6719969 | Hogaboam et al. | Apr 2004 | B1 |
| 6719970 | Costantino et al. | Apr 2004 | B1 |
| 6720340 | Cooke et al. | Apr 2004 | B1 |
| 6730314 | Jeschke et al. | May 2004 | B2 |
| 6730315 | Usala et al. | May 2004 | B2 |
| 6730510 | Roos et al. | May 2004 | B2 |
| 6733746 | Daley et al. | May 2004 | B2 |
| 6734000 | Chin et al. | May 2004 | B2 |
| 6740493 | Long et al. | May 2004 | B1 |
| 6759039 | Tsang et al. | Jul 2004 | B2 |
| 6759245 | Toner et al. | Jul 2004 | B1 |
| 6761883 | Weissman et al. | Jul 2004 | B2 |
| 6761887 | Kavalkovich et al. | Jul 2004 | B1 |
| 6767699 | Polo et al. | Jul 2004 | B2 |
| 6767737 | Wilson et al. | Jul 2004 | B1 |
| 6767738 | Gage et al. | Jul 2004 | B1 |
| 6767740 | Sramek et al. | Jul 2004 | B2 |
| 6770478 | Crowe et al. | Aug 2004 | B2 |
| 6777227 | Ricci et al. | Aug 2004 | B2 |
| 6777231 | Katz et al. | Aug 2004 | B1 |
| 6780612 | Ford et al. | Aug 2004 | B1 |
| 6787355 | Miller et al. | Sep 2004 | B1 |
| 6790455 | Chu et al. | Sep 2004 | B2 |
| 6793939 | Badylak | Sep 2004 | B2 |
| 6797269 | Mosca et al. | Sep 2004 | B2 |
| 6797514 | Berenson et al. | Sep 2004 | B2 |
| 6800480 | Bodnar et al. | Oct 2004 | B1 |
| 6802971 | Gorsuch et al. | Oct 2004 | B2 |
| 6805860 | Alt | Oct 2004 | B1 |
| 6809117 | Enikolopov et al. | Oct 2004 | B2 |
| 6811773 | Gentz et al. | Nov 2004 | B1 |
| 6811776 | Kale et al. | Nov 2004 | B2 |
| 6814961 | Jensen et al. | Nov 2004 | B1 |
| 6821513 | Fleming | Nov 2004 | B1 |
| 6821790 | Mahant et al. | Nov 2004 | B2 |
| 6828145 | Avital et al. | Dec 2004 | B2 |
| 6833269 | Carpenter | Dec 2004 | B2 |
| 6835377 | Goldberg et al. | Dec 2004 | B2 |
| 6835566 | Smith et al. | Dec 2004 | B2 |
| 6838284 | de Bruijn et al. | Jan 2005 | B2 |
| 6841150 | Halvorsen et al. | Jan 2005 | B2 |
| 6841151 | Stringer | Jan 2005 | B2 |
| 6841294 | Morrissey et al. | Jan 2005 | B1 |
| 6841355 | Livant | Jan 2005 | B2 |
| 6841386 | Kraus et al. | Jan 2005 | B2 |
| 6841542 | Bartelmez et al. | Jan 2005 | B2 |
| 6844011 | Faustman | Jan 2005 | B1 |
| 6849051 | Sramek et al. | Feb 2005 | B2 |
| 6849255 | Gazit et al. | Feb 2005 | B2 |
| 6849454 | Kelly et al. | Feb 2005 | B2 |
| 6849662 | Enikolopov et al. | Feb 2005 | B2 |
| 6852308 | Kohn et al. | Feb 2005 | B2 |
| 6852321 | Colucci et al. | Feb 2005 | B2 |
| 6852533 | Rafii et al. | Feb 2005 | B1 |
| 6855242 | Comninellis et al. | Feb 2005 | B1 |
| 6855542 | DiMilla et al. | Feb 2005 | B2 |
| 6863900 | Kadiyala et al. | Mar 2005 | B2 |
| 6866843 | Habener et al. | Mar 2005 | B2 |
| 6872389 | Faris | Mar 2005 | B1 |
| 6875430 | McIntosh et al. | Apr 2005 | B2 |
| 6887600 | Morrissey et al. | May 2005 | B2 |
| 6887704 | Peled et al. | May 2005 | B2 |
| 6908763 | Akashi et al. | Jun 2005 | B1 |
| 6911201 | Merchav et al. | Jun 2005 | B1 |
| 6914279 | Lu et al. | Jul 2005 | B2 |
| 6939955 | Rameshwar | Sep 2005 | B2 |
| 6965018 | Mikesell et al. | Nov 2005 | B2 |
| 6979321 | Geis et al. | Dec 2005 | B2 |
| 6988004 | Kanno et al. | Jan 2006 | B2 |
| 7008394 | Geise et al. | Mar 2006 | B2 |
| 7015037 | Furcht et al. | Mar 2006 | B1 |
| 7029666 | Bruder et al. | Apr 2006 | B2 |
| 7033339 | Lynn | Apr 2006 | B1 |
| 7045098 | Stephens | May 2006 | B2 |
| 7052517 | Murphy et al. | May 2006 | B2 |
| 7056493 | Kohn et al. | Jun 2006 | B2 |
| 7118672 | Husain et al. | Oct 2006 | B2 |
| 7122178 | Simmons et al. | Oct 2006 | B1 |
| 7160719 | Nyberg | Jan 2007 | B2 |
| 7169295 | Husain et al. | Jan 2007 | B2 |
| 7172696 | Martinez et al. | Feb 2007 | B1 |
| 7175763 | Husain et al. | Feb 2007 | B2 |
| 7192776 | Stephens | Mar 2007 | B2 |
| 7195711 | Gorsuch et al. | Mar 2007 | B2 |
| 7250154 | Kohn et al. | Jul 2007 | B2 |
| 7271234 | Kohn et al. | Sep 2007 | B2 |
| 7294259 | Cote et al. | Nov 2007 | B2 |
| 7300571 | Cote et al. | Nov 2007 | B2 |
| 7303676 | Husain et al. | Dec 2007 | B2 |
| 7303677 | Cote et al. | Dec 2007 | B2 |
| 7341062 | Chachques et al. | Mar 2008 | B2 |
| 7358001 | Morrissey et al. | Apr 2008 | B2 |
| 7361493 | Hammond et al. | Apr 2008 | B1 |
| 7368169 | Kohn et al. | May 2008 | B2 |
| 7378271 | Bader | May 2008 | B2 |
| 7399872 | Webster et al. | Jul 2008 | B2 |
| 7416884 | Gemmiti et al. | Aug 2008 | B2 |
| 7425440 | Malinge et al. | Sep 2008 | B2 |
| 7435586 | Bartlett et al. | Oct 2008 | B2 |
| 7438902 | Habener et al. | Oct 2008 | B2 |
| 7439057 | Frangos et al. | Oct 2008 | B2 |
| 7452529 | Brown, Jr. et al. | Nov 2008 | B2 |
| 7491388 | McIntosh et al. | Feb 2009 | B1 |
| 7494811 | Wolfinbarger, Jr. et al. | Feb 2009 | B2 |
| 7514074 | Pittenger et al. | Apr 2009 | B2 |
| 7514075 | Hedrick et al. | Apr 2009 | B2 |
| 7524676 | Reiter et al. | Apr 2009 | B2 |
| 7534609 | Merchav et al. | May 2009 | B2 |
| 7572374 | Gorsuch et al. | Aug 2009 | B2 |
| 7579179 | Bryhan et al. | Aug 2009 | B2 |
| 7585412 | Gorsuch et al. | Sep 2009 | B2 |
| 7588938 | Ma | Sep 2009 | B2 |
| 7598075 | Smith et al. | Oct 2009 | B2 |
| 7608447 | Cohen et al. | Oct 2009 | B2 |
| 7659118 | Furcht et al. | Feb 2010 | B2 |
| 7678573 | Merchav et al. | Mar 2010 | B2 |
| 7682823 | Runyon | Mar 2010 | B1 |
| 7722896 | Kohn et al. | May 2010 | B2 |
| D620732 | Andrews | Aug 2010 | S |
| 7838122 | Kohn et al. | Nov 2010 | B2 |
| 7838289 | Furcht et al. | Nov 2010 | B2 |
| 7892829 | Pittenger et al. | Feb 2011 | B2 |
| 7919307 | Klaus et al. | Apr 2011 | B2 |
| 7927587 | Blazer et al. | Apr 2011 | B2 |
| 7989851 | Lu et al. | Aug 2011 | B2 |
| 8008528 | Kohn et al. | Aug 2011 | B2 |
| 8034365 | Baluca | Oct 2011 | B2 |
| 8075881 | Verfaillie et al. | Dec 2011 | B2 |
| 8147824 | Maziarz et al. | Apr 2012 | B2 |
| 8147863 | Kohn et al. | Apr 2012 | B2 |
| 8158120 | Pittenger et al. | Apr 2012 | B2 |
| 8158121 | Pittenger et al. | Apr 2012 | B2 |
| 8252280 | Verfaillie et al. | Aug 2012 | B1 |
| 8252887 | Bolikal et al. | Aug 2012 | B2 |
| 8288159 | Warren et al. | Oct 2012 | B2 |
| 8288590 | Kohn et al. | Oct 2012 | B2 |
| 8298823 | Warren et al. | Oct 2012 | B2 |
| 8361453 | Uhrich et al. | Jan 2013 | B2 |
| 8377683 | Lu et al. | Feb 2013 | B2 |
| 8383397 | Wojciechowski et al. | Feb 2013 | B2 |
| 8383806 | Rameshwar | Feb 2013 | B2 |
| 8399245 | Leuthaeuser et al. | Mar 2013 | B2 |
| 8415449 | Kohn et al. | Apr 2013 | B2 |
| 8435781 | Kodama | May 2013 | B2 |
| 8461289 | Kohn et al. | Jun 2013 | B2 |
| 8476399 | Bolikal et al. | Jul 2013 | B2 |
| 8486621 | Luo et al. | Jul 2013 | B2 |
| 8486695 | Danilkovitch et al. | Jul 2013 | B2 |
| 8492140 | Smith et al. | Jul 2013 | B2 |
| 8492150 | Parker et al. | Jul 2013 | B2 |
| 8524496 | Meiron et al. | Sep 2013 | B2 |
| 8529888 | Meiron et al. | Sep 2013 | B2 |
| 8540499 | Page et al. | Sep 2013 | B2 |
| 8551511 | Brandom et al. | Oct 2013 | B2 |
| 8580249 | Blazar et al. | Nov 2013 | B2 |
| 8678638 | Wong | Mar 2014 | B2 |
| 8852570 | Pittenger et al. | Oct 2014 | B2 |
| 8852571 | Pittenger et al. | Oct 2014 | B2 |
| 8852572 | Pittenger et al. | Oct 2014 | B2 |
| 8852573 | Pittenger et al. | Oct 2014 | B2 |
| 8852574 | Pittenger et al. | Oct 2014 | B2 |
| 8852575 | Pittenger et al. | Oct 2014 | B2 |
| 9109193 | Galliher et al. | Aug 2015 | B2 |
| 9220810 | Ma et al. | Dec 2015 | B2 |
| 9441195 | Wojciechowski et al. | Sep 2016 | B2 |
| 9534198 | Page et al. | Jan 2017 | B2 |
| 9732313 | Hirschel et al. | Aug 2017 | B2 |
| 10093956 | Hirschel et al. | Oct 2018 | B2 |
| 10494421 | Castillo | Dec 2019 | B2 |
| 20010017188 | Cooley et al. | Aug 2001 | A1 |
| 20010020086 | Hubbell et al. | Sep 2001 | A1 |
| 20010021516 | Wei et al. | Sep 2001 | A1 |
| 20010029046 | Beaulieu | Oct 2001 | A1 |
| 20010033834 | Wilkison et al. | Oct 2001 | A1 |
| 20010036663 | Kraus et al. | Nov 2001 | A1 |
| 20010041687 | Mruk | Nov 2001 | A1 |
| 20010044413 | Pierce et al. | Nov 2001 | A1 |
| 20010049139 | Lagasse et al. | Dec 2001 | A1 |
| 20020015724 | Yang et al. | Feb 2002 | A1 |
| 20020018804 | Austin et al. | Feb 2002 | A1 |
| 20020028510 | Sanberg et al. | Mar 2002 | A1 |
| 20020031757 | Ohgushi et al. | Mar 2002 | A1 |
| 20020037278 | Jeno et al. | Mar 2002 | A1 |
| 20020045260 | Hung et al. | Apr 2002 | A1 |
| 20020064869 | Ebner et al. | May 2002 | A1 |
| 20020076400 | Katz et al. | Jun 2002 | A1 |
| 20020077687 | Ahn | Jun 2002 | A1 |
| 20020082698 | Parenteau et al. | Jun 2002 | A1 |
| 20020116054 | Lundell et al. | Aug 2002 | A1 |
| 20020128581 | Vishnoi et al. | Sep 2002 | A1 |
| 20020128582 | Farrell et al. | Sep 2002 | A1 |
| 20020128583 | Min et al. | Sep 2002 | A1 |
| 20020128584 | Brown et al. | Sep 2002 | A1 |
| 20020130100 | Smith | Sep 2002 | A1 |
| 20020132343 | Lum | Sep 2002 | A1 |
| 20020139743 | Critz et al. | Oct 2002 | A1 |
| 20020142457 | Umezawa et al. | Oct 2002 | A1 |
| 20020146678 | Benvenisty | Oct 2002 | A1 |
| 20020146817 | Cannon et al. | Oct 2002 | A1 |
| 20020150989 | Greene et al. | Oct 2002 | A1 |
| 20020151056 | Sasai et al. | Oct 2002 | A1 |
| 20020159981 | Peled et al. | Oct 2002 | A1 |
| 20020160032 | Long et al. | Oct 2002 | A1 |
| 20020160510 | Hariri | Oct 2002 | A1 |
| 20020168765 | Prockop et al. | Nov 2002 | A1 |
| 20020169408 | Beretta et al. | Nov 2002 | A1 |
| 20020182241 | Borenstein et al. | Dec 2002 | A1 |
| 20020182664 | Dolecek et al. | Dec 2002 | A1 |
| 20020188962 | Denhardt et al. | Dec 2002 | A1 |
| 20020197240 | Chiu | Dec 2002 | A1 |
| 20030021850 | Ku | Jan 2003 | A1 |
| 20030022390 | Stephens | Jan 2003 | A1 |
| 20030027330 | Anza et al. | Feb 2003 | A1 |
| 20030027331 | Yan et al. | Feb 2003 | A1 |
| 20030032143 | Neff et al. | Feb 2003 | A1 |
| 20030036168 | Ni et al. | Feb 2003 | A1 |
| 20030040113 | Mizuno et al. | Feb 2003 | A1 |
| 20030049236 | Kassem et al. | Mar 2003 | A1 |
| 20030054331 | Fraser et al. | Mar 2003 | A1 |
| 20030059851 | Smith | Mar 2003 | A1 |
| 20030059939 | Page et al. | Mar 2003 | A1 |
| 20030078345 | Morrisey | Apr 2003 | A1 |
| 20030082795 | Shuler et al. | May 2003 | A1 |
| 20030086915 | Rader et al. | May 2003 | A1 |
| 20030089471 | Gehr et al. | May 2003 | A1 |
| 20030092101 | Ni et al. | May 2003 | A1 |
| 20030101465 | Lawman et al. | May 2003 | A1 |
| 20030103957 | McKerracher | Jun 2003 | A1 |
| 20030104568 | Lee | Jun 2003 | A1 |
| 20030113813 | Heidaran et al. | Jun 2003 | A1 |
| 20030113910 | Levanduski | Jun 2003 | A1 |
| 20030124091 | Tuse et al. | Jul 2003 | A1 |
| 20030124721 | Cheatham et al. | Jul 2003 | A1 |
| 20030130593 | Gonzalez | Jul 2003 | A1 |
| 20030133918 | Sherley | Jul 2003 | A1 |
| 20030138950 | McAllister et al. | Jul 2003 | A1 |
| 20030143727 | Chang | Jul 2003 | A1 |
| 20030148152 | Morrisey | Aug 2003 | A1 |
| 20030149011 | Ackerman et al. | Aug 2003 | A1 |
| 20030152558 | Luft et al. | Aug 2003 | A1 |
| 20030157078 | Hall et al. | Aug 2003 | A1 |
| 20030157709 | DiMilla et al. | Aug 2003 | A1 |
| 20030161817 | Young et al. | Aug 2003 | A1 |
| 20030166272 | Abuljadayel | Sep 2003 | A1 |
| 20030170214 | Bader | Sep 2003 | A1 |
| 20030180296 | Salcedo et al. | Sep 2003 | A1 |
| 20030185817 | Thomas et al. | Oct 2003 | A1 |
| 20030202938 | Rameshwar | Oct 2003 | A1 |
| 20030203483 | Seshi | Oct 2003 | A1 |
| 20030204323 | Morrisey | Oct 2003 | A1 |
| 20030211602 | Atala | Nov 2003 | A1 |
| 20030211603 | Earp et al. | Nov 2003 | A1 |
| 20030216718 | Hamblin et al. | Nov 2003 | A1 |
| 20030219898 | Sugaya et al. | Nov 2003 | A1 |
| 20030223968 | Yang | Dec 2003 | A1 |
| 20030224420 | Hellerstein et al. | Dec 2003 | A1 |
| 20030224510 | Yamaguchi et al. | Dec 2003 | A1 |
| 20030225010 | Rameshwar | Dec 2003 | A1 |
| 20030232432 | Bhat | Dec 2003 | A1 |
| 20030232752 | Freeman et al. | Dec 2003 | A1 |
| 20030235909 | Hariri et al. | Dec 2003 | A1 |
| 20040009158 | Sands et al. | Jan 2004 | A1 |
| 20040009589 | Levenberg et al. | Jan 2004 | A1 |
| 20040010231 | Leonhardt et al. | Jan 2004 | A1 |
| 20040014209 | Lassar et al. | Jan 2004 | A1 |
| 20040018174 | Palasis | Jan 2004 | A1 |
| 20040018617 | Hwang | Jan 2004 | A1 |
| 20040023324 | Sakano et al. | Feb 2004 | A1 |
| 20040023370 | Yu et al. | Feb 2004 | A1 |
| 20040033214 | Young et al. | Feb 2004 | A1 |
| 20040033599 | Rosenberg | Feb 2004 | A1 |
| 20040037811 | Penn et al. | Feb 2004 | A1 |
| 20040037815 | Clarke et al. | Feb 2004 | A1 |
| 20040038316 | Kaiser et al. | Feb 2004 | A1 |
| 20040053869 | Andrews et al. | Mar 2004 | A1 |
| 20040062753 | Rezania et al. | Apr 2004 | A1 |
| 20040063205 | Xu | Apr 2004 | A1 |
| 20040067585 | Wang et al. | Apr 2004 | A1 |
| 20040071668 | Bays et al. | Apr 2004 | A1 |
| 20040072259 | Scadden et al. | Apr 2004 | A1 |
| 20040077079 | Storgaard et al. | Apr 2004 | A1 |
| 20040079248 | Mayer et al. | Apr 2004 | A1 |
| 20040087016 | Keating et al. | May 2004 | A1 |
| 20040091936 | West | May 2004 | A1 |
| 20040096476 | Uhrich et al. | May 2004 | A1 |
| 20040097408 | Leder et al. | May 2004 | A1 |
| 20040101959 | Marko et al. | May 2004 | A1 |
| 20040107453 | Furcht et al. | Jun 2004 | A1 |
| 20040110286 | Bhatia | Jun 2004 | A1 |
| 20040115804 | Fu et al. | Jun 2004 | A1 |
| 20040115806 | Fu | Jun 2004 | A1 |
| 20040120932 | Zahner | Jun 2004 | A1 |
| 20040121461 | Honmou et al. | Jun 2004 | A1 |
| 20040121464 | Rathjen et al. | Jun 2004 | A1 |
| 20040126405 | Sahatjian et al. | Jul 2004 | A1 |
| 20040128077 | Koebler et al. | Jul 2004 | A1 |
| 20040131601 | Epstein et al. | Jul 2004 | A1 |
| 20040132184 | Dennis et al. | Jul 2004 | A1 |
| 20040136967 | Weiss et al. | Jul 2004 | A1 |
| 20040137612 | Baksh | Jul 2004 | A1 |
| 20040137613 | Vacanti et al. | Jul 2004 | A1 |
| 20040143174 | Brubaker | Jul 2004 | A1 |
| 20040143863 | Li et al. | Jul 2004 | A1 |
| 20040151700 | Harlan et al. | Aug 2004 | A1 |
| 20040151701 | Kim et al. | Aug 2004 | A1 |
| 20040151706 | Shakhov et al. | Aug 2004 | A1 |
| 20040151729 | Michalopoulos et al. | Aug 2004 | A1 |
| 20040152190 | Sumita | Aug 2004 | A1 |
| 20040161419 | Strom et al. | Aug 2004 | A1 |
| 20040171533 | Zehentner et al. | Sep 2004 | A1 |
| 20040180347 | Stanton et al. | Sep 2004 | A1 |
| 20040191902 | Hambor et al. | Sep 2004 | A1 |
| 20040197310 | Sanberg et al. | Oct 2004 | A1 |
| 20040197375 | Rezania et al. | Oct 2004 | A1 |
| 20040208786 | Kevy et al. | Oct 2004 | A1 |
| 20040214275 | Soejima et al. | Oct 2004 | A1 |
| 20040219134 | Naughton et al. | Nov 2004 | A1 |
| 20040219136 | Hariri | Nov 2004 | A1 |
| 20040219563 | West et al. | Nov 2004 | A1 |
| 20040224403 | Bhatia | Nov 2004 | A1 |
| 20040229351 | Rodriguez et al. | Nov 2004 | A1 |
| 20040234972 | Owens et al. | Nov 2004 | A1 |
| 20040235158 | Bartlett et al. | Nov 2004 | A1 |
| 20040235160 | Nishikawa et al. | Nov 2004 | A1 |
| 20040235166 | Prockop et al. | Nov 2004 | A1 |
| 20040242469 | Lee et al. | Dec 2004 | A1 |
| 20040258669 | Dzau et al. | Dec 2004 | A1 |
| 20040259242 | Malinge et al. | Dec 2004 | A1 |
| 20040259254 | Honmou et al. | Dec 2004 | A1 |
| 20040260058 | Scheek et al. | Dec 2004 | A1 |
| 20040260318 | Hunter et al. | Dec 2004 | A1 |
| 20040265996 | Schwarz et al. | Dec 2004 | A1 |
| 20050002914 | Rosen et al. | Jan 2005 | A1 |
| 20050003460 | Nilsson et al. | Jan 2005 | A1 |
| 20050003527 | Lang et al. | Jan 2005 | A1 |
| 20050003534 | Huberman et al. | Jan 2005 | A1 |
| 20050008624 | Peled et al. | Jan 2005 | A1 |
| 20050008626 | Fraser et al. | Jan 2005 | A1 |
| 20050009178 | Yost et al. | Jan 2005 | A1 |
| 20050009179 | Gemmiti et al. | Jan 2005 | A1 |
| 20050009181 | Black et al. | Jan 2005 | A1 |
| 20050013804 | Kato et al. | Jan 2005 | A1 |
| 20050014252 | Chu et al. | Jan 2005 | A1 |
| 20050014253 | Ehmann et al. | Jan 2005 | A1 |
| 20050014254 | Kruse | Jan 2005 | A1 |
| 20050014255 | Tang et al. | Jan 2005 | A1 |
| 20050019801 | Rubin et al. | Jan 2005 | A1 |
| 20050019908 | Hariri | Jan 2005 | A1 |
| 20050019910 | Takagi et al. | Jan 2005 | A1 |
| 20050019911 | Gronthos et al. | Jan 2005 | A1 |
| 20050026836 | Dack et al. | Feb 2005 | A1 |
| 20050031587 | Tsutsui et al. | Feb 2005 | A1 |
| 20050031595 | Peled et al. | Feb 2005 | A1 |
| 20050031598 | Levenberg et al. | Feb 2005 | A1 |
| 20050032122 | Twang et al. | Feb 2005 | A1 |
| 20050032207 | Wobus et al. | Feb 2005 | A1 |
| 20050032209 | Messina et al. | Feb 2005 | A1 |
| 20050032218 | Gerlach | Feb 2005 | A1 |
| 20050036980 | Chaney et al. | Feb 2005 | A1 |
| 20050037488 | Mitalipova et al. | Feb 2005 | A1 |
| 20050037490 | Rosenberg et al. | Feb 2005 | A1 |
| 20050037492 | Xu et al. | Feb 2005 | A1 |
| 20050037493 | Mandalam et al. | Feb 2005 | A1 |
| 20050037949 | O'Brien et al. | Feb 2005 | A1 |
| 20050106119 | Brandom et al. | May 2005 | A1 |
| 20050106127 | Kraus et al. | May 2005 | A1 |
| 20050112447 | Fletcher et al. | May 2005 | A1 |
| 20050112762 | Hart et al. | May 2005 | A1 |
| 20050118712 | Tsai et al. | Jun 2005 | A1 |
| 20050130297 | Sarem et al. | Jun 2005 | A1 |
| 20050136093 | Denk | Jun 2005 | A1 |
| 20050137517 | Blickhan et al. | Jun 2005 | A1 |
| 20050142162 | Hunter et al. | Jun 2005 | A1 |
| 20050149157 | Hunter et al. | Jul 2005 | A1 |
| 20050152946 | Hunter et al. | Jul 2005 | A1 |
| 20050158289 | Simmons et al. | Jul 2005 | A1 |
| 20050172340 | Logvinov et al. | Aug 2005 | A1 |
| 20050175665 | Hunter et al. | Aug 2005 | A1 |
| 20050175703 | Hunter et al. | Aug 2005 | A1 |
| 20050178395 | Hunter et al. | Aug 2005 | A1 |
| 20050178396 | Hunter et al. | Aug 2005 | A1 |
| 20050180957 | Scharp et al. | Aug 2005 | A1 |
| 20050181502 | Furcht et al. | Aug 2005 | A1 |
| 20050182463 | Hunter et al. | Aug 2005 | A1 |
| 20050183731 | Hunter et al. | Aug 2005 | A1 |
| 20050186244 | Hunter et al. | Aug 2005 | A1 |
| 20050186671 | Cannon et al. | Aug 2005 | A1 |
| 20050187140 | Hunter et al. | Aug 2005 | A1 |
| 20050196421 | Hunter et al. | Sep 2005 | A1 |
| 20050208095 | Hunter et al. | Sep 2005 | A1 |
| 20050244963 | Teplyashin | Nov 2005 | A1 |
| 20050249731 | Aslan et al. | Nov 2005 | A1 |
| 20050255118 | Wehner | Nov 2005 | A1 |
| 20050261674 | Nobis et al. | Nov 2005 | A1 |
| 20050277577 | Hunter et al. | Dec 2005 | A1 |
| 20050281790 | Simmons et al. | Dec 2005 | A1 |
| 20050282733 | Prins et al. | Dec 2005 | A1 |
| 20050283844 | Furcht et al. | Dec 2005 | A1 |
| 20060002900 | Binder et al. | Jan 2006 | A1 |
| 20060008452 | Simmons et al. | Jan 2006 | A1 |
| 20060019389 | Yayon et al. | Jan 2006 | A1 |
| 20060054941 | Lu et al. | Mar 2006 | A1 |
| 20060083720 | Fraser et al. | Apr 2006 | A1 |
| 20060099198 | Thomson et al. | May 2006 | A1 |
| 20060166364 | Senesac | Jul 2006 | A1 |
| 20060172008 | Yayon et al. | Aug 2006 | A1 |
| 20060193840 | Gronthos et al. | Aug 2006 | A1 |
| 20060228798 | Verfaillie et al. | Oct 2006 | A1 |
| 20060239909 | Anderson et al. | Oct 2006 | A1 |
| 20060258586 | Sheppard et al. | Nov 2006 | A1 |
| 20060258933 | Ellis et al. | Nov 2006 | A1 |
| 20060259998 | Brumbley et al. | Nov 2006 | A1 |
| 20060280748 | Buckheit | Dec 2006 | A1 |
| 20060286077 | Gronthos et al. | Dec 2006 | A1 |
| 20070005148 | Barofsky et al. | Jan 2007 | A1 |
| 20070011752 | Paleyanda | Jan 2007 | A1 |
| 20070042462 | Hildinger | Feb 2007 | A1 |
| 20070065938 | Gronthos et al. | Mar 2007 | A1 |
| 20070105222 | Wolfinbarger et al. | May 2007 | A1 |
| 20070116612 | Williamson | May 2007 | A1 |
| 20070117180 | Morikawa et al. | May 2007 | A1 |
| 20070123996 | Sugaya et al. | May 2007 | A1 |
| 20070166834 | Williamson et al. | Jul 2007 | A1 |
| 20070178071 | Westenfelder | Aug 2007 | A1 |
| 20070196421 | Hunter et al. | Aug 2007 | A1 |
| 20070197957 | Hunter et al. | Aug 2007 | A1 |
| 20070198063 | Hunter et al. | Aug 2007 | A1 |
| 20070202485 | Nees et al. | Aug 2007 | A1 |
| 20070203330 | Kretschmar et al. | Aug 2007 | A1 |
| 20070208134 | Hunter et al. | Sep 2007 | A1 |
| 20070258943 | Penn et al. | Nov 2007 | A1 |
| 20070274970 | Gordon et al. | Nov 2007 | A1 |
| 20070275457 | Granchelli et al. | Nov 2007 | A1 |
| 20070295651 | Martinez et al. | Dec 2007 | A1 |
| 20070298015 | Beer et al. | Dec 2007 | A1 |
| 20080003663 | Bryhan et al. | Jan 2008 | A1 |
| 20080009458 | Dornan et al. | Jan 2008 | A1 |
| 20080032398 | Cannon et al. | Feb 2008 | A1 |
| 20080050770 | Zhang et al. | Feb 2008 | A1 |
| 20080063600 | Aguzzi et al. | Mar 2008 | A1 |
| 20080064649 | Rameshwar | Mar 2008 | A1 |
| 20080069807 | Jy et al. | Mar 2008 | A1 |
| 20080095676 | Andretta | Apr 2008 | A1 |
| 20080095690 | Liu | Apr 2008 | A1 |
| 20080103412 | Chin | May 2008 | A1 |
| 20080110827 | Cote et al. | May 2008 | A1 |
| 20080113426 | Smith et al. | May 2008 | A1 |
| 20080113440 | Gurney et al. | May 2008 | A1 |
| 20080153077 | Henry | Jun 2008 | A1 |
| 20080160597 | van der Heiden et al. | Jul 2008 | A1 |
| 20080166808 | Nyberg | Jul 2008 | A1 |
| 20080181879 | Catelas et al. | Jul 2008 | A1 |
| 20080190857 | Beretta et al. | Aug 2008 | A1 |
| 20080194017 | Esser et al. | Aug 2008 | A1 |
| 20080206831 | Coffey et al. | Aug 2008 | A1 |
| 20080220524 | Noll et al. | Sep 2008 | A1 |
| 20080220526 | Ellison et al. | Sep 2008 | A1 |
| 20080221443 | Ritchie et al. | Sep 2008 | A1 |
| 20080227189 | Bader | Sep 2008 | A1 |
| 20080268165 | Fekety et al. | Oct 2008 | A1 |
| 20080306095 | Crawford | Dec 2008 | A1 |
| 20090004738 | Merchav et al. | Jan 2009 | A1 |
| 20090011399 | Fischer | Jan 2009 | A1 |
| 20090047289 | Denhardt et al. | Feb 2009 | A1 |
| 20090074728 | Gronthos et al. | Mar 2009 | A1 |
| 20090075881 | Catelas et al. | Mar 2009 | A1 |
| 20090076481 | Stegmann et al. | Mar 2009 | A1 |
| 20090081770 | Srienc et al. | Mar 2009 | A1 |
| 20090081797 | Fadeev et al. | Mar 2009 | A1 |
| 20090092608 | Ni et al. | Apr 2009 | A1 |
| 20090098103 | Madison et al. | Apr 2009 | A1 |
| 20090098645 | Fang et al. | Apr 2009 | A1 |
| 20090100944 | Newby | Apr 2009 | A1 |
| 20090104163 | Deans et al. | Apr 2009 | A1 |
| 20090104692 | Bartfeld et al. | Apr 2009 | A1 |
| 20090104699 | Newby et al. | Apr 2009 | A1 |
| 20090118161 | Cruz | May 2009 | A1 |
| 20090181087 | Kraus et al. | Jul 2009 | A1 |
| 20090183581 | Wilkinson et al. | Jul 2009 | A1 |
| 20090191627 | Fadeev et al. | Jul 2009 | A1 |
| 20090191632 | Fadeev et al. | Jul 2009 | A1 |
| 20090191634 | Martin et al. | Jul 2009 | A1 |
| 20090203065 | Gehman et al. | Aug 2009 | A1 |
| 20090203129 | Furcht et al. | Aug 2009 | A1 |
| 20090203130 | Furcht et al. | Aug 2009 | A1 |
| 20090214382 | Burgess et al. | Aug 2009 | A1 |
| 20090214481 | Muhs et al. | Aug 2009 | A1 |
| 20090214652 | Hunter et al. | Aug 2009 | A1 |
| 20090215022 | Page et al. | Aug 2009 | A1 |
| 20090227024 | Baker et al. | Sep 2009 | A1 |
| 20090227027 | Baker et al. | Sep 2009 | A1 |
| 20090233334 | Hildinger et al. | Sep 2009 | A1 |
| 20090233353 | Furcht et al. | Sep 2009 | A1 |
| 20090233354 | Furcht et al. | Sep 2009 | A1 |
| 20090258379 | Klein et al. | Oct 2009 | A1 |
| 20090269841 | Wojciechowski et al. | Oct 2009 | A1 |
| 20090270725 | Leimbach et al. | Oct 2009 | A1 |
| 20090280153 | Hunter et al. | Nov 2009 | A1 |
| 20090280565 | Jolicoeur et al. | Nov 2009 | A1 |
| 20090291890 | Madison et al. | Nov 2009 | A1 |
| 20100009409 | Hubbell et al. | Jan 2010 | A1 |
| 20100021954 | Deshayes et al. | Jan 2010 | A1 |
| 20100021990 | Edwards et al. | Jan 2010 | A1 |
| 20100028311 | Motlagh et al. | Feb 2010 | A1 |
| 20100075410 | Desai et al. | Mar 2010 | A1 |
| 20100086481 | Baird et al. | Apr 2010 | A1 |
| 20100092536 | Hunter et al. | Apr 2010 | A1 |
| 20100093607 | Dickneite | Apr 2010 | A1 |
| 20100111910 | Rakoczy | May 2010 | A1 |
| 20100129376 | Denhardt et al. | May 2010 | A1 |
| 20100129912 | Su et al. | May 2010 | A1 |
| 20100136091 | Moghe et al. | Jun 2010 | A1 |
| 20100144634 | Zheng et al. | Jun 2010 | A1 |
| 20100183561 | Sakthivel et al. | Jul 2010 | A1 |
| 20100183585 | Van Zant et al. | Jul 2010 | A1 |
| 20100203020 | Ghosh | Aug 2010 | A1 |
| 20100230203 | Karayianni | Sep 2010 | A1 |
| 20100248366 | Fadeev et al. | Sep 2010 | A1 |
| 20100278933 | Sayeski et al. | Nov 2010 | A1 |
| 20100285453 | Goodrich | Nov 2010 | A1 |
| 20100285590 | Verfaillie et al. | Nov 2010 | A1 |
| 20100291180 | Uhrich | Nov 2010 | A1 |
| 20100291181 | Uhrich et al. | Nov 2010 | A1 |
| 20100297234 | Sugino et al. | Nov 2010 | A1 |
| 20100304427 | Faris et al. | Dec 2010 | A1 |
| 20100304482 | Deshayes et al. | Dec 2010 | A1 |
| 20100310524 | Bechor et al. | Dec 2010 | A1 |
| 20100316446 | Runyon | Dec 2010 | A1 |
| 20110085746 | Wong et al. | Apr 2011 | A1 |
| 20110111498 | Oh et al. | May 2011 | A1 |
| 20110129447 | Meretzki et al. | Jun 2011 | A1 |
| 20110129486 | Meiron | Jun 2011 | A1 |
| 20110143433 | Oh et al. | Jun 2011 | A1 |
| 20110159584 | Gibbons et al. | Jun 2011 | A1 |
| 20110171182 | Abelman | Jul 2011 | A1 |
| 20110171659 | Furcht et al. | Jul 2011 | A1 |
| 20110177595 | Furcht et al. | Jul 2011 | A1 |
| 20110212493 | Hirschel et al. | Sep 2011 | A1 |
| 20110256108 | Meiron et al. | Oct 2011 | A1 |
| 20110256160 | Meiron et al. | Oct 2011 | A1 |
| 20110293583 | Aberman | Dec 2011 | A1 |
| 20120028352 | Oh et al. | Feb 2012 | A1 |
| 20120051976 | Lu et al. | Mar 2012 | A1 |
| 20120058554 | Deshayes et al. | Mar 2012 | A1 |
| 20120064047 | Verfaillie et al. | Mar 2012 | A1 |
| 20120064583 | Edwards et al. | Mar 2012 | A1 |
| 20120118919 | Cianciolo | May 2012 | A1 |
| 20120122220 | Merchav et al. | May 2012 | A1 |
| 20120135043 | Maziarz et al. | May 2012 | A1 |
| 20120145580 | Paruit et al. | Jun 2012 | A1 |
| 20120156779 | Anneren et al. | Jun 2012 | A1 |
| 20120178885 | Kohn et al. | Jul 2012 | A1 |
| 20120189713 | Kohn et al. | Jul 2012 | A1 |
| 20120208039 | Barbaroux et al. | Aug 2012 | A1 |
| 20120219531 | Oh et al. | Aug 2012 | A1 |
| 20120219737 | Sugino et al. | Aug 2012 | A1 |
| 20120226013 | Kohn et al. | Sep 2012 | A1 |
| 20120231519 | Bushman et al. | Sep 2012 | A1 |
| 20120237557 | Ewitus et al. | Sep 2012 | A1 |
| 20120295352 | Antwiler | Nov 2012 | A1 |
| 20120308531 | Pinxteren et al. | Dec 2012 | A1 |
| 20120315696 | Luitjens et al. | Dec 2012 | A1 |
| 20130004465 | Aberman | Jan 2013 | A1 |
| 20130039892 | Aberman | Feb 2013 | A1 |
| 20130058907 | Wojciechowski et al. | Mar 2013 | A1 |
| 20130059383 | Dijkhuizen Borgart et al. | Mar 2013 | A1 |
| 20130101561 | Sabaawy | Apr 2013 | A1 |
| 20130143313 | Niazi | Jun 2013 | A1 |
| 20130157353 | Dijkhuizen Borgart et al. | Jun 2013 | A1 |
| 20130237453 | Chander | Sep 2013 | A1 |
| 20130259843 | Duda et al. | Oct 2013 | A1 |
| 20130319575 | Mendyk | Dec 2013 | A1 |
| 20130323213 | Meiron et al. | Dec 2013 | A1 |
| 20130337558 | Meiron et al. | Dec 2013 | A1 |
| 20140004553 | Parker et al. | Jan 2014 | A1 |
| 20140017209 | Aberman et al. | Jan 2014 | A1 |
| 20140030805 | Kasuto et al. | Jan 2014 | A1 |
| 20140051162 | Nankervis | Feb 2014 | A1 |
| 20140051167 | Nankervis et al. | Feb 2014 | A1 |
| 20140112893 | Tom et al. | Apr 2014 | A1 |
| 20140186937 | Smith et al. | Jul 2014 | A1 |
| 20140193895 | Smith et al. | Jul 2014 | A1 |
| 20140193911 | Newby et al. | Jul 2014 | A1 |
| 20140242039 | Meiron et al. | Aug 2014 | A1 |
| 20140248244 | Danilkovitch et al. | Sep 2014 | A1 |
| 20140315300 | Oh et al. | Oct 2014 | A1 |
| 20140342448 | Nagels | Nov 2014 | A1 |
| 20150004693 | Danilkovitch et al. | Jan 2015 | A1 |
| 20150104431 | Pittenger et al. | Apr 2015 | A1 |
| 20150111252 | Hirschel et al. | Apr 2015 | A1 |
| 20150125138 | Kamieli et al. | May 2015 | A1 |
| 20150175950 | Hirschel et al. | Jun 2015 | A1 |
| 20150225685 | Hirschel et al. | Aug 2015 | A1 |
| 20150247122 | Tom et al. | Sep 2015 | A1 |
| 20150259749 | Santos et al. | Sep 2015 | A1 |
| 20160362650 | Wojciechowski et al. | Dec 2016 | A1 |
| 20160362652 | Page et al. | Dec 2016 | A1 |
| 20180010082 | Jaques et al. | Jan 2018 | A1 |
| 20180030398 | Castillo | Feb 2018 | A1 |
| 20180155668 | Hirschel et al. | Jun 2018 | A1 |
| 20190194628 | Rao et al. | Jun 2019 | A1 |
| Number | Date | Country |
|---|---|---|
| 1016332 | Aug 1977 | CA |
| 4007703 | Sep 1991 | DE |
| 10244859 | Apr 2004 | DE |
| 10327988 | Jul 2004 | DE |
| 102012200939 | Jul 2013 | DE |
| 750938 | Jan 1997 | EP |
| 906415 | Apr 1999 | EP |
| 959980 | Dec 1999 | EP |
| 1007631 | Jun 2000 | EP |
| 1028737 | Aug 2000 | EP |
| 1028991 | Aug 2000 | EP |
| 1066052 | Jan 2001 | EP |
| 1066060 | Jan 2001 | EP |
| 1084230 | Mar 2001 | EP |
| 1147176 | Oct 2001 | EP |
| 1220611 | Jul 2002 | EP |
| 1223956 | Jul 2002 | EP |
| 1325953 | Jul 2003 | EP |
| 1437404 | Jul 2004 | EP |
| 1437406 | Jul 2004 | EP |
| 1447443 | Aug 2004 | EP |
| 1452594 | Sep 2004 | EP |
| 1062321 | Dec 2004 | EP |
| 1484080 | Dec 2004 | EP |
| 1498478 | Jan 2005 | EP |
| 1036057 | Oct 2005 | EP |
| 1605044 | Dec 2005 | EP |
| 1756262 | Feb 2007 | EP |
| 1771737 | Apr 2007 | EP |
| 1882030 | Jan 2008 | EP |
| 1908490 | Apr 2008 | EP |
| 1971679 | Sep 2008 | EP |
| 1991668 | Nov 2008 | EP |
| 2027247 | Feb 2009 | EP |
| 2200622 | Jun 2010 | EP |
| 2208782 | Jul 2010 | EP |
| 2264145 | Dec 2010 | EP |
| 2303293 | Apr 2011 | EP |
| 2311938 | Apr 2011 | EP |
| 2331957 | Jun 2011 | EP |
| 2334310 | Jun 2011 | EP |
| 2334783 | Jun 2011 | EP |
| 2361968 | Aug 2011 | EP |
| 2366775 | Sep 2011 | EP |
| 2465922 | Jun 2012 | EP |
| 2548951 | Jan 2013 | EP |
| 2561066 | Feb 2013 | EP |
| 2575831 | Apr 2013 | EP |
| 2591789 | May 2013 | EP |
| 2624845 | Aug 2013 | EP |
| 2626417 | Aug 2013 | EP |
| 2641606 | Sep 2013 | EP |
| 2689008 | Jan 2014 | EP |
| 2694639 | Feb 2014 | EP |
| 2697362 | Feb 2014 | EP |
| 2739720 | Jun 2014 | EP |
| 2807246 | Dec 2014 | EP |
| 1414671 | Nov 1975 | GB |
| 2297980 | Aug 1996 | GB |
| 2360789 | Oct 2001 | GB |
| 3285 | May 2007 | HU |
| 189272 | Jan 2003 | IN |
| 2003052360 | Feb 2003 | JP |
| 5548207 | Jul 2014 | JP |
| 115206 | Apr 2003 | MY |
| 9013306 | Nov 1990 | WO |
| 9105238 | Apr 1991 | WO |
| 9106641 | May 1991 | WO |
| 9109194 | Jun 1991 | WO |
| 9425571 | Nov 1994 | WO |
| 9629395 | Sep 1996 | WO |
| 9639035 | Dec 1996 | WO |
| 9705826 | Feb 1997 | WO |
| 9729792 | Aug 1997 | WO |
| 9739104 | Oct 1997 | WO |
| 1997-040137 | Oct 1997 | WO |
| 9831403 | Jul 1998 | WO |
| 9851317 | Nov 1998 | WO |
| 9851785 | Nov 1998 | WO |
| 9905180 | Feb 1999 | WO |
| 9924391 | May 1999 | WO |
| 9924490 | May 1999 | WO |
| 9927167 | Jun 1999 | WO |
| 9949015 | Sep 1999 | WO |
| 0006704 | Feb 2000 | WO |
| 0009018 | Feb 2000 | WO |
| 0016420 | Mar 2000 | WO |
| 0017326 | Mar 2000 | WO |
| 0029002 | May 2000 | WO |
| 0032225 | Jun 2000 | WO |
| 0044058 | Jul 2000 | WO |
| 0054651 | Sep 2000 | WO |
| 0056405 | Sep 2000 | WO |
| 0059933 | Oct 2000 | WO |
| 0069449 | Nov 2000 | WO |
| 0075196 | Dec 2000 | WO |
| 0077236 | Dec 2000 | WO |
| 2001000783 | Jan 2001 | WO |
| 2001011011 | Feb 2001 | WO |
| 2001018174 | Mar 2001 | WO |
| 2001021766 | Mar 2001 | WO |
| 2001025402 | Apr 2001 | WO |
| 2001029189 | Apr 2001 | WO |
| 0122810 | Apr 2001 | WO |
| 2001034167 | May 2001 | WO |
| 2001049851 | Jul 2001 | WO |
| 2001054706 | Aug 2001 | WO |
| 2001-094541 | Dec 2001 | WO |
| 2002042422 | May 2002 | WO |
| 2002057430 | Jul 2002 | WO |
| 2002092794 | Nov 2002 | WO |
| 2002101385 | Dec 2002 | WO |
| 2003010303 | Feb 2003 | WO |
| 2003014313 | Feb 2003 | WO |
| 2003016916 | Feb 2003 | WO |
| 2003023018 | Mar 2003 | WO |
| 2003023019 | Mar 2003 | WO |
| 2003025167 | Mar 2003 | WO |
| 2003029402 | Apr 2003 | WO |
| 2003040336 | May 2003 | WO |
| 2003042405 | May 2003 | WO |
| 2003046161 | Jun 2003 | WO |
| 2003055989 | Jul 2003 | WO |
| 2003061685 | Jul 2003 | WO |
| 2003061686 | Jul 2003 | WO |
| 2003068961 | Aug 2003 | WO |
| 2003072064 | Sep 2003 | WO |
| 2003078609 | Sep 2003 | WO |
| 2003078967 | Sep 2003 | WO |
| 2003080816 | Oct 2003 | WO |
| 2003082145 | Oct 2003 | WO |
| 2003085099 | Oct 2003 | WO |
| 2003089631 | Oct 2003 | WO |
| 2003091398 | Nov 2003 | WO |
| 2003095631 | Nov 2003 | WO |
| 2004001697 | Dec 2003 | WO |
| 2004012226 | Feb 2004 | WO |
| 2004016779 | Feb 2004 | WO |
| 2004018526 | Mar 2004 | WO |
| 2004018655 | Mar 2004 | WO |
| 2004026115 | Apr 2004 | WO |
| 2004029231 | Apr 2004 | WO |
| 2004042023 | May 2004 | WO |
| 2004042033 | May 2004 | WO |
| 2004042040 | May 2004 | WO |
| 2004044127 | May 2004 | WO |
| 2004044158 | May 2004 | WO |
| 2004046304 | Jun 2004 | WO |
| 2004050826 | Jun 2004 | WO |
| 2004053096 | Jun 2004 | WO |
| 2004055155 | Jul 2004 | WO |
| 2004056186 | Jul 2004 | WO |
| 2004065616 | Aug 2004 | WO |
| 2004069172 | Aug 2004 | WO |
| 2004070013 | Aug 2004 | WO |
| 2004072264 | Aug 2004 | WO |
| 2004073633 | Sep 2004 | WO |
| 2004074464 | Sep 2004 | WO |
| 2004076642 | Sep 2004 | WO |
| 2004076653 | Sep 2004 | WO |
| 2004087870 | Oct 2004 | WO |
| 2004094588 | Nov 2004 | WO |
| 2004096975 | Nov 2004 | WO |
| 2004104166 | Dec 2004 | WO |
| 2004106499 | Dec 2004 | WO |
| 2004113513 | Dec 2004 | WO |
| 2005001033 | Jan 2005 | WO |
| 2005001081 | Jan 2005 | WO |
| 2005003320 | Jan 2005 | WO |
| 2005007799 | Jan 2005 | WO |
| 2005010172 | Feb 2005 | WO |
| 2005011524 | Feb 2005 | WO |
| 2005012480 | Feb 2005 | WO |
| 2005012510 | Feb 2005 | WO |
| 2005012512 | Feb 2005 | WO |
| 05014775 | Feb 2005 | WO |
| 2005028433 | Mar 2005 | WO |
| 05044972 | May 2005 | WO |
| 2005056747 | Jun 2005 | WO |
| 05051316 | Jun 2005 | WO |
| 2005063303 | Jul 2005 | WO |
| 2005075636 | Aug 2005 | WO |
| 2005107760 | Nov 2005 | WO |
| 2006009291 | Jan 2006 | WO |
| 2006032075 | Mar 2006 | WO |
| 2006032092 | Mar 2006 | WO |
| 2006108229 | Oct 2006 | WO |
| 2006113881 | Oct 2006 | WO |
| 2006121445 | Nov 2006 | WO |
| 06124021 | Nov 2006 | WO |
| 06129312 | Dec 2006 | WO |
| 2007115367 | Oct 2007 | WO |
| 2007115368 | Oct 2007 | WO |
| 2008006168 | Jan 2008 | WO |
| 2008011664 | Jan 2008 | WO |
| 2008017128 | Feb 2008 | WO |
| 2008028241 | Mar 2008 | WO |
| 08040812 | Apr 2008 | WO |
| 2008116261 | Oct 2008 | WO |
| 2008149129 | Dec 2008 | WO |
| 2009026635 | Mar 2009 | WO |
| 09058146 | May 2009 | WO |
| 09080054 | Jul 2009 | WO |
| 09081408 | Jul 2009 | WO |
| 2009140452 | Nov 2009 | WO |
| 09132457 | Nov 2009 | WO |
| 2009144720 | Dec 2009 | WO |
| 10005527 | Jan 2010 | WO |
| 2010019886 | Feb 2010 | WO |
| 10014253 | Feb 2010 | WO |
| 10019997 | Feb 2010 | WO |
| 2010026573 | Mar 2010 | WO |
| 2010026574 | Mar 2010 | WO |
| 2010026575 | Mar 2010 | WO |
| 2010036760 | Apr 2010 | WO |
| 2010059487 | May 2010 | WO |
| 10061377 | Jun 2010 | WO |
| 10068710 | Jun 2010 | WO |
| 10071826 | Jun 2010 | WO |
| 10083385 | Jul 2010 | WO |
| 10111255 | Sep 2010 | WO |
| 10119036 | Oct 2010 | WO |
| 10123594 | Oct 2010 | WO |
| 2011025445 | Mar 2011 | WO |
| 2011132087 | Oct 2011 | WO |
| 2011147967 | Dec 2011 | WO |
| 2012072924 | Jun 2012 | WO |
| 2012127320 | Sep 2012 | WO |
| 2012138968 | Oct 2012 | WO |
| 2012140519 | Oct 2012 | WO |
| 2012171026 | Dec 2012 | WO |
| 2012171030 | Dec 2012 | WO |
| 2013110651 | Aug 2013 | WO |
| 2014037862 | Mar 2014 | WO |
| 2014037863 | Mar 2014 | WO |
| 2014068508 | May 2014 | WO |
| 2014128306 | Aug 2014 | WO |
| 2014128634 | Aug 2014 | WO |
| 2014131846 | Sep 2014 | WO |
| 2014141111 | Sep 2014 | WO |
| 2015004609 | Jan 2015 | WO |
| 2015118148 | Aug 2015 | WO |
| 2015118149 | Aug 2015 | WO |
| 2015131143 | Sep 2015 | WO |
| 2017072201 | May 2017 | WO |
| Entry |
|---|
| Mathew, James M., et al. “A phase I clinical trial with ex vivo expanded recipient regulatory T cells in living donor kidney transplants.” Scientific reports 8.1 (2018): 1-12. |
| Jeda, Ryosuke, et al. “Interaction of natural killer cells with neutrophils exerts a significant antitumor immunity in hematopoietic stem cell transplantation recipients.” Cancer medicine 5.1 (2015): 49-60. |
| Jin, H., and J. Bae. “Neuropeptide Y regulates the hematopoietic stem cell microenvironment and prevents nerve injury in the bone marrow.” 22nd Annual ISCT Meeting (2016): S29. |
| Bai, Tao, et al. “Expansion of primitive human hematopoietic stem cells by culture in a zwitterionic hydrogel.” Nature medicine 25.10 (2019): 1566-1575. |
| Horwitz, Mitchell E., et al. “Phase I/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide.” Journal of Clinical Oncology 37.5 (2019): 367-373. |
| Lee III, Daniel W., et al. “Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation.” Blood 128.22 (2016): 218. |
| Goh, Celeste, Sowmya Narayanan, and Young S. Hahn. “Myeloid-derived suppressor cells: the dark knight or the joker in viral infections ?.” Immunological reviews 255.1 (2013): 210-221. |
| Pati, Shibani, and Todd E. Rasmussen. “Cellular therapies in trauma and critical care medicine: Looking towards the future.” PLoS Medicine 14.7 (2017): e1002343. |
| Pati, Shibani, et al. “Lyophilized plasma attenuates vascular permeability, inflammation and lung injury in hemorrhagic shock.” PloS one 13.2 (2018): e0192363. |
| Streltsova et al., “Recurrent Stimulation of Natural Killer Cell Clones with K562 Expressing Membrane-Bound Interleukin-21 Affects Their Phenotype, Interferon-y Production, and Lifespan,” International Journal of Molecular Sciences, vol. 20, No. 443, 2019, pp. 1-18. |
| Nehlin JO, Just M, Rustan AC (2011) Human myotubes from myoblast cultures undergoing senescence exhibit defects in glucose and lipid metabolism. Biogerontology 12: 349-365. |
| Unknown author, “New Victories for Adult Stem Cell Research,” New York, Feb. 6, 2007. |
| Newton R, Priyadharshini B, Turka LA. Immunometabolism of regulatory T cells. Nat Immunol. 2016;17(6):618-25. |
| Ng TH, Britton GJ, Hill EV, Verhagen J, Burton BR, Wraith DC. Regulation of adaptive immunity; the role of Interleukin-10. Front Immunol. 2013;4:129. |
| Nikolaychik, V. V., M. M. Samet, and P. I. Lelkes. “A New, Cryoprecipitate Based Coating For Improved Endothelial Cell Attachment And Growth On Medical Grade Artificial Surfaces.” ASAIO Journal (American Society for Artificial Internal Organs: 1992) 40.3 (1994): M846-52. |
| Nish SA, Schenten D, Wunderlich FT, Pope SD, Gao Y, Hoshi N, Yu S, Yan X, Lee HK, Pasman L, Brodsky I, Yordy B, Zhao H, Bruning J, Medzhitov R. T cell-intrinsic role of IL-6 signaling in primary and memory responses. Elife. 2014;3: e01949. |
| Niwayama, Jun, et al. “Analysis of hemodynamics during blood purification therapy using a newly developed noninvasive continuous monitoring method.” Therapeutic Apheresis and Dialysis 10.4 (2006): 380-386. |
| Nugent, Helen M., et al. “Adventitial endothelial implants reduce matrix metalloproteinase-2 expression and increase luminal diameter in porcine arteriovenous grafts.” Journal of vascular surgery 46.3 (2007): 548-556. |
| Okano et al (Tokyo Women's Medical College, Japan) demonstrated the recovery of endothelial cells and hepatocytes from plasma-treated polystyrene dishes grafted with PNIAAm (Journal of Biomedical Materials Research, 1993). |
| Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A. 2008;105(29):10113-8. |
| Onyszchuk G, LeVine SM, Brooks WM, Berman NE. Post-acute pathological changes in the thalamus and internal capsule in aged mice following controlled cortical impact injury: A magnetic resonance imaging, iron histochemical, and glial immunohistochemical study. Neuroscience letters. 2009;452:204-208. |
| Pacella I, Procaccini C, Focaccetti C, Miacci S, Timperi E, Faicchia D, Severa M, Rizzo F, Coccia EM, Bonacina F, Mitro N, Norata GD, Rossetti G, Ranzani V, Pagani M, Giorda E, Wei Y, Matarese G, Barnaba V, Piconese S. Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth. Proc Natl Acad Sci U S A. 2018;115(28):E6546-E6555. |
| Parhi, Purnendu, Avantika Golas, and Erwin A. Vogler. “Role Of Proteins And Water In The Initial Attachment Of Mammalian Cells To Biomedical Surfaces: A Review.” Journal of Adhesion Science and Technology 24.5 (2010): 853-888. |
| Pati S, Gerber MH, Menge TD, Wataha KA, Zhao Y, Baumgartner JA, Zhao J, Letourneau PA, Huby MP, Baer LA, Salsbury JR, Kozar RA, Wade CE, Walker PA, Dash PK, Cox CS, Jr., Doursout MF, Holcomb JB. Bone marrow derived mesenchymal stem cells inhibit inflammation and preserve vascular endothelial integrity in the lungs after hemorrhagic shock. PloS one. 2011;6:e25171. |
| Pati S, Khakoo AY, Zhao J, Jimenez F, Gerber MH, Harting M, Redell JB, Grill R, Matsuo Y, Guha S, Cox CS, Reitz MS, Holcomb JB, Dash PK. Human mesenchymal stem cells inhibit vascular permeability by modulating vascular endothelial cadherin/beta-catenin signaling. Stem cells and development. 2011;20:89-101. |
| Peters JH, Preijers FW, Woestenenk R, Hilbrands LB, Koenen HJ, Joosten I. Clinical grade Treg: GMP isolation, improvement of purity by CD127 Depletion, Treg expansion, and Treg cryopreservation. PLoS One. 2008;3(9):e3161. |
| Peters, R.; Jones, M.; Brecheisen, M.; Startz, T.; Vang, B.; Nankervis, B.; Frank, N.; Nguyen, K. (2012) TerumoBCT. https://www.terumobct.com/location/north-america/products-and-services/Pages/Quantum-Materials.aspx. |
| Porter CM, Horvath-Arcidiacono JA, Singh AK, Horvath KA, Bloom ET, Mohiuddin MM. Characterization and expansion of baboon CD4+CD25+ Treg cells for potential use in a non-human primate xenotransplantation model. Xenotransplantation. 2007;14(4):298-308. |
| Povsic TJ, O'Connor CM, Henry T, et al. (2011) A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction. Am Heart J 162(4): 654-662. |
| Prockop, Darwin J., Carl A. Gregory, and Jeffery L. Spees. “One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues.” Proceedings of the National Academy of Sciences 100.suppl_1 (2003): 11917-11923. |
| Q. L. Hao, et al. A functional comparison of CD34+ CD38= cells in cord blood and bone marrow. Blood 86:3745-3753, 1995. |
| Rahmahwati, Nurlaela, Deana Wahyuningrum, and Anita Alni. “The Synthesis Of Polyethersulfone (PES) Derivatives For The Immobilization Of Lipase Enzyme.” Key Engineering Materials. vol. 811. Trans Tech Publications Ltd, 2019. |
| Rey-Jurado, Emma, et al. “Assessing the importance of domestic vaccine manufacturing centers: an overview of immunization programs, vaccine manufacture, and distribution.” Frontiers in immunology 9 (2018): 26. |
| Roballo KC, Dhungana S, Z. J, Oakey J, Bushman J. Localized delivery of immunosuppressive regulatory T cells to peripheral nerve allografts promotes regeneration of branched segmental defects. Biomaterials. 2019;209:1-9. |
| Rodrigues, C., Fernandes, T., Diogo, M., Lobato da Silva, C., Cabral, J. Stem Cell Cultivation in Bioreactors. 2011. Biotechnology Advances v. 29, pp. 815-829. |
| Ronco C1, Levin N, Brendolan A, Nalesso F, Cruz D, Ocampo C, Kuang D, Bonello M, De Cal M, Corradi V, Ricci Z. Flow distribution analysis by helical scanning in polysulfone hemodialyzers: effects of fiber structure and design on flow patterns and solute clearances. Hemodial Int. Oct. 2006; 10(4):380-8. |
| Ronco, C., Brendolan, A., Crepaldi, C., Todighiero, M., Scabardi, M. Blood and Dialysate Flow Distributions in Hollow-Fiber Hemodialyzers Analyzed by Computerized Helical Scanning Technique. 2002. Journal of the American Society of Nephrology. V. 13, pp. S53-S61. |
| Rosenblum MD, Way SS, Abbas AK. Regulatory T cell memory. Nat Rev Immunol. 2016;16(2):90-101. |
| Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, Treuting P, Siewe L, Roers A, Henderson WR, Jr., Muller W, Rudensky AY. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity. 2008;28(4):546-58. |
| Rudensky, Alexander Y. “Regulatory T cells and Foxp3.” Immunological reviews 241.1 (2011): 260-268. |
| Ryu, Min-Hyung, and Mark Gomelsky. “Near-infrared light responsive synthetic c-di-GMP module for optogenetic applications.” ACS synthetic biology 3.11 (2014): 802-810. |
| S. Koestenbauer, et al. Protocols for Hematopoietic Stem Cell Expansion from Umbilical Cord Blood. Cell Transplantation 18: 1059-1068, 2009. |
| S. L. Smith, et al. Expansion of neutrophil precursors and progenitors in suspension cultures of CD34+ cells enriched from human bone marrow. Experimental Hematology 21:870-877, 1993. |
| Safinia N, Grageda N, Scotta C, Thirkell S, Fry LJ, Vaikunthanathan T, Lechler RI, Lombardi G. Cell Therapy in Organ Transplantation: Our Experience on the Clinical Translation of Regulatory T Cells. Front Immunol. 2018;9:354. |
| Sahay A, Scobie KN, Hill AS, O'Carroll CM, Kheirbek MA, Burghardt NS, Fenton AA, Dranovsky A, Hen R. Increasing adult hippocampal neurogenesis is sufficient to improve pattern separation. Nature. 2011;472:466-470. |
| Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3):1151-64. |
| Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001;182:18-32. |
| Schild, Howard G. “Poly (N-isopropylacrylamide): experiment, theory and application.” Progress in polymer science 17.2 (1992): 163-249. |
| Schmitz R, Alessio A, Kina P. The Physics of PET/CT scanners. Imaging Research Laboratory, Department of Radiology, University of Washington http://depts.washington.edu/imreslab/education/Physics%20of%20PET.pdf, 2013, 16 pages. |
| Schwartz RH. T cell anergy. Annu Rev Immunol. 2003;21:305-34. |
| Shevkoplyas et al., “The Force Acting on a Superparamagnetic Bead due to an Applied Magnetic Field,” Lab on a Chip , 7, pp. 1294-1302, 2007. |
| Shimazu Y, Shimazu Y, Hishizawa M, Hamaguchi M, Nagai Y, Sugino N, Fujii S, Kawahara M, Kadowaki N, Nishikawa H, Sakaguchi S, Takaori-Kondo A. Hypomethylation of the Treg-Specific Demethylated Region in FOXP3 Is a Hallmark of the Regulatory T-cell Subtype in Adult T-cell Leukemia. Cancer Immunol Res. 2016;4(2):136-45. |
| Shimizu et all., “Fabrication of Pulsatile Cardiac Tissue Grafts Using a Novel 3-Dimensional Cell Sheet Manipulation Technique and Temperature-Responsive Cell Culture Surfaces,” Circulation Research, vol. 90, Feb. 22, 2022, e40-e48, pp. 1-9. |
| Sigma-Aldrich Cheimcals Mitomycin C (M4287) MSDS, v4.4, Jul. 7, 2011. |
| Sirsi, S. and Borden, M., “Microbubble Composition, Properties, and Biomedical Applications,” Bubble Science, Engineering & Technolology, vol. 1, No. 1-2, pp. 3-17, 2009. |
| Smith C, Okern G, Rehan S, et al. Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement. Clinical & Translational Immunology 2015;4:e31. |
| Somerville et al., “Clinical Scale Rapid Expansion of Lymphocytes for Adoptive Cell Transfer Therapy in the WAVE® Bioreactor,” Journal of Translational Medicine, vol. 10, No. 69, pp. 1-11, 2012. |
| Somerville, R. and Dudley, M., “Bioreactors Get Personal,” Oncolmmunology, vol. 1, No. 8, pp. 1435-1437, Nov. 2012. |
| Spectrum Labs KrosFlo Research IIi TFF System, 2013, Spectrum Laboratories, Inc., 4 pages. |
| Stafano Tiziani, et al. Metabolomic Profiling of Drug Response in Acute Myeloid Leukaemia Cell lines. PLOSone 4(1): e4251 (Jan. 22, 2009). |
| Creed JA, DiLeonardi AM, Fox DP, Tessler AR, Raghupathi R. Concussive brain trauma in the mouse results in acute cognitive deficits and sustained impairment of axonal function. Journal of neurotrauma. 2011;28:547-563. |
| Cuchiara, Maude L., et al. “Covalent immobilization of stem cell factor and stromal derived factor 1a for in vitro culture of hematopoietic progenitor cells.” Acta biomaterialia 9.12 (2013): 9258-9269. |
| Da Silva, Ricardo MP, Joao F. Mano, and Rui L. Reis. “Smart thermoresponsive coatings and surfaces for tissue engineering: switching cell-material boundaries.” Trends in Biotechnology 25.12 (2007): 577-583. |
| Dash PK, Hochner B, Kandel ER. Injection of the camp-responsive element into the nucleus of aplysia sensory heurons blocks long-term facilitation. Nature. 1990;345:718-721. |
| Dash PK, Johnson D, Clark J, Orsi SA, Zhang M, Zhao J, Grill RJ, Moore AN, Pati S. Involvement of the glycogen synthase kinase-3 signaling pathway in tbi pathology and neurocognitive outcome. PloS one. 2011;6:e24648. |
| Dash PK, Mach SA, Blum S, Moore AN. Intrahippocampal wortmannin infusion enhances long-term spatial and contextual memories. Learn Mem. 2002;9:167-177. |
| Dash PK, Orsi SA, Zhang M, Grill RJ, Pati S, Zhao J, Moore AN. Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats. PloS one. 2010;5:e11383. |
| Dash PK, Zhao J, Orsi SA, Zhang M, Moore AN. Sulforaphane improves cognitive function administered following traumatic brain injury. Neuroscience letters. 2009;460:103-107. |
| Davila et al., “Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B cell Acute Lymphoblastic Leukemia,” Science Translational Medicine, vol. 6, No. 224, pp. 1-10, Feb. 19, 2014. |
| Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and ve-cadherin in the control of vascular permeability. Journal of cell science. 2008;121:2115-2122. |
| Dejana E, Spagnuolo R, Bazzoni G. Interendothelial junctions and their role in the control of angiogenesis, vascular permeability and leukocyte transmigration. Thrombosis and haemostasis. 2001;86:308-315. |
| Dejana E, Tournier-Lasserve E, Weinstein BM. The control of vascular integrity by endothelial cell junctions: Molecular basis and pathological implications. Developmental cell. 2009;16:209-221. |
| Del Pino A, Ligero G, Lopez MB, et al. (2015) Morphology, cell viability, karyotype, expression of surface markers and plasticity of three primary cell line cultures before and after the cryostorage in LN2 and GN2. Cryobiology 70(1): 1-8. |
| Delaney, Colleen, et al. “Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution.” Nature medicine 16.2 (2010): 232-236. |
| Ding, Zhongli, Guohua Chen, and Allan S. Hoffman. “Synthesis and purification of thermally sensitive oligomer? enzyme conjugates of poly (N-isopropylacrylamide)? trypsin.” Bioconjugate chemistry 7.1 (1996): 121-125. |
| Dixon CE, Clifton GL, Lighthall JW, Yaghmai AA, Hayes RL. A controlled cortical impact model of traumatic brain injury in the rat. Journal of neuroscience methods. 1991;39:253-262. |
| Dominici M, Le Blanc K, Mueller I, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4): 315-317. |
| Durrani S, Konoplyannikov M, Ashraf M, Haider KH (2010) Skeletal myoblasts for cardiac repair. Regen Med 5(6): 919-932. |
| Esensten JH, Muller YD, Bluestone JA, Tang Q. Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier. J Allergy Clin Immunol. 2018;142(6):1710-1718. |
| Fakin R, Hamacher J, Gugger M, Gazdhar A, Moser H, Schmid RA. Prolonged amelioration of acute lung allograft rejection by sequential overexpression of human interleukin-10 and hepatocyte growth factor in rats. Exp Lung Res. 2011;37(9):555-62. |
| Fedorov et al., “PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses,” Science Translational Medicine, vol. 5, No. 215, pp. 1-12, Dec. 11, 2013. |
| Ferreira LMR, Muller YD, Bluestone JA, Tang Q. Next-generation regulatory T cell therapy. Nat Rev Drug Discov. 2019;18(10):749-769. |
| Fischbach, Michael A., Jeffrey A. Bluestone, and Wendell A. Lim. “Cell-based therapeutics: the next pillar of medicine.” Science translational medicine 5.179 (2013): 179ps7-179ps7. |
| Fisk, Nicholas M., et al. “Can routine commercial cord blood banking be scientifically and ethically justified ?.” PLoS medicine 2.2 (2005): e44. |
| Forbes Jun. 23, 2014 article “Will this man cure cancer?”. |
| Fowler DH. Rapamycin-resistant effector T-cell therapy. Immunol Rev. 2014;257(1):210-25. |
| Fraser H, Safinia N, Grageda N, Thirkell S, Lowe K, Fry LJ, Scotta C, Hope A, Fisher C, Hilton R, Game D, Harden P, Bushell A, Wood K, Lechler RI, Lombardi G. A Rapamycin-Based GMP-Compatible Process for the Isolation and Expansion of Regulatory T Cells for Clinical Trials. Mol Ther Methods Clin Dev. 2018;8:198-209. |
| Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, Elstrom RL, June CH, Thompson CB. The CD28 signaling pathway regulates glucose metabolism. Immunity. 2002;16(6):769-77. |
| Fuchs A, Gliwinski M, Grageda N, Spiering R, Abbas AK, Appel S, Bacchetta R, Battaglia M, Berglund D, Blazar B, Bluestone JA, Bornhauser M, Ten Brinke A, Brusko TM, Cools N, Cuturi MC, Geissler E, Giannoukakis N, Golab K, Hafler DA, van Ham SM, Hester J et al. Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Front Immunol. 2017;8:1844. |
| G0211: Study for Gamma Irradiation of Bioreactor Membranes, undated, available at least one year prior to Jun. 1, 2020, author unknown, 3 pages. |
| Galgani M, De Rosa V, La Cava A, Matarese G. Role of Metabolism in the Immunobiology of Regulatory T Cells. J Immunol. 2016;197(7):2567-75. |
| Garlie, Nina K., et al. “T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer.” Journal of immunotherapy (Hagerstown, MD.: 1997) 22.4 (1999): 336-345. |
| Gedaly R, De Stefano F, Turcios L, Hill M, Hidalgo G, Mitov MI, Alstott MC, Butterfield DA, Mitchell HC, Hart J, Al-Attar A, Jennings CD, Marti F. mTOR Inhibitor Everolimus in Regulatory T Cell Expansion for Clinical Application in Transplantation. Transplantation. 2019;103(4):705-715. |
| Gimble, Jeffrey M., Adam J. Katz, and Bruce A. Bunnell. “Adipose-derived stem cells for regenerative medicine.” Circulation research 100.9 (2007): 1249-1260. |
| Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001;15 (7):807-26. |
| Godin, Michel, et al. “Measuring the mass, density, and size of particles and cells using a suspended microchannel resonator.” Applied physics letters 91.12 (2007): 123121. |
| Golab K, Leveson-Gower D, Wang XJ, Grzanka J, Marek-Trzonkowska N, Krzystyniak A, Millis JM, Trzonkowski P, Witkowski P. Challenges in cryopreservation of regulatory T cells (Tregs) for clinical therapeutic applications. Int Immunopharmacol. 2013;16(3):371-5. |
| Goldring CE, Duffy PA, Benvenisty N, Andrews PW, Ben-David U, Eakins R, French N, Hanley NA, Kelly L, Kitteringham NR, Kurth J, Ladenheim D, Laverty H, McBlane J, Narayanan G, Patel S, Reinhardt J, Rossi A, Sharpe M, Park BK. Assessing the safety of stem cell therapeutics. Cell stem cell. 2011;8:618-628. |
| Griesche, Nadine, et al. “A simple modification of the separation method reduces heterogeneity of adipose-derived stem cells.” cells tissues organs 192.2 (2010): 106-115. |
| Gutcher I, Donkor MK, Ma Q, Rudensky AY, Flavell RA, Li MO. Autocrine transforming growth factor-beta1 promotes in vivo Th17 cell differentiation. Immunity. 2011;34(3):396-408. |
| Haack-Sorensen M, Follin B, Juhl M, et al. (2016) Culture expansion of adipose derived stromal cells. A closed automated Quantum Cell Expansion System compared with manual flask-based culture. J Transl Med 14(1): 319. |
| Hall ED, Sullivan PG, Gibson TR, Pavel KM, Thompson BM, Scheff SW. Spatial and temporal characteristics of neurodegeneration after controlled cortical impact in mice: More than a focal brain injury. Journal of neurotrauma. 2005;22:252-265. |
| Hami et al., “GMP Production and Testing of Xcellerated T Cells for the Treatment of Patients with CLL,” Cytotherapy, pp. 554-562, 2004. |
| Hamm RJ, Dixon CE, Gbadebo DM, Singha AK, Jenkins LW, Lyeth BG, Hayes RL. Cognitive deficits following traumatic brain injury produced by controlled cortical impact. Journal of neurotrauma. 1992;9:11-20. |
| Hanley PJ, Mei Z, Durett AG, et al. (2014) Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System. Cytotherapy 16(8): 1048-1058. |
| Harimoto, Masami, et al. “Novel approach for achieving double-layered cell sheets co-culture: overlaying endothelial cell sheets onto monolayer hepatocytes utilizing temperature-responsive culture dishes.” Journal of Biomedical Materials Research: An Official Journal of The Society for Biomaterials, The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials 62.3 (2002): 464-470. |
| He N, Fan W, Henriquez B, Yu RT, Atkins AR, Liddle C, Zheng Y, Downes M, Evans RM. Metabolic control of regulatory T cell (Treg) survival and function by Lkb1. Proc Natl Acad Sci U S A. 2017;114(47):12542-12547. |
| He X, Landman S, Bauland SC, van den Dolder J, Koenen HJ, Joosten I. A TNFR2-Agonist Facilitates High Purity Expansion of Human Low Purity Treg Cells. PLoS One. 2016;11(5):e0156311. |
| Heskins, Michael, and James E. Guillet. “Solution properties of poly (N-isopropylacrylamide).” Journal of Macromolecular Science—Chemistry 2.8 (1968): 1441-1455. |
| Hill JA, Feuerer M, Tash K, Haxhinasto S, Perez J, Melamed R, Mathis D, Benoist C. Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity. 2007;27 (5):786-800. |
| Unknown Author, StAR_Abstract, 2014, 1 page. |
| Startz et al.May 2016 TBCT T-cell White Paper. |
| Startz, T., et al. “Maturation of dendritic cells from CD14+ monocytes in an automated functionally closed hollow fiber bioreactor system.” Cytotherapy 16.4 (2014): S29. |
| Steven M. Bryce, et al.(Litron Laboratories). In vitro micronucleus assay scored by flow cytometry provides a comprehensive evaluation of cytogenetic damage and cytotoxicity. Mutation Research 630(1-2): 78-91, 2007. |
| Steven M. Bryce, et al.(Novartis Pharma AG, Johnson & Johnson Pharmaceutical Research, GlaxoSmithKline). Interlaboratory evaluation of a flow cytometric, high content in vitro micronucleus assay. Genetic Toxicology and Environmental Mutagenesis 650: 181-195, 2008. |
| Stuart, Martien A. Cohen, et al. “Emerging applications of stimuli-responsive polymer materials.” Nature materials 9.2 (2010): 101-113. |
| Su LF, Del Alcazar D, Stelekati E, Wherry EJ, Davis MM. Antigen exposure shapes the ratio between antigen-specific Tregs and conventional T cells in human peripheral blood. Proc Natl Acad Sci U S A. 2016; 113(41):E6192-E6198. |
| Takezawa, Toshiaki, Yuichi Mori, and Katsutoshi Yoshizato. “Cell culture on a thermo-responsive polymer surface.” Bio/technology 8.9 (1990): 854-856. |
| The effect of rocking rate and angle on T cell cultures grown in Xuri™ Cell Expansion Systems, Aug. 2014, GE Healthcare UK Limited, 4 pages. |
| Trzonkowski et al., “Ex Vivo Expansion of CD4+ CD25+ T Regulatory Cells for Immunosuppressive Therapy,” Cytometry Part A, 75A, pp. 175-188, 2009. |
| Trzonkowski, Piotr, et al. “First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+ CD25+ CD127? T regulatory cells.” Clinical immunology 133.1 (2009): 22-26. |
| Tsvetkov, Ts, et al. “Isolation and cryopreservation of human peripheral blood monocytes.” Cryobiology 23.6 (1986): 531-536. |
| Underwood, P. Anne, et al. “Effects of base material, plasma proteins and FGF2 on endothelial cell adhesion and growth.” Journal of Biomaterials Science, Polymer Edition 13.8 (2002): 845-862. |
| Urbich, et al from the Goethe-Universitat, demonstrated that human endothelial cells increased VEGFR-2 mRNA expression when exposed to 5-15 dynes/cm2 of constant shear force for a period of 6-24 hours (FEBS, 2002). |
| Van der Net JB, Bushell A, Wood KJ, Harden PN. Regulatory T cells: first steps of clinical application in solid organ transplantation. Transpl Int. 2016;29(1):3-11. |
| Van der Windt GJ, Pearce EL. Metabolic switching and fuel choice during T-cell differentiation and memory development. Immunol Rev. 2012;249(1):27-42. |
| Vera et al., “Accelerated Production of Antigen-Specific T-Cells for Pre-Clinical and Clinical Applications Using Gas-Permeable Rapid Expansion Cultureware (G-Rex),” J Immunother, vol. 33, No. 3, pp. 305-315, Apr. 2010. |
| Villa, Alma Y. Camacho, et al. “CD133+ CD34+ and CD133+ CD38+ blood progenitor cells as predictors of platelet engraftment in patients undergoing autologous peripheral blood stem cell transplantation.” Transfusion and Apheresis Science 46.3 (2012): 239-244. |
| Visser EP1, Disselhorst JA, Brom M, Laverman P, Gotthardt M, Oyen WJ, Boerman OC. Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med. Jan. 2009;50(1):139-47. |
| Von Laer, D., et al. “Loss of CD38 antigen on CD34+ CD38+ cells during short-term culture.” Leukemia 14.5 (2000): 947-948. |
| Wagner Jr, John E., et al. “Phase I/II trial of StemRegenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft.” Cell stem cell 18.1 (2016): 144-155. |
| Walker, Peter A., et al. “Direct intrathecal implantation of mesenchymal stromal cells leads to enhanced neuroprotection via an NF?B-mediated increase in interleukin-6 production.” Stem cells and development 19.6 (2010): 867-876. |
| Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, McCormick LL, Fitzgerald P, Chi H, Munger J, Green DR. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 2011;35(6):871-82. |
| Wang, Jiamian, John A. Jansen, and Fang Yang. “Electrospraying: possibilities and challenges of engineering carriers for biomedical applications—a mini review.” Frontiers in Chemistry 7 (2019): 258. |
| Ward H, Vigues S, Poole S, Bristow AF. The rat interleukin 10 receptor: cloning and sequencing of cDNA coding for the alpha-chain protein sequence, and demonstration by western blotting of expression in the rat brain. Cytokine. 2001;15(5):237-40. |
| Wawman, Rebecca Ellen, Helen Bartlett, and Ye Htun Oo. “Regulatory T cell metabolism in the hepatic microenvironment.” Frontiers in immunology 8 (2018): 1889. |
| Weber et al., “White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report of the CTEP Subcommittee on Adoptive Cell Therapy,” Clinical Cancer Research, vol. 17, No. 7, pp. 1664-1673, Apr. 1, 2011. |
| Weiss RA, Weiss MA, Beasley KL, Munavalli G (2007) Autologous cultured fibroblast injection for facial contour deformities: a prospective, placebo-controlled, Phase III clinical trial. Dermatol Surg 33(3): 263-268. |
| Widdel, F. 2010. “Theory and measurement of bacterial growth” http://www.mpi-bremen.de/Binaries/Binary13037/Wachstumsversuch.pdf. |
| Yamada, Noriko, et al. “Thermo?responsive polymeric surfaces; control of attachment and detachment of cultured cells.” Die Makromolekulare Chemie, Rapid Communications 11.11 (1990): 571-576. |
| Yang, Hee Seok, et al. “Suspension culture of mammalian cells using thermosensitive microcarrier that allows cell detachment without proteolytic enzyme treatment.” Cell transplantation 19.9 (2010): 1123-1132. |
| Yi, Zhuan, et al. “A readily modified polyethersulfone with amino-substituted groups: its amphiphilic copolymer synthesis and membrane application.” Polymer 53.2 (2012): 350-358. |
| Yoshinari, Masao, et al. “Effect of cold plasma-surface modification on surface wettability and initial cell attachment.” International Journal of Biomedical and Biological Engineering 3.10 (2009): 507-511. |
| Zappasodi et al., “The Effect Of Artificial Antigen-Presenting Cells with Preclustered Anit-CD28/-CD3/LFA-1 Monoclonal Antibodies on the Induction of ex vivo Expansion of Functional Human Antitumor T Cells,” Haematologica, vol. 93, No. 10, pp. 1523-1534, 2008. |
| Zemmour D, Zilionis R, Kiner E, Klein AM, Mathis D, Benoist C. Publisher Correction: Single-cell gene expression reveals a landscape of regulatory T cell phenotypes shaped by the TCR. Nat Immunol. 2018;19(6):645. |
| Zeng B, Kwak-Kim J, Liu Y, Liao AH. Treg cells are negatively correlated with increased memory B cells in pre-eclampsia while maintaining suppressive function on autologous B-cell proliferation. Am J Reprod Immunol. 2013;70(6):454-63. |
| Zheng, et al at the University of lowa have shown that the differential effects of pulsatile blood flow and cyclic stretch are an important growth stimulus (American Journal of Physiology—Heart and Circulatory Physiology, 2008). |
| Anamelechi, Charles C., et al. “Streptavidin binding and endothelial cell adhesion to biotinylated fibronectin.” Langmuir 23.25 (2007): 12583-12588. |
| Barker, Juliet N., et al. “CD34+ cell content of 126 341 cord blood units in the US inventory: implications for transplantation and banking.” Blood advances 3.8 (2019): 1267-1271. |
| Bluestone, Jeffrey A., et al. “Type 1 diabetes immunotherapy using polyclonal regulatory T cells.” Science translational medicine 7.315 (2015): 315ra189-315ra189. |
| Claudio G. Brunstein, Jeffrey S. Miller, Qing Cao, Daivd H. McKenna, Keli L. Hippen, Julie Curtsinger, Todd Defor, Bruce L. Levine, Carl H. June, Pablo Rubinstein, Philip B. McGlave, Bruce R. Blazar, and John E. Wagner. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood, 117(3): 1061-1070, 2010. |
| Lang, Julie, et al. “Generation of hematopoietic humanized mice in the newborn BALB/c-Rag2nullll2r?null mouse model: a multivariable optimization approach.” Clinical Immunology 140.1 (2011): 102-116. |
| Kim, Do-Hyung, et al. “mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.” Cell 110.2 (2002): 163-175. |
| Kishore M, Cheung KCP, Fu H, Bonacina F, Wang G, Coe D, Ward EJ, Colamatteo A, Jangani M, Baragetti A, Matarese G, Smith DM, Haas R, Mauro C, Wraith DC, Okkenhaug K, Catapano AL, De Rosa V, Norata GD, Marelli- Berg FM. Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis. Immunity. 2017;47 (5):875-889 e10. |
| Klysz D, Tai X, Robert PA, Craveiro M, Cretenet G, Oburoglu L, Mongellaz C, Floess S, Fritz V, Matias MI, Yong C, Surh N, Marie JC, Huehn J, Zimmermann V, Kinet S, Dardalhon V, Taylor N. Glutamine-dependent alpha-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation. Sci Signal. 2015;8(396): ra97. |
| Lampugnani MG, Caveda L, Breviario F, Del Maschio A, Dejana E. Endothelial cell-to-cell junctions. Structural characteristics and functional role in the regulation of vascular permeability and leukocyte extravasation. Bailliere's clinical haematology. 1993;6:539-558. |
| Lataillade, Jean-Jacques, et al. “Chemokine SDF-1 enhances circulating CD34+ cell proliferation in synergy with cytokines: possible role in progenitor survival.” Blood, The Journal of the American Society of Hematology 95.3 (2000): 756-768. |
| Lindstein, Tullia, et al. “Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway.” Science 244.4902 (1989): 339-343. |
| Liotta, Francesco, et al. “Frequency of regulatory T cells in peripheral blood and in tumour?infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma.” BJU international 107.9 (2011): 1500-1506. |
| Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203(7):1701-1711. |
| Hogstedt, Benkt, Anita Karlsson, and Anders Holmen. “Frequency and size distribution of micronuclei in lymphocytes stimulated with phytohemagglutinin and pokeweed mitogen in workers exposed to piperazine.” Hereditas 109.(1988): 139-142. |
| Hollyman et al., “Manufacturing Validation of Biologicall Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy,” J Immunother, vol. 32, No. 2, pp. 169-180, Feb.-Mar. 2009. |
| MRI| Small Animal Imaging| University of Colorado Cancer Center, http://www.ucdenver.edu/academics/colleges/medicalschool/centers/cancercenter/Research/sharedresources/AnimalImaging/smallanimalimaging/Pages/MRI.aspx, 2019, 2 pages. |
| ISCT Webinar “Volume Reduction technology for Large Scale Harvest or Post-thaw Manipulation of Cellular Therapeutics”. Feb. 8, 2012, 60 pages. |
| Itkin, Tomer, and Tsvee Lapidot. “SDF-1 keeps HSC quiescent at home.” Blood, The Journal of the American Society of Hematology 117.2 (2011): 373-374. |
| Iwashima, Shigejiro, et al. “Novel culture system of mesenchymal stromal cells from human subcutaneous adipose issue.” Stem cells and development 18.4 (2009): 533-544. |
| Jang, Eugene, et al. “Syndecan-4 proteoliposomes enhance fibroblast growth factor-2 (FGF-2)-induced proliferation, migration, and neovascularization of ischemic muscle.” Proceedings of the National Academy of Sciences 109.5 (2012): 1679-1684. |
| Jarocha D, Stangel-Wojcikiewicz K, Basta A, Majka M (2014) Efficient myoblast expansion for regenerative medicine use. Int J Mol Med 34(1): 83-91. |
| Jo CH, Lee YG, Shin WH, et al. (2014) Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells 32(5): 1254-1266. |
| Johansson, Ulrika, et al. “Pancreatic islet survival and engraftment is promoted by culture on functionalized spider silk matrices.” PloS one 10.6 (2015): e0130169. |
| John Carvell, et al. Monitoring Live Biomass in Disposable Bioreactors, BioProcess International 14(3)s, Mar. 2016. |
| John Nicolette, et al.(Abbott Laboratories). In Vitro Micronucleus Screening of Pharmaceutical Candidates by Flow Cyto9metry in Chinese Hamster V79 Cells, Environmental and Molecular Mutagenesis 00:000-000, 2010. |
| John P. Carvell and Jason E. Dowd. On-line measurements and control of viable cell density in cell culture manufacturing processes using radio frequency impedance. Cytotechnology 50: 35-48, 2006. |
| Johnson, Patrick A., et al. “Interplay of anionic charge, poly (ethylene glycol), and iodinated tyrosine incorporation within tyrosine?derived polycarbonates: Effects on vascular smooth muscle cell adhesion, proliferation, and motility.” Journal of Biomedical Materials Research Part A: An Official Journal of The Society for Biomaterials, The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials 93.2 (2010): 505-514. |
| Johnston LC, Su X, Maguire-Zeiss K, Horovitz K, Ankoudinova I, Guschin D, Hadaczek P, Federoff HJ, Bankiewicz K, Forsayeth J. Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease. Mol Ther. 2008;16(8):1392-9. |
| Jones M, Varella-Garcia M, Skokan M, et al. (2013) Genetic stability of bone marrow-derived human mesenchymal stromal cells in the Quantum System. Cytotherapy 15(11): 1323-1339. |
| Jones2016ISCT 2016 Poster 69. |
| Joy, Abraham, et al. “Control of surface chemistry, substrate stiffness, and cell function in a novel terpolymer methacrylate library.” Langmuir 27.5 (2011): 1891-1899. |
| Kalamasz et al., “Optimization of Human T-Cell Expansion Ex Vivo Using Magnetic Beads Conjugated with Anti-CD3 and Anti-CD28 Antibodies,” J Immunother, vol. 27, No. 5, pp. 405-418, Sep.-Oct. 2004. |
| Klapper et al., “Single-Pass, Closed-System Rapid Expansion of Lymphocyte Cultures for Adoptive Cell Therapy,” Journal of Immunological Methods, 345, pp. 90-99, Apr. 21, 2009. |
| Klein, Elias, Eva Eichholz, and Don H. Yeager. “Affinity membranes prepared from hydrophilic coatings on microporous polysulfone hollow fibers.” Journal of membrane science 90.1-2 (1994): 69-80. |
| Korpanty et al., “Tageting Vascular Enothelium with Avidin Microbubbles,” Ultrasound in Medicine and Biology, vol. 31, No. 9, pp. 1279-1283, May 24, 2005. |
| Krauss et al., “Signaling Takes a Breath—New Quantitative Perspectives on Bioenergetics and Signal Transduction,” Immunity, vol. 15, pp. 497-502, Oct. 2001. |
| Kulikov, A. V., et al. “Application of multipotent mesenchymal stromal cells from human adipose tissue for compensation of neurological deficiency induced by 3-nitropropionic acid in rats.” Bulletin of experimental biology and medicine 145.4 (2008): 514-519. |
| Kumar P, Marinelarena A, Raghunathan D, Ragothaman VK, Saini S, Bhattacharya P, Fan J, Epstein AL, Maker AV, Prabhakar BS. Critical role of OX40 signaling in the TCR-independent phase of human and murine thymic Treg generation. Cell Mol Immunol. 2019;16(2):138-153. |
| Kwan, J. and Borden, M., “Lipid Monolayer Collapse and Microbubble Stability,” Advances in Colloid and Interface Science, vols. 183-184, pp. 82-99, Aug. 21, 2012. |
| Lee et al., “Continued Antigen Stimulation Is Not Required During CD4+ T Cell Clonal Expansion,” The Journal of Immunology, 168, pp. 1682-1689, 2002. |
| Lee, Jae W., et al. “Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung.” Proceedings of the national academy of Sciences 106.38 (2009): 16357-16362. |
| Levine, B., “T Lymphocyte Engineering ex vivo for Cancer and Infectious Disease,” Expert Opinion on Biological Therapy, vol. 4, No. 4, pp. 475-489, 2008. |
| Lum et al., “Ultrasound Radiation Force Enables Targeted Deposition of Model Drug Carriers Loaded on Microbubbles,” Journal of Controlled Release, 111, pp. 128-134, 2006. |
| M. R. Koller, et al. Clinical-scale human umbilical cord blood cell expansion in a novel automated perfusion culture system. Bone Marrow Transplantion 21:653-663, 1998. |
| Malin, Stephen F., et al. “Noninvasive prediction of glucose by near-infrared diffuse reflectance spectroscopy.” (1999): 1651-1658. |
| Malone et al., “Characterization of Human Tumor-Infiltrating Lymphocytes Expanded in Hollow-Fiber Bioreactors for Immunotherapy of Cancer,” Cancer Biotherapy & Radiopharmaceuticals, vol. 16, No. 5, pp. 381-390, 2001. |
| Mao AS, Mooney DJ (2015) Regenerative medicine: current therapies and future directions. Proc Natl Acad Sci USA 112(47): 14452-14459. |
| Marek-Trzonkowska, Natalia, et al. “Administration of CD4+ CD25highCD127-regulatory T cells preserves β-cell function in type 1 diabetes in children.” Diabetes care 35.9 (2012): 1817-1820. |
| Maria Streltsova, Dean Lee (Nationwide Children's Hospital, OSU, Columbus, OH) et al.(Int'l Journal of Molecular Sciences, 2019). |
| Markgraf CG, Clifton GL, Aguirre M, Chaney SF, Knox-Du Bois C, Kennon K, Verma N. Injury severity and sensitivity to treatment after controlled cortical impact in rats. Journal of neurotrauma. 2001;18:175-186. |
| Mathew et al. A Phase I Clinical Trials I with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants. Nature, Scientific Reports 8:7428 (1-12), 2018. |
| Matthay, Michael A., et al. “Therapeutic potential of mesenchymal stem cells for severe acute lung injury.” Chest 138.4 (2010): 965-972. |
| Maynard CL, Harrington LE, Janowski KM, Oliver JR, Zindl CL, Rudensky AY, Weaver CT. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3-precursor cells in the absence of interleukin 10. Nat Immunol. 2007;8(9):931-41. |
| McKenna DH, Jr., Sumstad D, Kadidlo DM, et al. Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. Cytotherapy 2017;19:250-62. |
| McLimans W, Kinetics of Gas Diffusion in Mammalian Cell Culture Systems. Biotechnology and Bioengineering 1968; 10:725-740. |
| McMurtrey, Richard J. “Analytic models of oxygen and nutrient diffusion, metabolism dynamics, and architecture optimization in three-dimensional tissue constructs with applications and insights in cerebral organoids.” Tissue Engineering Part C: Methods 22.3 (2016): 221-249. |
| Menge, Tyler, et al. “Mesenchymal stem cells regulate blood-brain barrier integrity through TIMP3 release after traumatic brain injury.” Science translational medicine 4.161 (2012): 161ra150-161ra150. |
| Miska J, Lee-Chang C, Rashidi A, Muroski ME, Chang AL, Lopez-Rosas A, Zhang P, Panek WK, Cordero A, Han Y, Ahmed AU, Chandel NS, Lesniak MS. HIF-1alpha Is a Metabolic Switch between Glycolytic-Driven Migration and Oxidative Phosphorylation-Driven Immunosuppression of Tregs in Glioblastoma. Cell Rep. 2019;27(1):226-237 e4. |
| Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D, Mathian A, Nakahata T, Yamaguchi T, Nomura T, Ono M, Amoura Z, Gorochov G, Sakaguchi S. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30(6):899-911. |
| Murugappan, G., et al. “Human hematopoietic progenitor cells grow faster under rotational laminar flows.” Biotechnology progress 26.5 (2010): 1465-1473. |
| Nankervis B, Jones M, Vang B et al. (2018) Optimizing T Cell Expansion in a Hollow-Fiber Bioreactor. Curr Stem Cell Rep. Advanced online publication. https://doi.org/10.1007/s40778-018-0116-x. |
| Nankervis, Brian, et al. “Optimizing T cell expansion in a hollow-fiber bioreactor.” Current Stem Cell Reports 4.1(2018): 46-51. |
| Nedoszytko B, Lange M, Sokolowska-Wojdylo M, Renke J, Trzonkowski P, Sobjanek M, Szczerkowska-Dobosz A, Niedoszytko M, Gorska A, Romantowski J, Czarny J, Skokowski J, Kalinowski L, Nowicki R. The role of regulatory T cells and genes involved in their differentiation in pathogenesis of selected inflammatory and neoplastic skin diseases. Part II: The Treg role in skin diseases pathogenesis. Postepy Dermatol Alergol. 2017;34(5):405-417. |
| Abumiya, et al at National Cardiovascular Center Research Institute in Japan, suggest that subjecting human umbilical vein endothelial cells (HUVECs) to laminar shear stress for a period of 8 hours increased the relative expression of VEGFR-2 mRNA (Ateriosclerosis, Thrombosis, and Vascular Biology, 2002). |
| Afzali B, Edozie FC, Fazekasova H, Scotta C, Mitchell PJ, Canavan JB, Kordasti SY, Chana PS, Ellis R, Lord GM, John S, Hilton R, Lechler RI, Lombardi G. Comparison of regulatory T cells in hemodialysis patients and healthy controls: implications for cell therapy in transplantation. Clin J Am Soc Nephrol. 2013;8(8):1396-405. |
| Akram, Khondoker M., et al. “Mesenchymal stem cells promote alveolar epithelial cell wound repair in vitro through distinct migratory and paracrine mechanisms.” Respiratory research 14.1 (2013): 1-16. |
| Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002. Fibroblasts and Their Transformations: The Connective-Tissue Cell Family. Available from: https://www.ncbi.nlm.nih.gov/books/NBK26889. |
| Alenazi, Noof A., et al. “Modified polyether-sulfone membrane: A mini review.” Designed monomers and polymers 20.1 (2017): 532-546. |
| Almeida L, Lochner M, Berod L, Sparwasser T. Metabolic pathways in T cell activation and lineage differentiation. Semin Immunol. 2016;28(5):514-524. |
| Amy Putnam, Todd M. Brusko, Michael R. Lee, Weihong Liu, Gregory L. Szot, Taumoha Ghosh, Mark A. Atkinson, and Jeffrey A. Bluestone. Expansion of human regulatory T-Cells from patients with Type 1 Diabetes. Diabetes, 58: 652-662, 2009. |
| Anurathapan et al., “Engineered T cells for cancer treatment,” Cytotherapy, vol. 16, pp. 713-733, 2014. |
| Aronowski J, Samways E, Strong R, Rhoades HM, Grotta JC. An alternative method for the quantitation of neuronal damage after experimental middle cerebral artery occlusion in rats: Analysis of behavioral deficit. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 1996;16:705-713. |
| Arrigoni, Chiara, et al. “Rotating versus perfusion bioreactor for the culture of engineered vascular constructs based on hyaluronic acid.” Biotechnology and bioengineering 100.5 (2008): 988-997. |
| Azar, Toni, Jody Sharp, and David Lawson. “Heart rates of male and female Sprague-Dawley and spontaneously hypertensive rats housed singly or in groups.” Journal of the American Association for Laboratory Animal Science 50.2 (2011): 175-184. |
| Baecher-Allan, Clare, et al. “CD4+ CD25high regulatory cells in human peripheral blood.” The Journal of Immunology 167.3 (2001): 1245-1253. |
| Bai/Delaney (Nohla Therapeutics) showed that expanding Cord Blood-derived CD34+CD38-CD45RA-HSPCs in a biodegradable zwitterionic hydrogel with a rNotch ligand cocktail for 24 days mitigated HSPC differentiation and promoted self-renewal of lymphoid and myeloid cell phenotypes in an NSG mouse model (Nature Medicine, 2019). |
| Ballas CB, Zielske SP, Gerson SL (2002) Adult bone marrow stem cells for cell and gene therapies: implications for greater use. J Cell Biochem Suppl 38: 20-28. |
| Ballke C, Gran E, Baekkevold ES, Jahnsen FL. Characterization of Regulatory T-Cell Markers in CD4+ T Cells of the Upper Airway Mucosa. PLoS One. 2016;11(2):e0148826. |
| Baraniak PR, McDevitt TC (2010) Stem cell paracrine actions and tissue regeneration. Regen Med 5(1): 121-143. |
| Barckhausen C, Rice B, Baila S, et al. (2016) GMP-Compliant Expansion of Clinical-Grade Human Mesenchymal Stromal/Stem Cells Using a Closed Hollow Fiber Bioreactor. Methods Mol Biol 1416: 389-412. |
| Barker et al. “CD34+ Cell Content of 126 341 Cord Blood Units in the US Inventory: Implications for Transplantation and Banking,” blood Advances, vol. 3, No. 8, pp. 1267-1271, Apr. 23, 2019. |
| Bazarian JJ, Cernak I, Noble-Haeusslein L, Potolicchio S, Temkin N. Long-term neurologic outcomes after traumatic brain injury. The Journal of head trauma rehabilitation. 2009;24:439-451. |
| Bending D, Pesenacker AM, Ursu S, Wu Q, Lom H, Thirugnanabalan B, Wedderburn LR. Hypomethylation at the regulatory T cell-specific demethylated region in CD25hi T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis. J Immunol. 2014;193(6):2699-708. |
| Berendse M, Grounds MD, Lloyd CM (2003) Myoblast structure affects subsequent skeletal myotube morphology and sarcomere assembly. Exp Cell Res 291(2): 435-450. |
| Bernard, A., Payton, Mar. 1995. “Fermentation and Growth of Escherichia coli for Optimal Protein Production”, John Wiley & Sons. Current Protocols in Protein Science (1995) 5.3.1-5.3.18. |
| Berney SM, Schaan T, Wolf RE, van der Heyde H, Atkinson TP. CD2 (OKT11) augments CD3-mediated intracellular signaling events in human T lymphocytes. J Investig Med. 2000;48(2):102-9. |
| Bioheart Clinical Trial Clinica 1302 Apr. 18, 2008. |
| Biomolecular and Cellular Interactions with the Hollow Fiber Membrane Currently Used in the Quantum® Cell Expansion System. 12th NJ Symposium on Biomaterials Science, Oct. 6-7, 2014, New Brunswick, NJ. |
| Blache C, Chauvin JM, Marie-Cardine A, Contentin N, Pommier P, Dedreux I, Francois S, Jacquot S, Bastit D, Boyer O. Reduced frequency of regulatory T cells in peripheral blood stem cell compared to bone marrow transplantations. Biol Blood Marrow Transplant. 2010;16(3):430-4. |
| Bluestone et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Science Translational Medicine 7 (315):1-34, 2015. |
| Bluestone JA, Tang Q. Treg cells-the next frontier of cell therapy. Science. 2018;362(6411):154-155. |
| Blum S, Moore AN, Adams F, Dash PK. A mitogen-activated protein kinase cascade in the ca1/ca2 subfield of the dorsal hippocampus is essential for long-term spatial memory. The Journal of neuroscience : the official journal of the Society for Neuroscience. 1999;19:3535-3544. |
| Boitano, Anthony E., et al. “Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells.” Science 329.5997 (2010): 1345-1348. |
| Bojun Li et al. Heparin-induced conformation changes of fibronectin within the extracellular matrix promote hMSC osteogenic differentiation. Biomaterials Science 3: 73-84, 2015. |
| Boquest AC, Shahdadfar A, Brinchmann JE, Collas P. Isolation of Stromal Stem Cells from Human Adipose Tissue. Methods Mol Biol. 2006;325:35-46. doi: 10.1385/1-59745-005-7:35. PMID: 16761717. |
| Borden, M. and Longo, M., “Dissolution Behavior of Lipid Monolayer-Coated, Air-Filled Microbubbles: Effect of Lipid Hydrophobic Chain Length,” Langmuir, vol. 18, pp. 9225-9233, 2002. |
| Bourke, Sharon L., and Joachim Kohn. “Polymers derived from the amino acid L-tyrosine: polycarbonates, polyarylates and copolymers with poly (ethylene glycol).” Advanced drug delivery reviews 55.4 (2003): 447-466. |
| Brand, K. and Hermfisse, U., “Aerobic Glycolysis by Proliferating Cells: a Protective Strategy against Reactive Oxygen Species,” The FASEB Journal, vol. 11, pp. 388-395, Apr. 1997. |
| Brentjens et al., “CD19-Targeted T Cells Rapidly Induce Molecular Remission in Adults with Chemotherapy-Refractory Acute Lympohblastic Leukemia,” Science Translational Medicine, vol. 5, Issue 177, pp. 1-9, Mar. 20, 2013. |
| Brentjens et al., “Safety and Persistance of Adoptively Transferred Autologous CD19-Target T Cells in Patients with Relapsed or Chemotherapy Refractory B-Cell Leukemias,” Blood, vol. 118, No. 18, pp. 4817-4828, Nov. 3, 2011. |
| Brunstein C, Miller J, Cao Q, McKenna D, Hippen K, Curtsinger J, DeFor T, Levine B, June C, Rubinstein P, McGlave P, Blazar B, Wagner J. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117(3):1061-1070. |
| C. H. Weaver, et al. An Analysis of Engraftment Kinetics as a function of the CD34 Content of the Peripheral Blood Progenitor Cell Collections in 692 Patients After the Administration of Myeloblative Chemotherapy. Blood 86(10): 3691-3969, 1995. |
| Cano, Ángels, Cristina Minguillon, and Cristina Palet. “Immobilization of endo-1, 4-β-xylanase on polysulfone acrylate membranes: Synthesis and characterization.” Journal of membrane science 280.1-2 (2006): 383-388. |
| Carswell, K. and Papoutsakis, E. “Culture of Human T Cells in Stirred Bioreactors for Cellular Immunotherapy Applications: Shear, Proliferation, and the IL-2 Receptor,” Biotechnology and Bioengineering, vol. 68, No. 3, pp. 329-338, May 5, 2000. |
| Celeste Nelson et al., Emergent patterns of growth controlled by multicellular form and mechanics, (in Christopher Chen's Lab demonstrated, in separate experiments, that curved surfaces with a radius of curvature (200 ?m) that is greater than the cell diameter and surfaces that have undulating special patterning (depressions) increase the patterned growth of ECs [PNAS 102(33): 11594-11599, 2005]. |
| Chapman NM, Chi H. mTOR signaling, Tregs and immune modulation. Immunotherapy. 2014;6(12):1295-311. |
| Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, Jack RS, Wunderlich FT, Bruning JC, Muller W, Rudensky AY. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated Inflammation. Immunity. 2011;34(4):566-78. |
| Chen, C. and Broden, M., “The Role of Poly(theylene glycol) Brush Architecture in Complement Activation on Targeted Microbubble Surfaces,” Biomaterials, vol. 32, No. 27, pp. 6579-6587, Jun. 17, 2011. |
| Choi W, Kwon SJ, Jin HJ, et al. (2017) Optimization of culture conditions for rapid clinical-scale expansion of human umbilical cord blood-derived mesenchymal stem cells. Clin Transl Med 6(1): 38. |
| Chullikana A, Majumdar AS, Gottipamula S, et al. (2015) Randomized, double-blind, phase I/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction. Cytotherapy 17(3): 250-261. |
| Coeshott C, Vang B, Jones M, Nankervis B. Large-scale expansion and characterization of CD3(+) T-cells in the Quantum((R)) Cell Expansion System. J Transl Med. 2019;17(1):258. |
| Coombes JL, Robinson NJ, Maloy KJ, Uhlig HH, Powrie F. Regulatory T cells and intestinal homeostasis. Immunol Rev. 2005;204:184-94. |
| Coquillard C. mTOR Signaling in Regulatory T cell Differentiation and Expansion. SOJ Immunology. 2015;3(1):1-10. |
| Number | Date | Country | |
|---|---|---|---|
| 20230193180 A1 | Jun 2023 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62347012 | Jun 2016 | US | |
| 62347025 | Jun 2016 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16845791 | Apr 2020 | US |
| Child | 18169961 | US | |
| Parent | 15616876 | Jun 2017 | US |
| Child | 16845791 | US |
